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Abstract 
Clinical research should aim to broaden and translate the understanding of health 
and disease by designing and successfully implementing interventions to achieve 
healthcare improvement.  This thesis reports clinical research that moves from 
laboratory to clinic and investigates the potential challenges of dissemination and 
adoption into clinical practice.   
Initially an established gingivitis was used as a model to evaluate a personalised 
plaque control intervention.  The evaluation used traditional clinical monitoring 
techniques and pioneering laboratory technologies.  Subsequently the 
personalised plaque control intervention was developed further and applied to a 
new clinical situation, the gingival manifestations of oral lichen planus.  The 
personalised plaque control intervention was then evaluated as part of a 
randomised controlled trial using traditional clinically observed, patient-centred 
and health-economic outcome measures.  Finally, a qualitative study investigated 
the potential barriers in disseminating research through continuing education to 
general dental practitioners. 
The research findings showed that in the established gingivitis model, sequential 
plaque control interventions, comprising powered toothbrushing and professional 
prophylaxis, were effective in reducing the clinical signs of established gingivitis.  
Changes in clinical signs were associated with a shift in bacterial species, and 
transient changes were observed in host inflammatory biomarker concentrations.  
Personalised plaque control was cost-effective and reduced clinical signs of 
inflammation and brought about improvements in quality of life for patients with 
gingival manifestations of oral lichen planus.  The qualitative study identified 
barriers to the successful translation and implementation of contemporary clinical 
research.   
The plaque control intervention evaluated in the established gingivitis model and 
successfully implemented in a new clinical situation.  Personalised plaque control 
should form part of the initial management phase for patients with gingival 
manifestations of oral lichen planus.  Researchers should investigate alternative 
methods for engaging with general dental practitioners in disseminating research 
to ensure that relevant findings are translated into improvements in healthcare. 
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Introduction 
One of the greatest challenges in contemporary medical and dental research is 
efficiently utilising scarce resources to translate results into meaningful health 
benefits for patients, whilst further broadening our understanding of the basic 
processes that underlie states of both health and disease.  The traditional 
surrogate outcome measures that are so often applied to controlled clinical trials 
are very much clinician centred, despite the growing acceptance of qualitative 
research within medicine.  In some studies, when patient-centred outcome 
measures do not show the intended outcome, claims are made that the instrument 
itself is at fault and it may not be appropriately measuring the correct construct.   
Some fields of medical research use the most finite of endpoints, life and death. The 
majority of chronic debilitating disorders, however, have recognisable symptoms 
and measurable signs that can be managed.  These finite outcome measures are 
therefore not appropriate.  In dentistry, perhaps the absolute finite outcome 
measure is tooth loss, and whilst this could be appropriate with the more common 
oral diseases of caries and periodontal disease, it cannot be used for soft tissue 
pathologies (other than cancer).  The ethical responsibilities of healthcare 
professionals ensure that cost effective and efficacious interventions are 
recommended and delivered before these finite endpoints are reached.  Identifying 
predictors of future disease, therefore, has been the focus of contemporary oral 
health research.  Interventions have been designed to not only resolve pathologies 
but also to help understand the underlying disease mechanisms and aetiologies.  
The demand on finite resources also means that studies that are funded and 
approved should maximise the potential for gaining valuable information on the 
disease or intervention being examined. 
Ultimately, research must also be accessible to those that can most easily 
implement improvements in practice.  In dentistry this lies outside of research-
intensive institutions in general dental practice.  As such researchers must 
understand the challenges and pressures that are placed on practitioners so that 
they might engage positively together to bring about change. 
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Oral health interventions are recommended by general dental practitioners, 
industry and through the media every day.  Tailoring an intervention to an 
individual patient requires a deeper understanding of the disease being treated, 
how the intervention affects the underlying biology, and how it will bring about 
improvements in oral health and, even, potentially quality of life. 
This thesis describes the evaluation of such an intervention, exploring the 
underlying pathologies and examining the effect it has from the patients’ 
perspective.  It also attempts to distil down some of the problems that general 
dental practitioners face in making meaningful and cost-effective changes to their 
practice. 
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Chapter 1  
Literature Review 
Prologue 
This literature review is focussed upon the areas that are pertinent to the 
development and translation of the investigations described within this thesis.  It 
will examine the aetiology of gingival manifestations of oro-mucosal disease, with 
specific reference to oral lichen planus.  The role of patient-centred outcome 
measures, biomarkers, and health economics will be discussed along with the 
relevance, importance, and practicalities of their use within clinical trials.  Clinical 
research must be accessible and relevant for it to be successfully translated into 
practice.  The potential challenges and barriers that may prevent this from 
occurring are presented. 
1.1 Lichen planus 
Lichen planus is a chronic autoimmune inflammatory disease with T-cell mediated 
immunological dysfunction.  The aetiology of the disease is poorly understood.  
Links have been hypothesised between lichen planus and the local environment, 
high stress levels, viruses and abnormal host response, but there is little evidence 
to categorically support or dismiss any of these claims (Koray et al., 2003; Sun et 
al., 2005; Annes and Szepietowski, 2007; Lodi et al., 2010).  Lichen planus is often 
symptomatic, however current available treatments are not curative and are aimed 
at controlling painful symptoms to comfortable levels (Thornhill, 2001; Lodi et al., 
2005a; Thongprasom et al., 2011).   
Lichen planus may affect multiple sites including the skin, oral and nasal mucosa, 
ears, eyes, as well as the gastrointestinal tract and the genitalia (Neumann et al., 
1993; Eisen, 1999; Abraham et al., 2000; Cheng et al., 2012).  The most common 
cutaneous presentations are on the flexural surfaces of wrists or ankles and appear 
as purple plaques or raised areas.  The surface of these lesions may have a lacy 
white appearance known as Whickham’s striae (Figure 1) (Boyd and Nelder, 1991; 
Breathnach and Black, 2004; Cheng et al., 2012). The skin symptomatology is that 
of itchiness, and in contrast to some of the more erosive presentations that often 
affect mucosal surface, skin lesions have the best prognosis with many resolving 
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with treatment within 2 years (Boyd and Nelder, 1991; Breathnach and Black, 
2004).   
1.1.1 Oral lichen planus 
The majority of patients with cutaneous lesions (up to 70%) also have oral 
involvement.  The oral presentations vary from mild keratosis to extensive 
erosions and ulceration (Figure 2) (Altman and Perry, 1961; Samman, 1961; Leao 
et al., 2008; Lo Russo et al., 2008).  The prevalence of oral lichen planus is between 
0.5% and 2.0% of studied populations with the most recent estimation being 
1.27% (Thongprasom et al., 2011). The distribution of oral lichen planus in the 
population shows an increased prevalence in females with a higher percentage of 
women between 30 and 60 years of age being affected (McCartan and Healy, 2008; 
Thongprasom et al., 2011).  The terms commonly used to describe the appearance 
of oral lichen planus lesions are: reticular, papular, desquamative, erosive 
(ulcerative), atrophic, bullous, plaque-like and combination forms (Andreasen, 
1968; Eisen, 2002; Lodi et al., 2005a; Escudier et al., 2007; Thongprasom et al., 
2011). The most common and least symptomatic oral presentation is that of 
reticular lichen planus which occurs symmetrically on the buccal mucosa but may 
also present on the gingivae, tongue, palate and lips (Kramer et al., 1978; Lozada-
Nur and Miranda, 1997; Thongprasom et al., 2011). The only presenting 
complaints of patients with milder presentations may be sensitivity to spicy or 
acidic foods.  The more widespread atrophic, erosive and ulcerative presentations 
of the disease are much more likely to be symptomatic and have a significant 
impact on patients’ lives (Cheng et al., 2012).   
Those with erosive oral lesions may also have genital involvement.  This more 
severe presentation in women is known as the vulvovaginal-gingival syndrome, 
and in men the peno-gingival syndrome (Pelisse et al., 1982; Pelisse, 1989; Cribier 
et al., 1993).  The various sites affected by oral lichen planus may lead to 
presentation in different healthcare settings including general practice, specialist 
oral medicine, dermatology, genitourinary or gastroenterology clinics (Cheng et al., 
2012). There may be the need for multidisciplinary management or joint specialist 
consultations in the cases where multiple sites are affected to ensure appropriate 
diagnosis and management.  
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Figure 1.  A cutaneous presentation of oral lichen planus. 
 
 
 
 
Figure 2.  A classical reticular presentation of oral lichen planus. 
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Diagnosis can usually be made on the clinical presentation alone although biopsy 
and histopathological examination are seen as the gold standard to eliminate the 
diagnoses of vesiculobullous disorders, dysplasia or malignancy (Eisen et al., 2005; 
Scully and Carrozzo, 2008; BSOM, 2010). Although there is some controversy over 
whether all cases of suspected oral lichen planus are biopsied, cases that have an 
atypical presentation, are atrophic or ulcerative should be biopsied (BSOM, 2010).   
There are characteristic histopathological features in oral lichen planus (Figure 3).  
Care must be taken in interpreting the microscopic appearance by relating it to the 
normal structure for the area from which it was taken.  
Haematoxylin and Eosin stained samples of affected oral mucosa clearly show 
characteristic rete processes with a ‘saw tooth’ like appearance and epithelial 
atrophy may be also seen (Figure 3) .  The basal cell layer will usually include signs 
of liquefactive degeneration with a superficial band of T-lymphocytes present in 
the connective tissue (Kramer et al., 1978; Eisenberg, 2000; Thongprasom et al., 
2011).   
There is a large but inconsistent body of evidence to suggest that oral lichen planus 
may be a pre-malignant condition.  In 1978 the World Health Organisation (WHO) 
proposed that oral lichen planus has a predisposition to malignant change (Kramer 
et al., 1978).  The most recent observations found that the frequency of 
transformation into squamous cell carcinoma ranged between 0% to 12.5%, 
whereas previous data suggest that the rate of transformation into squamous cell 
carcinoma is much lower, between 0.5% and 5% (Silverman et al., 1985; 
Holmstrup et al., 1988; Lo Muzio et al., 1998; Gandolfo et al., 2004; Rodstrom et al., 
2004; Hsue et al., 2007; Gonzalez-Moles et al., 2008). The problem with identifying 
a precise transformation rate lies with the differing definitions of oral lichen 
planus, in particular whether all presentations were included in the studies along 
with the size of the populations observed.  The transformation rate is further 
skewed by the difficulty in differentiating between true malignant transformation 
and a carcinoma occurring in patients with oral lichen planus who also are tobacco 
and alcohol users and, therefore, inherently have a higher risk for oral malignancy 
(Gonzalez-Moles et al., 2008).  There is some evidence to suggest that patients with 
erosive and atrophic presentations along with these risk factors will have a higher 
risk of malignant transformation (Scully and Carrozzo, 2008).   
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Figure 3.  Haematoxylin eosin (H&E) staining of incisional biopsy of oral lichen planus 
indicating sub-epithelial lymphocytic infiltration, ‘saw like’ rete processes and disorder at 
the basement membrane at x10 (a), x20 (b) and x30 (c) magnifications.  
  
b 
a 
c 
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It is for this reason that patients with oral lichen planus are reviewed routinely and 
there is a low threshold for further biopsy if the clinical features of the lesions 
worsen (Gonzalez-Moles et al., 2008).  
1.1.2 Oral lichenoid lesions 
Oral lichenoid lesions (OLL) closely mimic those of oral lichen planus in both their 
clinical and histological appearance. The aetiology is reactionary in nature and is 
widely attributed to dental amalgam and a number of medications.  These drugs 
include beta-blockers, thiazide diuretics, angiotensin converting enzyme 
inhibitors, calcium channel blockers, sulphonylureas, anti-malarials, gold, 
penicillamine, allopurinol and non-steroidal anti-inflammatory agents (Chau et al., 
1984; Potts et al., 1987; Firth and Reade, 1989; Thornhill et al., 2006; BSOM, 2010).  
A comprehensive medical history and clinical examination is essential in 
formulating a diagnosis and differentiating oral lichen planus from that of an oral 
lichenoid lesion.  Even following clinical examination, biopsy and histopathological 
analysis, the final diagnosis may lie somewhere between oral lichen planus and an 
oral lichenoid lesion. 
1.1.3 Gingival manifestations of oral lichen planus 
Desquamative gingivitis is a frequently used descriptive term for the gingival 
manifestations of oral lichen planus comprising chronic epithelial desquamation, 
erythema, erosion and blistering of the attached and marginal gingiva (Prinz, 1932; 
Guiglia et al., 2007). The extent of the desquamation varies from mild localised 
patches to widespread intense erythema, ulceration and areas of spontaneous 
haemorrhage (Figure 4) (Scully and Porter, 1997). Originally described as a 
‘chronic desquamative gingivitis’ and later as a ‘chronic diffuse desquamative 
gingivitis,’ the aetiology was initially considered to be either idiopathic or related 
to hormone changes around menopause in middle aged females (Tomes and 
Tomes, 1894; Prinz, 1932).  It is now attributed to a number of autoimmune 
conditions as well as adverse reactions to a variety of pharmaceuticals, chemicals 
and allergens (Scully and Porter, 1997; Stoopler et al., 2003; Leao et al., 2008; Lo 
Russo et al., 2009).   
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Figure 4.  Presentations of the gingival manifestations of oral lichen planus (from 
participants in Clinical Trial 2 in this thesis). 
The clinical appearance varies from mild keratosis and classical Whickham’s striae (a) to 
localised (c) and widespread erythema and glazing (d, e).  Localised areas of ulceration (a, 
b, c, d) and spontaneous haemorrhage (a) are also shown. 
a 
e 
b 
c 
d 
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Desquamative gingivitis has been linked or associated with:  
 oral lichen planus; 
 oral lichenoid lesions; 
 mucous membrane pemphigoid; 
 pemphigus vulgaris, erythema multiforme;  
 graft versus host disease; 
 lupus erythematosus; 
 paraneoplastic pemphigus; 
 epidermolysis bullosa acquitista; 
 linear immunoglobulin A (IgA) disease; 
 ulcerative stomatitis; 
 plasma call gingivitis; 
 dermatitis herpetiformis; 
 foreign body gingivitis; 
 psoriasis. 
Many of these conditions are rare and most commonly, oral lichen planus is the 
underlying cause of a desquamative gingivitis (Lo Russo et al., 2009).  It is seen 
most commonly in the erosive, ulcerative and atrophic forms and may be the only 
sign of oral involvement (Jadinski and Shklar, 1976; Scully and Porter, 1997).   
1.1.2 Treatment of oral lichen planus 
Treatment is normally initiated to manage the pain and severity of the symptoms.  
Current evidence and guidance suggests that topical corticosteroids should be the 
first line treatment.  There is however no universally agreed second line treatment 
but short courses of systemic corticosteroids have been suggested (Cribier et al., 
1998; Carrozzo and Gandolfo, 1999; Eisen, 2002; Eisen et al., 2005; Lodi et al., 
2005b; Al-Hashimi et al., 2007; Scully and Carrozzo, 2008; Carrozzo and Thorpe, 
2009; BSOM, 2010; Cheng et al., 2012).  The current pathway outlining the 
recommendations for the clinical management of symptomatic oral lichen planus 
is outlined in Figure 5 (Lodi et al., 2005b).  
Despite the widespread acceptance and use of topical corticosteroids in the 
treatment of symptomatic oral lichen planus, there are currently no randomised 
controlled trials that investigate their effectiveness against a placebo (Lodi et al., 
2012).  Studies have compared topical corticosteroids of varying potencies and 
have included fluticasone propionate, betamethasone sodium phosphate, 
prednisolone, clobetasol propionate and triamcinolone. 
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Figure 5.  An overview of the clinical management of oral lichen planus (Lodi et al., 2005a). 
  
Diagnosis 
Initial treatment: 
Control oral hygiene; 
avoid precipitating 
factors e.g. drugs, 
food, chemicals; 
provide reassurance. 
Asymptomatic Erosive and/or 
symptomatic 
No treatment: 
follow up every 
6 months 
Topical 
steroids 
Unsatisfactory 
response: 
Systemic corticosteroid 
Satisfactory response: 
Maintain with topical 
corticosteroid and 
follow-up 
Unsatisfactory response: 
Alternative treatments 
(tacrolimus, retinoids, 
PUVA, intra-lesional 
steroids) 
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The majority of trials have recruited patients with erosive lichen planus and 
effectiveness of one preparation over another remains inconclusive (Rödström et 
al., 1994; Hegarty et al., 2002a; Campisi et al., 2004; Malhotra et al., 2008; Carbone 
et al., 2009; Ghabanchi et al., 2009; Lodi et al., 2012).   
Topical calcineurin inhibitors have been widely investigated and compared with 
the effectiveness of topical corticosteroids. Of these, the most commonly used are 
ciclosporin, tacrolimus and pimecrolimus.  Evidence suggests that there is little 
difference in the effectiveness of these drugs against topical corticosteroids (Eisen 
et al., 1990; Conrotto et al., 2006; Yoke et al., 2006; Gorouhi et al., 2007; Passeron 
et al., 2007; Volz et al., 2008).  Their use may be less frequent due to the need to 
monitor blood biochemistry (electrolytes, blood urea, creatinine, magnesium, 
lipids, liver function tests and uric acid) during the first few weeks of treatment 
(Lebwohl et al., 1998). 
In comparison, topical corticosteroids are generally well tolerated and have less 
systemic toxicity than their systemic counterparts (such as adrenocortical 
insufficiency) (Gonzalez-Moles et al., 2002; Lodi et al., 2012; Varoni et al., 2012).  
Other topical treatments for symptomatic lesions have included topical 
anaesthetics (lidocaine gel 2%; benzydamine hydrochloride 0.15% mouthrinse) or 
barrier agents such as carmellose sodium protective paste (Orabase®).   
The outcome of the two most recent systematic reviews of interventions for 
treating oral lichen planus has recommended that future studies should be 
designed to better allow meta-analysis of data (Zakrzewska et al., 2005; Lodi et al., 
2012).  Although not recommending which specific standardised outcome 
measures should be used, they recommend that all adverse events of treatment are 
reported and some evaluation of cost-effectiveness should also take place 
(Zakrzewska et al., 2005; Lodi et al., 2012).  The studies included in the review 
evaluated pharmacological treatment whilst conservative management strategies, 
for example, were not included (Table 1).  
Despite the lack of credence given to conservative strategies in the systematic 
reviews, factors that have been found to expedite improvement of symptomatic 
lesions include: reassurance; avoidance of exacerbating factors such as certain 
foods; avoidance of smoking and alcohol; and improving oral hygiene (Ramon-
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Fluixa et al., 1999; Thongprasom et al., 2003; Thongprasom et al., 2011).  There are 
currently no randomised controlled trials investigating the effectiveness of more 
conservative, non-pharmacological interventions.  
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Intervention  Author  Number of 
participants 
Outcome measure Follow up 
period 
Ciclosporin rinse 100 mgml-1 vs placebo Eisen et al., 1990 16 Pain (4-point scale), erosion and erythema (4-
point scale)  
8 weeks 
Ciclosporin 16mg gel vs placebo Gombos et al., 1992 20 Complete healing, reduction in clinical signs of 
oral lichen planus 
10 weeks 
Flucinonide 0.025% vs placebo Voute et al., 1993 40 Pain (5-point scale), clinical score (5-point scale) 9 weeks 
Clobetasol propionate vs triamcinolone Rödström et al., 1994 40 Pain (Visual Analogue Scale), clinical score (4-
point score) 
9 weeks 
Photochemotherapy with 8-methoxypsoralen (0.6 mgkg1) 
and long-wave ultraviolet light vs no treatment 
Lundquist et al., 1995 18 Clinical score (3-point scale) 12 months 
Fluticasone propionate 50μg spray vs betamethasone 
sodium phosphate 500μg mouthwash 
Hegarty et al., 2002a 39 Pain (Visual Analogue Scale), clinical score (area 
mm2 lesions), quality of life (OHIP, OHQoL) 
6 weeks 
Traditional Chinese medicine (herbal medicine plus 
prednisolone 5-10mg plus chlorphenamine 4 mg plus 
vitamin C ) vs western drugs (prednisolone 5-10 mg, 
chlorphenamine 4mg plus vitamin C) 
Xu et al., 2002 39 Clinical score (4-point scale), relapse rate 6 weeks 
Mycostatin (nystatin) paste and dexamethasone paste Wei et al., 2003 57 Clinical score (4-point scale) 6 weeks 
Comparing 2 formulations of  clobetasol propionate 
0.025% (lipid-loaded microspheres & lipophilic ointment 
in a hydrophilic phase) 
Campisi et al., 2004 45 Pain (Visual Analogue Scale), Clinical score 
(Thongprasom et al., 1992) 
2 months 
1% pimecrolimus cream vs placebo Swift et al., 2005 20 Pain (Visual Analogue Scale), clinical score 
(weighted area) 
4 weeks 
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Clobetasol propionate 0.025% vs ciclosporin 1.5% Conrotto et al., 2006 39 Pain (Visual Analogue Scale), clinical score 
(Thongprasom et al., 1992), cost 
2 months 
Tacrolimus 0.1% ointment vs triamcinolone acetonide 
0.1% 
Laeijendecker et al., 
2006 
40 Clinical score (4-point scale) 6 weeks 
Ciclosporin solution 0.1% vs triamcinolone acetonide 
0.1% in orabase 
Yoke et al., 2006 139 Pain (Visual Analogue Scale), clinical score 
(Thongprasom et al., 1992) 
8 weeks 
Curcuminoids 2000mg and prednisolone 60mg vs 
prednisolone 60mg plus placebo  
Chainani-Wu et al., 
2007 
33 Pain (Visual Analogue Scale), clinical score 
(modified oral mucositis index), global change 
scale,  
7 weeks 
Pimecrolimus 1% cream vs triamcinolone acetonide 0.1% 
 
Gorouhi et al., 2007 40 Pain (Visual Analogue Scale), clinical score 
(Thongprasom et al., 1992), quality of life (OHIP)  
2 months 
Clobetasol propionate 0.05% with adjunctive miconazole 
2% vs clobetasol propionate 0.05% with placebo 
Lodi et al., 2007 35 Pain (Visual Analogue Scale), clinical score 
(percentage of mucosa affected) 
6 weeks 
1% pimecrolimus cream vs placebo Passeron et al., 2007 12 Pain (5 point score), clinical score (erosive area) 4 weeks 
Aloe vera 70% vs placebo Choonhakarn et al., 
2008 
54 Pain (Visual Analogue Scale), clinical response (4-
point scale) 
8 weeks 
Tacrolimus 0.1% ointment vs clobetasol propionate 
0.05% 
Corrocher et al., 2008 32 Pain (4-point scale), clinical score (4-point scale) 4 weeks 
Betamethasone oral mini-pulse therapy vs triamcinolone 
acetonide 0.1% 
Malhotra et al., 2008 49 Pain, clinical score 6 months 
1% pimecrolimus cream vs placebo Volz et al., 2008 20 Pain (Visual Analogue Scale), clinical score 
(composite score) 
30 days 
Clobetasol propionate 0.025 vs clobetasol propionate 
0.05% 
Carbone et al., 2009 35 Pain (Visual Analogue Scale), clinical score 2 months 
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Triamcinolone acetonide 0.1% vs prednisolone 5mg 
mucoadhesive tablet   
Ghabanchi et al., 2009 20 Clinical score (5-point scale) 2 weeks 
Ignatia 30c (homeopathic medicine) Mousavi et al., 2009 30 Pain (Visual Analogue Scale), clinical score (semi-
quantitative scoring system) 
4 months 
Hyaluronic acid vs placebo Nolan et al., 2009 124 Clinical score (erosive area), functional score 
(eating) 
28 days 
Intralesional injection 0.5ml BCG-PSN vs 10mg 
triamcinolone acetonide 0.25ml from solution 40 mgml-1 
mixed 0.25ml 2% lidocaine for injection 
Xiong et al., 2009 56 Pain (Visual Analogue Scale), clinical score 
(erosive area) 
3 months 
Pursulane 235mg (herbal medicine) vs placebo Agha-Hosseini et al., 
2010 
37 Pain (Visual Analogue Scale), clinical score 
(percentage of mucosa affected)  
3 months 
Aloe vera vs placebo Salazar-Sanchez et al., 
2010 
55 Pain (Visual Analogue Scale), clinical score 
(Thongprasom et al., 1992), treatment response, 
quality of life (OHIP-49), hospital anxiety and 
depression scale (Snaith, 2003)) 
12 weeks 
 
Table 1.  Interventions for the management of oral lichen planus, adapted from a Cochrane systematic review (Thongprasom et al., 2011; Lodi et al., 2012).
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A painful ulcerative or erosive desquamative gingivitis has the potential to 
interfere with effective implementation of daily oral hygiene procedures (Lo Russo 
et al., 2009).  This may lead to the accumulation of dental plaque, which has been 
reported to induce or worsen the activity of the lesions especially in the case of 
oral lichen planus (Holmstrup et al., 1990; Lo Russo et al., 2008).  The importance 
of mechanical and self-performed plaque control in patients with periodontal 
disease and in patients undergoing periodontal maintenance is well documented 
(Ramfjord et al., 1982; Rosling, 1983; Ramfjord, 1987; Rosen et al., 1999; Allen et 
al., 2008).  The reported effect of dental plaque on the gingival manifestations of 
oral lichen planus, suggests that whilst good oral hygiene may not bring about 
complete resolution, the presence of plaque and calculus deposits irritates, 
aggravates and exacerbates the disease (Erpenstein, 1985; Holmstrup et al., 1990; 
Guiglia et al., 2007).  Although poor plaque control is likely to compromise 
periodontal health, little evidence exists to suggest that patients with gingival 
manifestations of oral lichen planus generally have poorer oral hygiene or exhibit 
greater or more frequent periodontal attachment loss (Ramfjord et al., 1982; 
Rosling, 1983; Ramfjord, 1987; Rosen et al., 1999; Allen et al., 2008; Lo Russo et al., 
2008).  The optimisation of plaque control may prevent periodontal damage and 
reduce symptoms associated with the gingival manifestations of oral lichen planus 
despite the current limited evidence and lack of well-designed trials (Lo Russo et 
al., 2008).   
Despite this weak evidence, most guidelines and reviews have recommended that 
as part of the initial treatment, oral hygiene should be improved and controlled.  
Improvements in oral hygiene may convey a benefit in reducing the frequency and 
severity of symptomatic oral lichen planus but other factors may confound the 
strength of this evidence (Erpenstein, 1985; Holmstrup et al., 1990; Guiglia et al., 
2007; Lopez-Jornet and Camacho-Alonso, 2010a). 
Holmstrup et al. (1990) followed a small cohort of 11 patients with oral lichen 
planus-attributed desquamative gingivitis who were treated with an ‘intensive 
individual hygiene programme’ with ‘frequent professional assistance over one 
year’.  This assistance included advice on the use of toothbrushes, toothsticks, floss, 
chlorhexidine 0.2% mouthwash and hibitane toothpaste (1% chlorhexidine) 
(Holmstrup et al., 1990).  In addition to receiving this regimen of hygiene phase 
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therapy, patients also underwent treatment of caries and renewal of deficient 
restorations.  The authors do not discuss the materials used or if amalgam 
restorations were replaced with alternatives.  They measured subjective 
symptoms by using a global change scale.  Whilst this study noted improvements 
in all of the patients’ symptoms, the study cohort was small and the subjective 
outcome measure used was not previously tested for validity or reliability.  These 
confounding factors and the size of this study make drawing firm associations 
between the improvement of poor plaque control and symptomatic gingival 
lesions difficult. 
Guiglia et al. (2007) conducted an open-label, single-blinded study of 30 subjects 
with gingival manifestations of oral lichen planus over a 3-month period.  The aim 
was to evaluate a combined regimen of oral hygiene and corticosteroid therapy.  As 
part of this, subjects underwent supra and subgingival scaling (if necessary) as 
well as 30 minutes of oral hygiene advice with soft manual toothbrushes, 
appropriate interdental cleaning aids, and chlorhexidine.  As well as instructions to 
exercise meticulous, self-performed plaque control they underwent concurrent 
pharmacological treatment with topical clobetasol propionate, a potent topical 
corticosteriod (Guiglia et al., 2007).  Furthermore, there was no standardisation of 
how many times per day the subjects were asked to apply the clobetasol ointment 
(5 minutes once, twice or three times daily).  Clinical improvement was assessed 
using the Silness and Löe plaque index and bleeding on probing.  Clinical 
photographs were also used and two examiners were asked to grade improvement 
on a yes/no dichotomous scale.  The paper did not indicate if the examiners were 
calibrated for any of the outcome measures; stating that they were trained in 
‘periodontology.’  There are flaws within the design that make it difficult to 
ascertain how much of the improvement noted in plaque score and bleeding was 
due to one particular mechanical intervention; either the professional intervention 
of scaling and polishing or the oral hygiene carried out over the duration of the 
study.  There may also have been benefit from the use of topical steroids, either 
directly or indirectly, in reducing the inflammation to allow self-performed plaque 
control.  The study did not account for subjects’ symptoms and the change in 
severity of the clinical signs was not robustly recorded (Guiglia et al., 2007). 
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The most recent study to examine the relationship between the gingival 
manifestations of oral lichen planus and plaque control examined 40 patients who 
were provided with a combined protocol of a ‘motivation-behavioural skills’ for 
improving oral hygiene and topical corticosteroids (Lopez-Jornet and Camacho-
Alonso, 2010a).  The design was a pre- and post-test descriptive study with no 
control group and a follow-up period of 4 and 8 weeks.  As with the study by 
Guiglia et al. (2007) the subjects did not receive any topical steroid treatment for 
three months prior to their involvement in the study.  The outcome measures were 
all related directly to gingival health and plaque control: Gingival Index (Löe and 
Silness, 1967); the modified Quigley and Hein Plaque Index (Turesky et al., 1970); 
and the Community Index of Periodontal Treatment Need (CPITN) (WHO, 1987).  
The interventions were scaling and polishing, oral hygiene instruction based on 
the Bass method of tooth brushing and use of topical triamcinolone mouthrinse 
0.1% for 1 minute, three times daily.  There was no mention of any interdental 
cleaning aids or the type of toothbrush recommended (Lopez-Jornet and Camacho-
Alonso, 2010a).  The focus was on the effectiveness of the advice provided and self-
care performed by the subjects upon plaque scores and gingival health.  Whilst 
gingival health improved and plaque levels decreased, the study did not identify 
what were the most important factors between gingival lichen planus and 
suboptimal plaque control.  For example, was the concomitant use of topical 
corticosteroids the most important factor to facilitate improved plaque control or 
was it the effectiveness of the motivational-behavioural skills protocol?  The focus 
of the previous studies was centered on change in plaque and not the effect that 
plaque control has on the severity or activity of oral mucosal disease or symptoms. 
The studies that have looked at conservative treatment strategies for oral lichen 
planus have used traditional approaches to measure oral disease through the use 
of clinical parameters and indices such as plaque indices, gingival indices, probing 
depths and attachment levels (Silness and Löe, 1964; Löe and Silness, 1967; 
Turesky et al., 1970; WHO, 1987).  These purely clinical measures may 
underestimate the effect that the disease has on a patient (Allen et al., 1999).  The 
symptoms of redness, bleeding on brushing, loosening of affected teeth, and 
persistent bad breath are highly relevant from the patient’s perspective (Ng and 
Leung, 2006) and have the potential to impact adversely on quality of life (Locker, 
1988; Aslund et al., 2008).   
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Where clinical indices are used they should be valid, reliable and reproducible and 
be able to record a small but clinically important change (Lodi et al., 2012).  
Various scoring systems have been proposed to monitor the extent of oral lichen 
planus, but a uniform, standardised approach is not always taken (Sloberg et al., 
1983; Eisen et al., 1990; Silverman et al., 1991; Bagan-Sebastian et al., 1992; 
Thongprasom et al., 1992; Harpenau et al., 1995; Buajeeb et al., 1997; Kaliakatsou 
et al., 2002; Rozycki et al., 2002; Bethke and Reichart, 2005; Piboonniyom et al., 
2005; Escudier et al., 2007; Leao et al., 2008).  Most of the interventional trials and 
studies investigating the effectiveness of treatment of oral lichen planus have 
relatively simple outcome measures.  The efficacy for conservative, topical or 
systemic management for oral lichen planus currently carries little objective 
evidence (Escudier et al., 2007).  Outcome measures have therefore focused upon 
simple subjective scores of pain and disease activity (Lodi et al., 2012).    
The most frequently encountered scoring system for reporting disease activity in 
oral lichen planus research was originally reported in a clinical trial of two topical 
corticosteroids: triamcinolone acetonide 0.1% and fluocinolone acetonide 0.1% 
(Thongprasom et al., 1992).  It recorded disease activity on a 6-point scale relating 
to the severity of the lesion and the area of erosion or erythema present and the 
scoring was undertaken by two clinicians (Table 2) (Thongprasom et al., 1992).  It 
has been used in a number of studies as an outcome for comparing the 
effectiveness of different topical treatments (Campisi et al., 2004; Swift et al., 2005; 
Conrotto et al., 2006; Yoke et al., 2006; Gorouhi et al., 2007; Salazar-Sanchez et al., 
2010). 
Despite proposing this now widely adopted scoring system, few data have been 
presented or any analysis carried out on its validity or reproducibility in the 
original or subsequent papers (Thongprasom et al., 1992; Campisi et al., 2004; 
Conrotto et al., 2006; Gorouhi et al., 2007; Carbone et al., 2009; Salazar-Sanchez et 
al., 2010).   
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Score Description 
0 No lesion, normal mucosa. 
1 Mild white striae, no erythematous areas. 
2 White striae with atrophic area less than 1cm2. 
3 White striae with atrophic area more than 1cm2. 
4 White striae with erosive area less than 1cm2. 
5 White striae with erosive area more than 1cm2. 
 
 
 
Table 2.  Shows a scoring system frequently used as an outcome measure in oral lichen 
planus research (Thongprasom et al., 1992). 
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In the majority of clinical studies the primary outcome measure used accounts for 
the patient’s symptoms by simple pain scales such as the visual analogue scale 
(VAS) (Lundquist et al., 1995; Hegarty et al., 2002a; Campisi et al., 2004; Swift et 
al., 2005; Conrotto et al., 2006; Yoke et al., 2006; Chainani-Wu et al., 2007; 
Cheretakis et al., 2007; Gorouhi et al., 2007; Lodi et al., 2007; Choonhakarn et al., 
2008; Volz et al., 2008; Carbone et al., 2009; Mousavi et al., 2009; Agha-Hosseini et 
al., 2010; Salazar-Sanchez et al., 2010).  
VAS scales are usually administered as a 100mm straight line with the anchors 
being ‘no pain at all’ and ‘worst imaginable pain;’ respondents are asked to place a 
mark on the line that best fits with their current experience of pain (Hjermstad et 
al., 2011).  These are one-dimensional scales that are generally straightforward to 
administer.  The VAS was originally used to record pain intensity in cancer patients 
but has subsequently been used in many different aspects of healthcare (Seymour, 
1982; Breivik et al., 2000; Jensen, 2003; Caraceni et al., 2005; Hjermstad et al., 
2011).  Since pain is a frequently encountered symptom by patients with oral 
lichen planus, VAS scales have been extensively used as an outcome measure.  
When considered for use in a new study, they should be administered in a 
standardised manner so that comparisons can be made between patients but more 
importantly between interventions (Hegarty et al., 2002a; Campisi et al., 2004; 
Swift et al., 2005; Conrotto et al., 2006; Chainani-Wu et al., 2007; Gorouhi et al., 
2007; Lodi et al., 2007; Choonhakarn et al., 2008; Volz et al., 2008; Carbone et al., 
2009; Mousavi et al., 2009; Salazar-Sanchez et al., 2010; Lodi et al., 2012).  
Although VAS scales are the most frequently encountered method of recording 
pain, other subjective assessments of pain exist such as numerical rating scales and 
verbal rating scales.  More complex, validated instruments have also been 
developed with which to assess pain.  These include the full and short form 
versions of the McGill Pain Questionnaire, the Brief Pain Inventory and the 
European Palliative Care Research Collaborative Computerised Symptom 
Assessment (EPCRC).  Their use within a clinical study might be considered if 
change in pain was considered to be the primary outcome measure (Melzack, 
1975; Daut et al., 1983; Melzack, 1987; Kaasa et al., 2008).   
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Two scoring systems have been published specifically to monitor the extent and 
severity of oral lichen planus.  The aim of these instruments was to allow objective 
monitoring of the disease over time and provide an outcome measure by which to 
assess the efficacy of treatments in clinical trials.  The Escudier Index (Table 3) 
records the site of the lesion, its severity and also its activity (Escudier et al., 2007).  
The Malhotra instrument (Table 4) groups anatomical areas together summarising 
the extent of the lesions by allocating more points to widespread disease (Malhotra 
et al., 2008).  The Escudier Index scores each clinical presentation of oral lichen 
planus (reticular, atrophic, desquamative, ulcerative and mixed) with a numerical 
value attributed to the severity of its presentation. The authors combined the 
clinical component with a subjective visual analogue scale (VAS) (0-100) to assess 
pain and assess the correlation between disease activity and pain.  In a subgroup 
(n=23) they repeated the scores following 3 months of treatment with 
betamethasone 500μg mouthwash and conclusions suggest that the disease 
activity and pain scores were sensitive to clinical changes in the disease condition 
(Escudier et al., 2007).   
The clinical application of the indices described by Escudier et al. (2007) and 
Malhotra et al. (2008) were subsequently evaluated and correlated to pain and 
type of presentation (Lopez-Jornet and Camacho-Alonso, 2010b).  They compared 
100 biopsy proven patients with oral lichen planus and examined them according 
to the two scoring methods.  The indices correlated with pain but the Escudier 
Index was more accurately able to differentiate between different forms of the 
disease (reticular vs mixed presentations). 
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Site Site score (a) Severity Score (b) Activity Score (a x b) 
Outer lips (0 or 1) 0-3 0-3 
Inner lips (0 or 1) 0-3 0-3 
Left buccal mucosa (0,1 or 2) 0-3 0-6 
Right buccal mucosa (0,1 or 2) 0-3 0-6 
Gingiva upper right (0 or 1) 0-3 0-3 
Gingiva upper central (0 or 1) 0-3 0-3 
Gingiva upper left distal (0 or 1) 0-3 0-3 
Gingiva lower left distal (0 or 1) 0-3 0-3 
Gingiva lower central (0 or 1) 0-3 0-3 
Gingiva lower right distal (0 or 1) 0-3 0-3 
Dorsum of tongue (0,1 or 2) 0-3 0-6 
Right lateral tongue (0 or 1) 0-3 0-3 
Left lateral tongue (0 or 1) 0-3 0-3 
Floor of mouth (0,1 or 2) 0-3 0-6 
Hard Palate (0,1 or 2) 0-3 0-6 
Soft Palate (0,1 or 2) 0-3 0-6 
Oropharynx (0,1 or 2) 0-3 0-6 
Maximum score 24 51 72 
 
 
 
Table 3.  Shows a scoring system for mucosal disease severity with special reference to 
oral lichen planus (Escudier et al., 2007). 
The mouth is divided into 17 sections and each attributed a score which reflects the extent 
and severity of the lesions  
Site score (a) 0 = no detectable lesion, 1 = evidence of lichen planus, 2 = >50% of buccal 
mucosa, dorsum of tongue, floor of mouth, hard palate, soft palate, or oropharynx affected.   
Severity score (b) 0 = keratosis only, 1 = keratosis with mild erythema (<3mm from 
gingival margin); 2 = marked erythema (e.g. full thickness of gingivae, extensive with 
atrophy or oedema on nonkeratinised mucosa); 3 = ulceration.  
Activity is calculated by multiplying site score by severity score, (a x b).  
The overall score is calculated by the site score + activity score + pain score (0-10) to give 
an overall maximum score of 106.   
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Site Area involved Points allotted 
Right buccal mucosa <50% 1 
 >50% 2 
Left buccal mucosa <50% 1 
 >50% 2 
Tongue back surface <50% 1 
 >50% 2 
Tongue front surface <50% 1 
 >50% 2 
Upper lips Uninvolved 0 
 Involved 1 
Lower lips Uninvolved 0 
 Involved 1 
Gingiva Uninvolved 0 
 Involved 1 
Palate Uninvolved 0 
 Involved 1 
Maximum score  12 
 
 
 
Table 4.  Shows an objective clinical scoring system for assessing oral lichen planus 
(Malhotra et al. 2008). 
It aims to classify and grade the severity of the disease based on the surface area affected.  
The patients are then graded based on the sum score of the points allotted; the severity is 
determined based on the grade where: 
Grade 0 = 0 points; Grade 1 = 1-3 points; Grade 2 = 4-6 points; Grade 3 = 7-12 points 
This is then interpreted by the clinician into three categories of oral lichen planus, mild, moderate 
and severe as follows: 
Mild Moderate Severe 
Asymptomatic grade 1 disease Symptomatic grade 1 disease 
Grade 2 disease 
Grade 3 disease 
Erosive lesion of any grade 
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1.2 Social impact of disease 
The 2012 systematic review into interventions for symptomatic oral lichen planus 
indicated that standardised pain and clinical assessments should feature in future 
studies and any adverse effects of treatment should be transparently reported 
(Lodi et al., 2012).  Pain scores may represent a common symptom but they do not 
capture other symptoms, which may be more pertinent to the patient.  These might 
include an inability to eat, avoidance of particular foods that may exacerbate 
symptoms, chronic soreness, frequency of ulcers, aching, general discomfort or 
even changes in mood.  Over recent years there has been a shift to understand, in a 
greater way, the effect that diseases impact on patients’ lives.  This should lead to 
treatment strategies that address the issues that are important to patients.  
Research has focussed on developing a series of surrogate instruments, often 
questionnaires that aim to assess the consequences of disease in this way.  If these 
are to be used in a clinical setting or as outcome measures within clinical trials, an 
understanding is required of what they are designed to measure, the underpinning 
theory that fed into their development and in practical terms, how they should be 
administered. 
Traditional theoretical models of health do not combine the more personal, human, 
psychosocial aspects of health and disease (George, 1978).  Historically, the 
theoretical, biomedical model of health has regarded the human mind and body 
separately, in some ways almost mechanistically.  This isolation of the body and 
the person ignores the patient’s subjective experiences about health and illness 
with a greater emphasis on disease (Allen, 2003).  The WHO defined health as “a 
complete state of physical, mental, and social well-being and not just the absence 
of disease” (World Health Organisation, 1948).  It is essential that the effectiveness 
of health care interventions must still take the clinical findings into account but is 
inclusive of subjective experiences of health and well-being.  The socio-
environmental model of health has therefore challenged the traditional concept 
and accounts for subjective experiences of health, illness and demonstrates the 
need for a holistic approach to delivering healthcare (Labonte, 1993; Slade et al., 
1998; Allen, 2003).  
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1.2.1 Oral health 
Oral health can be considered to be an integral part of general health.  In clinical 
dentistry and oral health research, there is a tendency to consider the oral cavity 
(and its pathologies) as an isolated anatomical structure (Slade et al., 1998).  
Defining oral health should account for the presence or absence of clinical 
pathology, as well as the social impact that health has on the individual.  Various 
definitions of oral health exist that account the presence and absence of oral 
disease and include an acknowledgement of its social impact.  Dolan defined oral 
health as “a comfortable and functional dentition, which allows individuals to 
continue in their desired social role” (Dolan, 1993).  The UK Department of Health 
defines oral health as “a standard of health of the oral and related tissues which 
enables an individual to eat, speak and socialise without active disease or 
embarrassment and which contributes to general wellbeing” (Health, 2005a). 
Locker (1997) proposed that the focus should be much more at the individual level 
and in particular, the way in which oral conditions and diseases threaten health, 
well-being and quality of life (Locker, 1988; Locker, 1997).  The conceptual model 
of oral health attempts to demonstrate the existence of relationships between oral 
health and impairment, function, discomfort and disability (Figure 6) (Locker, 
1988; Locker, 1997).  These definitions acknowledge the importance of being able 
to maintain social roles in comfort and function (Slade et al., 1998). 
  
 28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  Locker’s theoretical model of oral health.   
This theoretical model, adapted from the original, forms the basis for a number of 
instruments that attempt to measure the social impact of oral conditions on well-being 
and quality of life. 
This model comprises seven dimensions: functional limitation, physical pain, 
psychological discomfort, physical disability, psychological disability, social disability 
(shown collectively as disability) and handicap (Locker, 1988; Locker, 1997).   
  
Disease 
Impairment 
Functional 
limitation 
Discomfort and 
pain 
Disability 
 Physical  
 Psychological 
 Social 
Handicap 
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1.2.2 Quality of life 
The terms health related quality of life (HRQOL) and quality of life (QOL) are often 
used interchangeably to define the social impact of health within medical contexts 
(Gill and Feinstein, 1994; Slade et al., 1998; Carr et al., 2001).  Definitions vary 
from those with a holistic emphasis on the social, emotional and physical well-
being of patients after treatment to others that describe the impact of a person’s 
health on his or her ability to lead a fulfilling life (Greer, 1984; Bullinger et al., 
1993; Carr et al., 2001).  Despite these discrepancies there is a consensus that 
measures addressing quality of life should be patient-centred and reflect patients’ 
perspectives (Leplege and Hunt, 1997; Locker and Allen, 2007).  Some of these 
measures have been criticised for not addressing the concerns of patients and 
more accurately reflecting the views of the authors of the specific instruments 
(Leplege and Hunt, 1997).   
Although diseases may impact on quality of life, this may not be true in every case, 
with healthcare professionals often assuming that poor health relates directly to 
poor quality of life (Allen, 2003).  Measuring health related quality of life within 
interventional studies requires the use of validated, reliable instruments.  Their 
use as an outcome measure within clinical trials has been recommended in 
conjunction with other clinical variables (Allison et al., 1997; Sischo and Broder, 
2011).  Within medicine and dentistry, a multitude of different measures and 
instruments exist that aim to evaluate and measure this concept (Table 5).  These 
are often self- or interviewer-administered questionnaires that have been 
developed and validated to measure differences in quality of life between patients 
at a particular point in time (discriminative instruments) or measure longitudinal 
changes within patients (evaluative instruments) (Guyatt et al., 1993).  
1.2.3 Development of quality of life outcome measures 
A multitude of outcome measures have been developed to measure health related 
quality of life and oral health related quality of life (Table 5).  The methods by 
which these measures have been developed originate from theoretical models and 
concepts or from the use of structured qualitative interviews to develop a series of 
statements or questionnaires. 
Two types of patient-based outcome measures have been developed in an attempt 
to measure quality of life, a generic instrument that provides a summary of health 
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related quality of life and specific instruments that are focussed on problems 
associated with single disease states, patient groups or areas of function (Guyatt et 
al., 1993).  Generic health related quality of life instruments are designed to be 
relevant to anyone and, therefore, can be applied to a range of interventions and 
study populations. Disease targeted measures have been developed to identify 
features of heath related quality of life that are relevant to people with the 
condition, or disease of interest (Guyatt et al., 1986; Vickrey et al., 1992; Hays et al., 
1994; Wu et al., 1997; Mangione et al., 1998).  These measures are potentially 
more sensitive than generic measures to smaller changes over time because they 
are selected to be particularly relevant to a given condition (Hays, 2005a).  Ideally, 
the questionnaires should be developed following in-depth interviews of a sample 
of the population who will ultimately be asked to complete the final questionnaire 
or tool.  These in-depth interviews should reveal a variety of experiences that are 
important to the respondents which can then be assimilated into statements or 
questions (Guyatt et al., 1986).  They must, however, be viewed in the context of 
overall health; in fact some advocate using generic and disease-targeted measures 
in combination to adopt the strengths of both approaches (Guyatt et al., 1986; 
Guyatt et al., 1993).  Significant problems exist with the ever-increasing number of 
quality of life outcome measures (generic and disease targeted) and making 
comparisons between these different instruments as outcome measures even 
when examining the same disease or condition. 
One of the earliest attempts at developing a multidimensional measure of health 
status was the Sickness Impact Profile (SIP).  Its intended use was to measure 
change in the functional abilities of patients (Gilson et al., 1975; Bergner et al., 
1981).  The tool came under criticism for being too long (136 items) in comparison 
with the more widely accepted short forms (SF) comprising 12 (SF-12), 24 (Roland 
Scale) and 36 (SF-36) questions which were much easier to administer (Roland 
and Morris, 1983; Ware and Sherbourne, 1992; Slade et al., 1998).  Generic 
measures such as this have been used widely to compare the relative burden of 
disease between groups of patients. 
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Instrument  Author Dimensions  
Social Impacts of Dental Disease Cushing et al., 1986 Eating restrictions, communication restrictions, pain, discomfort and aesthetic 
dissatisfaction. 
General (Geriatric) Oral Health Assessment 
Index (GOHAI) 
Atchison and Dolan, 1990 
 
Physical function (including eating, speech and swallowing), Psychosocial (including 
worry or concern about oral health, dissatisfaction with appearance, self-consciousness 
about oral health and avoidance of social contacts because of oral problems), Pain and 
discomfort (including the use of medication to relieve pain or discomfort from the 
mouth). 
Dental Impact Profile (DIP) Strauss and Hunt, 1993 
 
Eating (eating, chewing, biting, enjoyment of eating, food choice, tasting), Health/Well-
being (feeling comfortable, enjoyment of life, general happiness, general health, appetite, 
weight, living a long life), Social relations (facial appearance to self and others, smiling 
and laughing, moods, speech, breath, confidence around others attendance at activities, 
success at work), Romance (social life, romantic relationships, having sex appeal, 
kissing). 
Oral Health Impact Profile (OHIP) Slade and Spencer, 1994 
 
Functional limitation (difficulty chewing), physical pain (sensitivity of teeth), 
psychological discomfort (self-consciousness), physical disability (changes to diet), 
social disability (avoiding social interaction), handicap (being unable to work 
productively). 
Subjective Oral Health Status Indicators 
(SOHSI)  
Locker and Miller, 1994 Ability to chew, ability to speak, oral and facial pain symptoms, other oral symptoms, 
eating impact scale, activities of daily living impact scale, worry/concern impact scale. 
Oral Impacts on Daily Performance (OIDP)  Adulyanon et al., 1996 Performance in eating, speaking, oral hygiene, sleeping, appearance, emotion. 
Oral Health Related Quality of life (OHQOL) Kressin et al., 1996 Effect on daily activities such as work or hobbies, affected social activities with family 
friends or co-workers, avoids conversations with people because of appearance. 
Dental Impact on Daily Living (DIDL) Leao and Sheiham, 1996 Comfort (related to bleeding gums and food packing), Appearance (consisting of self-
image, pain, performance (the ability to carry out daily activities and to interact with 
people, eating restriction (relating to difficulties in biting and chewing). 
Oral Health Quality of life Inventory (OH-QoL) Cornell et al., 1997  Importance and satisfaction of oral health and functional status. 
Rand Dental Questions Dolan and Gooch, 1997 Pain, worry or concern, reduced social interactions. 
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OHRQoL for Dental Hygiene Gadbury-Amyot et al., 1999 Symptom status, functional status, health perceptions. 
Orthognathic QoL Questionnaire Cunningham et al., 2000 Social aspects of deformity, facial aesthetics, function, awareness of facial deformity. 
OHQoL-UK McGrath and Bedi, 2001 Physical, social, psychological.  
Child Oral Health Quality of life Questionnaire 
(COHQoL) 
Jokovic et al., 2002 Oral symptoms, functional limitations, emotional well-being, social well-being (peer 
interaction, schooling and leisure activities). 
Child OIDP Gherunpong et al., 2004 Eating, speaking, cleaning mouth, doing activity, sleeping, emotion, smiling, emotion, 
study, social contact. 
Liverpool Oral Rehabilitation Questionnaire Pace-Balzan et al., 2004 Oral Function, dentures/denture satisfaction. 
Surgical Orthodontic Outcome Questionnaire 
(SOOQ) 
Locker et al., 2007 Function 1 (issues before surgery), function 2 (issues after surgery), dental aesthetics, 
facial aesthetics, emotional and social well-being. 
Outcomes of Prosthodontic Treatment Leles et al., 2008 Benefits, risks, perceived consequences of treatment or no treatment. 
Chronic Oral Mucosal Disease Questionnaire 
(COMDQ) 
Ni Riordain et al., 2011 Pain and functional limitation, medication and treatment, social and emotional, patient 
support. 
 
 
Table 5.  Shows the measures of oral health related quality of life, adapted from Locker and Allen (2007).   
Many shortened versions of these questionnaires have also been published and the questionnaires translated into different languages (Locker and Allen, 
2007). 
 33 
 
1.3 Oral health related quality of life instruments 
The dental profession and the general population have markedly different 
perceptions about what the outcomes of dental treatment should be (Kay and 
Blinkhorn, 1996).  There may be consequences of oral disease that go far beyond 
the clinical presentation including alterations to self-esteem; social interaction; 
diet; education and job performance (Allen et al., 1999; Sischo and Broder, 2011).  
The term ‘oral health related quality of life’ under the umbrella of patient-based 
outcomes, has replaced earlier terms like socio-dental indicators, oral health 
status, subjective oral health or social impacts of oral disease that were used to 
describe factors that drew on patients’ perspectives about their oral health (Locker 
and Allen, 2007; Tsakos et al., 2012).  Research followed that then attempted to 
understand the interrelationships between traditional clinical findings, the 
presence or absence of disease and patient-centered, self-reported health (Gift and 
Atchison, 1995; Sischo and Broder, 2011).  
The generic Sickness Impact Profile has been used to assess the social impact of 
oral and dental disease including in temporomandibular joint dysfunction, 
periodontitis, prosthodontics and those presenting for routine recall (Slade et al., 
1998).  Whilst it was used with some success where the impact of the oral 
conditions was expected to be high, the lack of sensitivity to changes in oral 
functional status have led to it (and other generic methods) being infrequently 
used to evaluate the social impact of oral conditions (Reisine, 1988; Reisine et al., 
1989; Reisine and Weber, 1989; Slade, 1998).   
Following the initial proposal that social indicators should be developed and used 
within dentistry, Reisine and co-workers were among the first to use a multitude 
of validated scales to determine the impact of dental conditions on quality of life 
(Cohen and Jago, 1976; Reisine, 1981; Reisine et al., 1989).  There are now a 
significant number of instruments that exist and are dedicated to assessing oral 
health related quality of life (Table 5) (Locker and Allen, 2007).   
The aim of these measures, usually questionnaires, is to assess the consequences 
of impaired oral health from the patient’s perspective, attempting to measure the 
impact of oral health on quality of life (Birch and Ismail, 2002; Ng and Leung, 
2006).  Many of these have been used in population surveys or clinical trials to 
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measure the social impact of oral disorders (Locker and Allen, 2007).  It is 
important to understand what each of the evaluative instruments is trying to 
measure and to distinguish between a measure of oral health status and a measure 
of oral health related quality of life.  In a trial or study the evaluative tool chosen 
must be relevant to the population being examined.  Ideally it should be developed 
from responses of a similar cohort of people to those who will ultimately complete 
the questionnaires or surveys (Guyatt et al., 1986; Locker and Allen, 2007).  
Evaluating the large number of health related quality of life and oral health related 
quality of life measures that have been developed requires a systematic approach 
to assess their applicability, reliability and validity for use in research (Gill and 
Feinstein, 1994; Guyatt and Cook, 1994; Locker and Allen, 2007).   
If any of the existing patient-based outcome measures are to be utilised, they 
should attempt to assess the broader meaning and context of the social effects of 
oral health, particularly in relation to overall health (Locker and Allen, 2007; 
Tsakos et al., 2012).  These authors also suggest that this may be partly achieved 
through the concurrent use of global ratings which can accommodate individual 
meaning and significance of disease-related events (Locker and Allen, 2007).  Oral 
health related quality of life measures have been utilised in clinical research 
studies as primary and secondary outcome measures, in epidemiological studies 
and health services research to identify trends in oral health (Sischo and Broder, 
2011; Tsakos et al., 2012).  It is the outcomes of population-based studies that are 
most likely to influence healthcare promotion and provision; identifying specific 
groups which are likely to have low oral health related quality of life and may 
benefit from tailored oral health programmes (Sischo and Broder, 2011).   
Clinical studies using patient-based outcomes have evaluated the effectiveness of 
interventions on quality of life; despite their existence there are a limited number 
in oral medicine and fewer still related to oral lichen planus (Hegarty et al., 2002a; 
Hegarty et al., 2002b; McGrath et al., 2003b; Gorouhi et al., 2007; Heffernan et al., 
2007; Lopez-Jornet et al., 2009; Ni Riordain and McCreary, 2010).  Generic, oral 
specific and condition specific quality of life outcome measures have been used in 
an attempt to calculate the degree that conditions presenting to oral medicine 
clinics which include oral lichen planus, Behçet’s, recurrent aphthous ulceration, 
pemphigus vulgaris and burning mouth syndrome, impact on quality of life 
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(Hegarty et al., 2002b; McGrath et al., 2003b; Paradisi et al., 2009; Tabolli et al., 
2009; Ni Riordain and McCreary, 2010; Ni Riordain and McCreary, 2012).  The 
generic SF-36, EuroQol, and Hospital Anxiety and Depression (HAD) scales have 
been used separately and in conjunction with other generic health related quality 
of life indices in studies of oral mucosal disease (Paradisi et al., 2009; Tabolli et al., 
2009).  More frequently, they have been used in conjunction with the oral health 
related quality of life questionnaires such as the full and shortened versions of the 
oral health impact profile (Lopez-Jornet et al., 2009; Salazar-Sanchez et al., 2010; 
Liu et al., 2012).   The most frequently utilised measures are the Oral Health Impact 
Profile (OHIP-49), its shortened version (OHIP-14) and the OHQoL-UK.  More 
recently a condition specific quality of life questionnaire has been developed for 
chronic oral mucosal diseases (COMDQ) (Hegarty et al., 2002a; McGrath et al., 
2003a; McGrath et al., 2003b; Lopez-Jornet et al., 2009; Salazar-Sanchez et al., 
2010; Ni Riordain et al., 2011; Liu et al., 2012; Ni Riordain and McCreary, 2012). 
In oral lichen planus research, a robust approach to identifying and using 
appropriate outcome measures has not been seen, some have used multiple 
measures of oral health related quality of life (OHQoL-UK and OHIP-14), multiple 
methods of assessing pain (McGill Pain Questionnaire and VAS scales) alongside 
clinical indices (Hegarty et al., 2002a).  Few studies that use quality of life 
outcomes measures in oral medicine research have attempted to contextualise the 
findings with change in size or severity of oral lesions (Hegarty et al., 2002a).  
Those that have, more appropriately, used a single oral health related quality of life 
measure in combination with a global scale and visual analogue scales to provide 
more context and meaning of the quality of life outcome measure (McGrath and 
Bedi, 2003). 
If a new quality of life instrument is to be developed or one chosen from an 
existing array of instruments (Table 5) careful consideration should be given to 
examine the characteristics of the individual instruments and whether they are the 
most applicable instruments to use.  The psychometric properties of a measure 
should reveal reliability, validity and the instrument should be relatively 
straightforward to use (Guyatt et al., 1987).  The authors of an instrument should 
be able to demonstrate that it measures the same outcome consistently; test-retest 
reliability is one such evaluation and should be investigated during the 
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development of a questionnaire (Kirshner and Guyatt, 1985). Reliability is further 
complicated by changes that may have occurred between administrations of the 
questionnaires over time, therefore reliability is key in longitudinal studies (Carr et 
al., 2001; Hays, 2005b).  Validity is the degree to which the instrument assesses 
what it is intended to measure.  This differs to the concept of reliability, whilst a 
measure may always provide identical scores for the same patient, it may be 
consistently measuring the wrong outcome.  The evidence for an instrument’s 
validity is continuous and a patient-based outcome measure must, therefore, be 
shown to be both valid and reliable.  When identifying which measure to use, the 
validity of that measure for a particular group or population must be evaluated 
(Hays, 2005b).  Although a measure may be reliable and valid, it may not have the 
ability to capture small but meaningful changes over time.  Responsiveness, 
therefore, ultimately reflects any underlying change (Guyatt et al., 1987; Hadorn 
and Hays, 1991).  If validity, reliability and responsiveness have been 
demonstrated for a measure, comparisons can be made between clinical status and 
quality of life (Chambers et al., 1987).  
In quality of life research, investigators need to have confidence that a difference, 
where one exists, will be detected (Guyatt et al., 1993).  Responsiveness is related 
to the magnitude of the difference in score in patients who have improved or 
deteriorated (the signal) and the extent to which patients who have not changed 
provide the same scores (the noise).  Responsiveness to change is most frequently 
assessed using effect size, standard response mean and/or a responsiveness 
statistic.  With respect to the magnitude of change in response to the intervention: 
an effect size of 0.2 represents a small change, 0.5 a medium change and 0.8 a large 
change (Cohen, 1992). Whilst this may be statistically significant, interpreting the 
clinical significance can be difficult.  Within quality of life research, the term 
minimally important clinical difference has been used to contextualise scores 
produced by quality of life measures (Jaeschke et al., 1989; Juniper et al., 1994; 
Locker et al., 2004; Allen et al., 2009; Tsakos et al., 2012).  This also allows an a 
priori calculation of the sample size needed to detect a certain effect size for a 
particular measure (Hays, 2005b).  Assessments of minimally important difference 
are particularly important where patient-based outcomes are the sole outcome 
measure and there are no other (clinical) anchors.  Of the more commonly used 
measures of oral health related quality of life, the minimally important difference 
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for the OHIP-14 was estimated to be 5 points, the OHIP-20 between 7-10 points, 
the OHIP-49, 6 points and the OIDP, 5 points (Locker et al., 2004; Allen et al., 2009; 
John et al., 2009).  
1.3.1 The Oral Health Impact Profile  
The Oral Heath Impact Profile (OHIP) was developed with the aim of providing a 
comprehensive measure of self-reported dysfunction, discomfort and disability 
attributed to oral conditions (Slade and Spencer, 1994; Slade, 1997).  It has been 
described as the most comprehensive measure of the impact of oral conditions on 
quality of life (Allen et al., 1999).  The OHIP is the most widely used measures of 
oral health related quality of life that has been shown to be valid and reliable.  It 
has also been translated into a number of languages and used successfully as 
primary and secondary outcome measures in clinical trials (Allen and Locker, 
2002; Hegarty et al., 2002a; John et al., 2002; Allen and McMillan, 2003; Ekanayake 
and Perera, 2003; Ikebe et al., 2004; John et al., 2004b; Kushnir et al., 2004; 
Larsson et al., 2004; Heydecke et al., 2005; Wolfart et al., 2005; Allen et al., 2006; 
Pires et al., 2006; Al-Jundi et al., 2007; Barer et al., 2007; Heffernan et al., 2007; 
Ozcelik et al., 2007; Saub et al., 2007; Hassel et al., 2008; Rener-Sitar et al., 2008; 
Wostmann et al., 2008; Linsen et al., 2009). Originally developed for measuring the 
impact of oral disorders in epidemiological research, OHIP was based on the seven 
conceptual dimensions of oral health proposed by Locker (Locker, 1988): 
 Functional limitation (for example difficulty chewing); 
 Physical pain (for example sensitivity of teeth); 
 Psychological discomfort (for example self-consciousness); 
 Physical disability (for example reduced ability to concentrate); 
 Social Disability (for example avoiding social interaction); 
 Handicap (for example being unable to work properly). 
The OHIP consists of a 49-point questionnaire (Appendix 1).  Initially statements 
rather than questions were produced following structured interviews using open-
ended questions.  The subjects were drawn from a convenience sample of 64 adult 
dental patients in Adelaide, Australia.  535 distinct statements were initially 
scrutinised resulting in 46 individual statements.  These were then classified into 
the seven conceptual dimensions (Slade and Spencer, 1994).  Three further 
statements were added to the handicap dimension before all 49 statements were 
rephrased as questions (Hunt et al., 1985).  The method by which the items were 
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selected reflected their fit with Locker’s conceptual framework.  As such the 
selection was expert-centred rather than accounting for the relative importance to 
the patients from which they were initially developed.  The questionnaire was not 
designed to measure any positive aspects of health and relates to general oral 
conditions rather than specific oral disorders or syndromes.  OHIP attempts to 
measure the burden of illness and provides information on the frequency rather 
than severity of the impact of oral health. 
Respondents to the original questionnaire were provided with a 5-point Likert 
scale to rate the frequency that each problem was experienced over a reference 
period of twelve months. Responses on the 5-point Likert scale were coded 0 
(never or not applicable), 1 (hardly ever), 2 (occasionally), 3 (fairly often), 4 (very 
often).  The qualitative nature of the responses can then be quantified and the data 
interpreted and analysed.  Frequency can also be ascertained by calculating the 
sum of the impacts (Slade et al., 1998).  In the original study, each question was 
also weighted according to Thurlstone’s method of paired comparisons 
(Thurlstone, 1927).  Subsequent studies have suggested that simple scoring 
methods were as good as more sophisticated ones despite item weights improving 
the performance of OHIP (Allen and Locker, 1997).  The reliability of OHIP to 
capture oral health related quality of life has been assessed on a number of 
occasions and in subsequent translations of the measure (John et al., 2002; Wong 
et al., 2002; Larsson et al., 2004; Szentpetery et al., 2006; Al-Jundi et al., 2007; Bae 
et al., 2007; Saub et al., 2007; Souza et al., 2007; Yamazaki et al., 2007). 
Shortened Versions of the OHIP 
There are a number of shortened versions of the Oral Health Impact Profile (OHIP) 
for use in different settings and for different patient populations.  The original 
short version (Slade, 1997) used regression analysis to derive a 14-question 
version (OHIP-14) from the original OHIP instrument.  Locker and Allen (2002) 
derived their shortened version of OHIP using the item impact method, which only 
had two items in common with the version published by Slade (1997).  The 
regression short form is considered to be better when the aim is to discriminate 
while the impact short form is preferable when describing the oral health-related 
quality of life of populations or when working to detect a change (Slade, 1997; 
Locker and Allen, 2002).   
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1.3.2 Practicalities of administration 
Questionnaire based tools can be either self-administered or managed by a trained 
interviewer; the method of administration has the potential to influence the results 
and completion rates of the questionnaire.  Interviewer administration is resource 
intensive but ensures compliance, decreases errors and decreases missing items 
(Guyatt et al., 1993).  Self-administration is much less expensive, but increases the 
number of missing responses and missing subjects (Guyatt et al., 1993).  In a study 
by Robinson and co-workers (2001) the completion rate of OHIP-14 and Oral 
Impacts on Daily Performance (OIDP) questionnaires were similar in interview 
format although in questionnaire format, usable data were provided on 92.9% of 
the OHIP-14 responses and only in 86.5% of OIDP responses. They concluded that 
the method of administration did not affect the psychometric properties of the 
OHIP-14 and OIDP questionnaires (Robinson et al., 2001).  In the medical field 
both self- and interviewer-administered questionnaires yielded similar results 
demonstrating the ability to discriminate between individuals. Self-administered 
questionnaires, however, were associated with greater health related quality of life 
impairment and may be more appropriate to evaluate the true impact of disease 
(Cook et al., 1993).   
The majority of the measures of oral health related quality of life have good 
psychometric properties, in addition they have been shown to be reliable, valid 
and responsive to clinical change (Locker and Allen, 2002).   Although interviewer-
administered questionnaires may increase response rates, Locker and Allen 
proposed that longer scales are more likely to be subject to item non-response, 
giving rise to problems of how to manage missing data.  The use of these 
instruments in some clinical settings and population-based surveys may be limited 
by questionnaire length and the complexities involved in completing the 
instruments (Locker and Allen, 2002).  The distillation of measurements to form 
reliable shortened questionnaires has been a goal for clinical investigators to 
improve the efficiency of patient and clinical time (Ware and Sherbourne, 1992; 
Guyatt et al., 1993; Coste et al., 1997; Guillemin et al., 1997; Allen and Locker, 
2002).  One approach to this problem has been to develop a long instrument, test it 
and use its performance to choose key questions to include in a shorter index.  This 
approach has been used to create shorter questionnaires based on the lengthy 
instruments from the Medical Outcomes Survey and to develop shortened versions 
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of the Oral Health Impact Profile (OHIP) (Stewart et al., 1988; Slade, 1997; Allen 
and Locker, 2002; Locker and Allen, 2002; Broder et al., 2007; Durham et al., 
2011).   
Questionnaires evaluating subjective oral health status use a reference period of 
time in which respondents are asked to recall their experiences of oral health 
(Sutinen et al., 2007).  The length of the reference period may have marked 
influence on the responses obtained. The Oral Heath Impact Profile has a 
standardised reference period of 12 months, however for some studies this 
reference period is not practical.  Investigations into the reference period of this 
measure have shown that for use in population surveys the shortening of this 
reference period did not seem to influence the responses (Sutinen et al., 2007).  
Other questionnaires have successfully used different reference periods: for 
example 1 or 6 months instead of 12 months (John et al., 2004a; Allen et al., 2006). 
Item Weights 
The scoring methods used by some quality of life instruments simply involve 
summing up the item scores with each given equal weighting (Atchison and Dolan, 
1990).  It has been proposed that some items within questionnaires may be more 
important to the underlying concept of oral health related quality of life than 
others (McGrath and Bedi, 1999; McGrath and Bedi, 2004).  As such, other 
instruments use a ‘weighting’ scoring system that incorporates an assessment of 
the importance or severity of oral health on quality of life (Leao and Sheiham, 
1995; Slade, 1998; Sheiham et al., 2001; McGrath and Bedi, 2004).  Different 
questionnaires have used various methods to weight questionnaires; some weight 
the measure at an individual level, others at the domain level (McGrath and Bedi, 
2004).  Some have also argued that weighting questions in this way is not 
necessary and has little or no advantage over using un-weighted, summing of the 
response scores (Trauer and Mackinnon, 2001; McGrath and Bedi, 2004).   
The Oral Health Impact Profile and the OHQoL-UK(W)© were both found to have 
similar psychometric properties when used in weighted or unweighted forms and 
their use yielded no additional benefit (Allen and Locker, 1997; McGrath and Bedi, 
2004).  McGrath and Bedi (2004) did however discuss the need for further work 
on item weighting when specific clinical conditions are assessed or in longitudinal 
studies (McGrath and Bedi, 2004). 
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1.3.3 Global self-rating 
The concept of self-rated health is not assessed in all generic or disease-specific 
instruments.  Asking individuals to rate their health on a scale ranging from 
excellent to poor has become standard practice in population-based health surveys 
and health evaluations (Locker et al., 2005). It has been argued that all health 
related quality of life instruments should include at least one simple global 
question about overall health and/or overall quality of life (Bjorner et al., 2004).  It 
has been proposed that in this way, respondents can weight together different 
aspects of their health status emphasising those aspects of health that they 
consider to be most relevant (Gill and Feinstein, 1994).  Single item ratings can be 
as useful as more complex, multi-item scales and indices in health status 
assessment (Ware et al., 1993; Locker et al., 2005).  One study looked at the 
relationship between global self-rating, oral health related quality of life and self-
reported treatment need.  They identified that the global rating varied over time 
and that the changes were consistent with those measured by both these tools 
(Dolan et al., 1998).  Others have gone one stage further to suggest that if only one 
question was allowed to measure health status, the rating of health as excellent, 
very good, good, poor or fair would be a good candidate (Bjorner et al., 2004).   
Global self-ratings are also used to test the construct validity of patient-based 
measures of health related quality of life (Locker et al., 2005).  There is also 
evidence that these ratings are powerful predictors of functional decline and 
survival and are predictors of the use of health care services (Evashwick et al., 
1984; Idler and Benyamini, 1997; Shadbolt et al., 2002; Locker et al., 2005).  Others 
have criticised the use of these measures as being less precise than more extensive 
multi-item instruments, if used as the only outcome measure, with the lack of 
precision and sensitivity being a potential disadvantage in small trials (McHorney 
et al., 1992). 
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1.4 Biomarkers of inflammation 
Periodontal diseases arise from inflammation of the supporting structures of the 
teeth and can be subdivided into two basic categories, gingivitis and periodontitis. 
Gingivitis is more superficial inflammation confined to the gingival tissues and is 
reversible with effective, simple interventions such as tailored oral hygiene advice 
and professional prophylaxis (Armitage, 1999).  Periodontitis is irreversible and 
affects the deeper structures leading to progressive breakdown of the periodontal 
ligament and alveolar bone (Savage et al., 2009).  Bacterial infection is the primary 
causative agent of both gingivitis and periodontitis with certain species being 
associated with more destructive disease.  The presence of gingivitis has been 
demonstrated in animal studies to be a precursor to periodontitis, however 
progression in human subjects is not always linear (Heijl et al., 1976; Socransky et 
al., 1984; Löe et al., 1986).  There are differences between individuals in their 
susceptibility to periodontal diseases, which may be due to variations in 
environmental exposures or genetic factors or a combination of both (Page and 
Kornman, 1997).  
The most widely utilised methods for diagnosing diseases affecting the 
periodontium and assessing outcomes in trials are clinical signs such as tissue 
colour and contour, presence or absence of bleeding on probing, gingival recession, 
probing pocket depths and attachment levels, suppuration, tooth mobility and 
radiographic assessment of bone loss (Lindhe et al., 1986; Buduneli and Kinane, 
2011).  Some of these are subjective but those that can be quantified, such as 
pocket probing depths, are subject to variations in reproducibility.  These all 
provide retrospective assessments eliciting evidence of past disease progress; they 
give very little information regarding susceptibility of future disease.   
Biological indicators or biomarkers are biochemical, genetic or molecular 
substances that are indicative of a clinical disease or pathology.  They can provide 
a more objective assessment by which to diagnose inflammatory disease and 
predict or assess future risk (Buduneli and Kinane, 2011).  Periodontal diseases 
have complex aetiology and one single marker is unlikely to address all the issues 
relating to diagnosis and prognosis; the use of a combination of tests may provide 
a better understanding of these complex interactions in order to implement timely 
preventive strategies or initiate targeted therapy (Buduneli and Kinane, 2011).  
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Molecules in gingival crevicular fluid (GCF) and saliva as well as in blood, serum or 
plasma have been examined to determine a sensitive and specific marker for 
periodontal disease susceptibility (Buduneli and Kinane, 2011). 
The site-specific nature of periodontal disease led to many research studies 
focussing on collecting biomarkers from sites that were easily accessible such as 
the gingival sulcus by collecting GCF.  GCF has become the medium of choice 
through which inflammatory biomarkers are collected and analysed.  Biomarkers 
have been used in periodontal research as objective outcome measures in clinical 
trials (Heasman et al., 1993; Gamonal et al., 2000; Offenbacher et al., 2007; 
Offenbacher et al., 2010).  GCF is a serum transudate that is described as being 
enriched with microbial and host products that arise from the dynamics of the 
host-biofilm interaction and is therefore the ideal medium to look at gingival 
inflammation (Offenbacher et al., 2010).  It originates from the gingival plexus of 
blood vessels in the gingival connective tissue close to the epithelial lining of the 
gingival sulcus and provides a good representation of tissue and serum 
concentrations of inflammatory mediators (Armitage, 2004; Buduneli and Kinane, 
2011).  There have been over 90 components of GCF that have been evaluated as 
possible biomarkers for diagnosis of periodontal disease; some are host-derived 
enzymes and their inhibitors, inflammatory mediators and by-products of tissue 
destruction (Loos and Tjoa, 2005; Lamster and Ahlo, 2007).   
Whole saliva is easily collected and contains exocrine gland secretions, GCF, 
dietary and oral plaque.  It represents a pooled sample with contributions from all 
periodontal sites and provides an overall assessment not a site specific analysis 
(Silverman et al., 1985).  Several mediators of chronic inflammation and tissue 
destruction have been detected in whole saliva however in elderly patients 
collecting saliva samples may prove challenging due to hypo-salivation (Kaufman 
and Lamster, 2000; Buduneli and Kinane, 2011).   
Pro-inflammatory cytokines also play a significant role in the pathogenesis of both 
hard and soft tissue destruction, interleukin-1α (IL-1α), interleukin 1-β (IL-1β), 
interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-18 (IL-18) and tissue necrosis 
factor-α (TNF-α) are all expressed in human gingiva.  Increased levels of several of 
these mediators of inflammation, (IL-1α, IL-1β, IL-6, IL-8, IL-18) have been 
reported in sites exhibiting signs of gingivitis and periodontitis (Offenbacher et al., 
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2007; Toker et al., 2008; Pradeep et al., 2009; Teles et al., 2009; Fitzsimmons et al., 
2010; Offenbacher et al., 2010).  Matrix metalloproteinases (MMPs) are considered 
to be modifiers of host response and in pathological tissue destruction, in 
particular degradation of extracellular matrix and basement membrane (Buduneli 
and Kinane, 2011).  They are divided into five groups: collagenases (MMP-1, MMP-
8, MMP-13); gelatinases (MMP-2, MMP-9); stromelysins (MMP-3, MMP-10, MMP-
11); and membrane type (MMP-14, MMP-15, MMP-16, MMP-17).  It is the 
interrelationships and interactions between the cell-cell and cell-matrix involving 
enzyme production, activators, inhibitors, cytokines and growth factors that 
regulates connective tissue remodelling and connective tissue matrix destruction 
(Reynolds and Meikle, 1997; Buduneli and Kinane, 2011).  The tissue inhibitors of 
MMPs (TIMPs) control the MMPs that are produced by fibroblasts, macrophages, 
neutrophils and epithelial cells (Buduneli et al., 2007).  Experimental gingivitis in 
vivo studies have demonstrated the presence of markers of neutrophil activation 
and recruitment, such as interleukin-8 (IL-8) and neutrophil degranulation such as 
β-glucuronidase, elastase and other matrix-metalloproteinases (MMPs) (Heasman 
et al., 1993; Lamster et al., 1994; Soder et al., 2002; Offenbacher et al., 2010).  
Clinical diagnoses have correlated with a change in MMP levels in GCF, saliva and 
blood samples (serum or plasma) (Alpagot et al., 2001; Kinane et al., 2003; Alfant 
et al., 2008; Passoja et al., 2008).  Changes in biomarkers as outcome measures 
within longitudinal studies and prospective clinical trials have also been assessed 
(Pozo et al., 2005; Chapple et al., 2007; Golub et al., 2008; Toker et al., 2008; Gapski 
et al., 2009; Offenbacher et al., 2010).   
The use of protein-based suspension bead multiplex immunoassays allows the 
simultaneous analysis of multiple inflammatory mediators. In an experimental 
gingivitis study, 16 separate inflammatory mediators were analysed that were 
associated with gingivitis (Offenbacher et al., 2007).   
As well as gingival crevicular fluid, the accessibility of the periodontal pocket also 
allows for samples of supra- and sub-gingival plaque to be collected and analysed 
for the presence or absence of certain bacterial species associated with healthy 
periodontium, gingivitis and periodontitis.  There are more than 700 bacterial 
species that have been detected in the oral environment.  Some are considered 
important for maintaining oral health whereas others are implicated in the 
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pathogenesis of oral diseases such as dental caries and periodontitis (Socransky et 
al., 2002; Hojo et al., 2009).  Some bacteria, such as Aggregatibacter 
actinomycetemcomitans, Porphyromonas gingivalis, Treponema denticola, Tanerella 
forsythia are specifically associated with more destructive periodontal diseases 
(Socransky et al., 1998).  They are supplied by the wide availability of nutrients 
from saliva, GCF, food debris as well as the metabolites produced by other 
organisms.  The gingival sulcus is an ideal environment for bacteria to thrive (Hojo 
et al., 2009). Bacteria do not live in isolation but exist in complex biofilms, and 
since some biofilms exist in health it has been proposed that certain commensal 
bacteria may have a protective role in excluding pathogenic bacteria although, the 
role of individual species within the microbiological ecology and their interactions 
with the host are not particularly well understood (Kumar et al., 2006; Hojo et al., 
2009).  Bacteria within a dental biofilm will interact with one another co-
operatively and competitively with other species, the metabolites that they 
produce will also impact on the host and the type of response that is produced 
(Hojo et al., 2009).  Bacterial culturing is considered to be the classical diagnostic 
method to study bacterial species in dental plaque; it is also the standard against 
which new technologies should be measured against (Lau et al., 2004; D’Ercole et 
al., 2008). 
Cultivation techniques and subsequently nucleic acid amplification methods such 
as PCR have been used to target bacteria obtained from small sample volumes 
(MacFarlane et al., 1988; Listgarten et al., 1991; Machtei et al., 1997; Tanner et al., 
1998; Kumar et al., 2006).  Some bacteria, in particular anaerobic bacteria, are 
sometimes difficult to culture and analyse.  Advances in technology, and in 
particular the cloning and sequencing of bacterial 16s rRNA genes, has allowed 
many previously uncultured bacteria to be identified (Kumar et al., 2006). 
Immunoassays target and identify specific bacteria by using monoclonal or 
polyclonal antibodies against specific bacterial antigens.  Methods include the 
enzyme linked immunosorbent assay (ELISA), multiplex flow cytometry, and direct 
or indirect immunofluorescent microscopy.  
1.4.1 Potential biomarkers in oral lichen planus 
Pilot studies have looked at levels of biomarkers in patients with oral lichen planus 
(Thornhill, 2001; Khan et al., 2003; Rhodus et al., 2005; Rhodus et al., 2007; Zhang 
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et al., 2008).  These studies have used whole unstimulated saliva, a mixture of 
saliva and isotonic saline rinse, lesion tissue transudate, blood serum, biopsy tissue 
samples to measure different cytokines and MMPs (Khan et al., 2003; Rhodus et al., 
2005; Rhodus et al., 2007; Zhang et al., 2008).  Many of the cytokines that have 
been investigated within the periodontal disease model are not specific and are 
part of the innate immune response; it is likely that they will have a role in lichen 
planus.  Cytokine release is fundamental to functioning T-cells; in particular IL-1 
and IL-1 are involved in T-cell activation and will be produced in response to a 
variety of stimuli.  IL-2 is considered to be a potent T-cell growth factor and 
involved in long-term proliferation of activated t-cells and it is this pathway that is 
inhibited in immunosuppressive treatments (Simark-Mattsson et al., 1999; Zhao et 
al., 2002).  T-Cells, neutrophils, basophils and eosinophils are chemically attracted 
to areas by gradients set up by the CXC chemokines (e.g. IL-8) and the CC cytokines 
(e.g. MIP-1, MIP-1, RANTES) (Baggiolini et al., 1997; Zlotnik and Yoshie, 2000; 
Little et al., 2003).   
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1.5 Health Economics 
Within healthcare there are finite resources, so careful consideration should 
therefore be given to the most appropriate treatment options to provide (Heasman 
et al., 2011).  Within dentistry, cost-effectiveness is recognised as an important 
aspect of evaluating dental treatment and interventions (Antczak-Bouckoms and 
Weinstein, 1987; Braegger, 2005; Pennington et al., 2009a; Pennington et al., 
2009b).  Consideration should be given to which treatments are: effective (capable 
of achieving objective); available (does it reach those who need it?); efficient (is it 
the best use of time and resource?); and efficacious (has the capacity for beneficial 
change) (Drummond et al., 2005).  The focus of an economic evaluation is 
concerned with comparing costs and benefits, but very few of these evaluations 
have been carried out in dentistry, and even fewer in oral medicine (van der Meij 
et al., 2002; Pennington et al., 2009a; Pennington et al., 2009b).  A treatment that is 
cost-effective is one for which the benefits of that treatment exceed the costs 
(Pennington et al., 2009a; Pennington et al., 2009b).  In dentistry, the current 
literature has investigated: caries prevention; third molar removal; root canal 
treatment vs dental implants; local and systemic antibiotics for management of 
periodontal disease; and supportive periodontal care.  The majority of dentistry 
within the UK is provided through the NHS and patients will normally pay towards 
the cost of their treatment.  When examining health economics, the costs should 
also be evaluated from the patients’ perspectives, which may include loss of 
earnings, time travelled to and from the appointment and out of pocket expenses 
for travel costs (Gaunt et al., 2008).  There are various types of economic 
evaluation: the cost-benefit analysis, cost-effectiveness analysis and cost-utility 
analysis which differ in the way they value benefits (Pennington et al., 2009a).  A 
cost-benefit analysis attaches a monetary value to the benefit, in contrast to the 
cost-utility analysis which uses a quality of life measure such as the generic quality 
adjusted life year (QALY) or the oral health impact profile.  A cost-effectiveness 
analysis compares outcomes on an appropriate quantitative scale (Gold et al., 
1996).  A common misconception is that the benefits of treatment are simply the 
costs avoided by that treatment, whilst the costs avoided should be included, as a 
negative cost (Pennington et al., 2009a).  There is a need to assign costs correctly 
when carrying out an economic analysis and to determine both the incremental 
cost and incremental benefit of treatment compared to the alternatives.  This is 
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calculated by [all costs arising from and following treatment] – [all costs arising 
from and following the alternative intervention] (Pennington et al., 2009a).  If an 
economic analysis is conducted as part of a clinical trial, all economic issues can be 
considered in the design of the trial and the ideal outcomes for the economic 
analysis can be planned and recorded (Gaunt et al., 2008).   
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1.6 Translating research 
General dental practitioners (GDPs) and other dental care professionals will 
normally tailor the advice that they provide to patients based on their own 
knowledge and expertise as well as adhering to clinical guidelines (Newman, 
1996).  For much of the 60 years of NHS dentistry, its main focus has been that of 
delivering treatment rather than focussing on prevention or quality.  A recent 
review into NHS dentistry has suggested that future contracts must incentivise 
general practitioners into providing a high quality service and educating their 
patients in order to improve health (Steele, 2009).   
The aim of preventive dentistry is to educate patients so that they can prevent 
many of the common oral diseases such as caries and periodontitis.  As novel 
research is published and technological advancements in techniques and materials 
occur, dentists must be in a position to evaluate these innovations and make 
decisions whether or not to implement these findings and translate them into their 
own clinical practice. 
Dentistry is almost entirely carried out within primary care, either through the 
NHS or in the private sector, with a limited number of more specialised services 
taking place in tertiary referral centres (Haines and Donald, 1998; McGlone et al., 
2001; Chapple et al., 2003).  The cost burden in NHS primary care dentistry, for the 
majority of adults, is paid for partly by the patient, which occurs to a much lesser 
extent in primary or secondary care medicine through prescription charges.  The 
majority of the published literature focuses on changing medical practice and 
whilst there are likely to be many similarities between medicine and dentistry, 
there are also likely to be many differences (McGlone et al., 2001).   
Barriers and challenges have been identified to the uptake of new knowledge and 
research findings at various levels including at the level of the patient, the 
healthcare professional, the team in which they are working, the heath care 
organisation (for example the NHS or private sector) and also the wider 
environment (Grol and Grimshaw, 2003).  Through the acknowledgement and 
identification of these challenges it may be possible to design an effective 
intervention that if presented in an appropriate manner will be adopted and used 
successfully in general dental practice (Grol and Grimshaw, 2003). 
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Decisions made by GDPs directly influence the oral health of the population in 
their care (Kay and Blinkhorn, 1996). Despite the existence of clinical practice 
guidelines and printed and online publications, there remains substantial variation 
in the clinical decisions that are made by dentists (Knutsson et al., 2000; Maupomé 
and Sheiham, 2000).   The decision-making process has evolved from planned 
treatment which is based around pathology to that of a greater involvement from 
the patient regarding choice and preference (Kay and Blinkhorn, 1996).  Patients 
are encouraged to make an informed decision about their treatment options rather 
than be led by clinicians.  This evolution has encouraged a two-way dialogue 
between practitioners and their patients, with healthcare policy in the UK driving 
this change (NHS, 1996; Health, 2000; NHS, 2001).  The concept that clinicians 
always know what is best for their patients is now considered out-of-date, the 
most appropriate choice for a particular patient may not necessarily be the 
medically ‘best’ option (Kay and Blinkhorn, 1996; Charles et al., 1999; Richards, 
1999).   
It has been suggested that the best decisions are those that are made following 
consideration of the likelihood of a successful outcome but also taking into account 
patients’ views (Kay and Blinkhorn, 1996; Redford and Gift, 1997).  The 
examination style, personality and ability of the dentist to relate to their patients 
facilitates the acceptance of treatment and engagement in decision-making (Kay 
and Blinkhorn, 1996; Redford and Gift, 1997).  Making good decisions must, 
however, be underpinned by scientific evidence so that bias, however 
unintentional, may not be allowed to influence the decision process (Newman, 
1996).   
Once a diagnosis has been reached, the clinician must then decide on the most 
appropriate therapy that addresses the underlying pathology (Newman, 1996).  
Both simple and complex treatments are usually planned based upon a patient’s 
general health, dental experience, current disease status as well as some 
evaluation of behaviour and emotional condition (Heinikainen et al., 2002).  Some 
treatment strategies may carry risk of failure or morbidity or higher cost and it is 
the role of the practitioner to consider these trade-offs whilst ensuring that the 
treatment provided is predictable, has a strong chance of clinical success and will 
not harm the patient (Newman, 1996).  Dental practitioners will often use their 
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own clinical experience to develop their own treatment strategies, they do so 
without the benefit of controlled or blinded observations that often take place in 
clinical research trials that cannot take place in routine clinical practice (Newman, 
1996).  Some compromises may, however, be inevitable particularly where there 
are financial constraints leading to the provision of treatment that may not be the 
‘ideal’ option (Kay et al., 1995; Kay and Blinkhorn, 1996).   
The published literature is a resource to which clinicians may refer to access 
information on evidenced-based, peer-reviewed best practice (Newman, 1996).  
The translation of clinical research findings into practice in dentistry, however, has 
been described as being ‘slow, unpredictable and incomplete’ (Grol and Grimshaw, 
1999; Flodgren et al., 2011b).  The existence of published, peer-reviewed, printed 
educational material does not necessarily lead to an improvement in patient care 
and practice (Freemantle et al., 1997).  There is little evidence to suggest that 
printed material, despite the increasing volume of published material now 
available, results in any substantial changes in clinical practice (Freemantle et al., 
1997).  There is also little information on how cost-effective the publication of 
printed material is if the hope is to elicit change in clinical practice (Freemantle et 
al., 1997).  
Many general dental practitioners may have limited access to publications in a 
specific field of interest.  Access to articles from other disciplines many not be 
possible without considerable expense.  Larger databases may be searched and 
abstracts viewed but only older articles are freely available with complete text.  
This cost may be prohibitive for some who access these resources rarely or do not 
have affiliations with secondary care organisations or higher education 
establishments.  Reviews and systematic reviews have looked at the evidence base 
for the effectiveness of distributing educational materials and have shown that the 
evidence base for clinical practice may be changed on the basis of printed material 
alone (Cohen and Dacanay, 1992; Oxman et al., 1995; Freemantle et al., 1997; Gill 
et al., 1999; Hulscher et al., 1999).   
Up-to-date knowledge of treatment options and strategies will undoubtedly 
influence clinical decision-making, but the way in which the knowledge was 
obtained may affect whether it is implemented into practice or not (Soumerai et 
al., 1993). Scientific meetings and conferences are the obvious place for 
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researchers to disseminate their research findings; however the audiences for 
some of the more specialist meetings are likely to be other specialists within the 
field and may not be attended by GDPs (Newman, 1996). 
Changing the decisions made by GDPs to those supported by a contemporary 
evidence base may improve the opportunity for achieving more predictable results 
and better health outcomes (Hall et al., 1993; Newman, 1996).  Primary care dental 
practitioners may be able to more readily translate the research findings into 
changes in clinical practice due to the substantially higher numbers of people that 
attend on a regular basis.  Recommendations exist for practitioners to try to 
evaluate the evidence from dental research in a way that can be translated into 
their own general practice.  These include examining the demographics of the 
cohort of patients for similarities to their own in age, type of treatment offered, 
general health, ethnic background, disease level, the physical surroundings and 
appropriate recall periods (Newman, 1996).  Whilst some of these may not be 
fulfilled in every case, this guidance recognises that methodology of the study 
design should reflect every day clinical practice in determining the value of the 
evidence and its applicability (Newman, 1996).  One difficulty that dental 
practitioners face is evaluating the significance of the research findings and 
determining whether the statistical differences found in clinical research can 
translate into meaningful clinical outcomes for their patients (Newman et al., 
2003).   
Alongside publications, interactive educational meetings, multi-faceted 
interventions, reminders, educational outreach, audit, comments from opinion 
leaders, patient-mediated interventions, distributed educational materials and 
didactic teaching have all been the subject of a systematic review into their relative 
effectiveness (Bero et al., 1998; York, 1999).  Educational outreach is one method 
that has been used to achieve improvements in healthcare through the use of a 
trained person or team who will visit individual practitioners or practices and 
provide information on how a healthcare professional could modify their practice 
(Gurwitz et al., 1990; Oxman et al., 1995; Soumerai et al., 1998; Hulscher et al., 
1999; O’Brien et al., 2007).  Some studies have used teams of healthcare 
professionals: nurses, physicians, and other professionals within a hospital 
environment as part of an outreach team (Hendryx et al., 1998; Solomon et al., 
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2001; Martin et al., 2004). Other studies have looked at this type of intervention in 
a community with some specifically targeting continuing education in dentistry 
(Brown et al., 1994).  Educational outreach, particularly with a team approach, has 
been found to have modest effects in comparison with no intervention at all 
(Grimshaw et al., 2004). 
The use of experts or opinion leaders to disseminate information on best practice 
has been proposed as another method to bridge the gap between scientific 
research and everyday clinical practice (Flodgren et al., 2011b).  It is hoped that 
improving and optimising the method of translating evidence-based clinical 
practice may be achieved in this way either by individuals (Soumerai et al., 1998; 
Leviton et al., 1999; Guadagnoli et al., 2000; Berner et al., 2003; Sisk et al., 2004) or 
through multidisciplinary opinion leader teams (Hong et al., 1990; Elliott et al., 
1997; Leviton et al., 1999; Cabana et al., 2006; Majumdar et al., 2007; Althabe et al., 
2008; Majumdar et al., 2008; Flodgren et al., 2011b). Nevertheless, the social 
theory suggests that the opinion leaders are perceived as being ‘credible, likable 
and trustworthy’ and are likely to be persuasive in changing behaviour and 
therefore established practice (Flodgren et al., 2011b).   
Within medicine complete uptake and implementation of national guidelines by 
general medical practitioners has sometimes been unsuccessful because the 
manner in which the guidance is published and disseminated.  The passive 
distribution of clinical guidelines and publications has been found to have little or 
no effect (Bero et al., 1998). Yet within the United Kingdom (UK) there is a 
plethora of guidance that continues to be issued from a number of sources 
including the National Institute of Clinical Excellence (NICE), the Scottish 
Intercollegiate Guidelines Network (SIGN), the Cochrane Collaboration, Royal 
College of Surgeons of England, national and European specialist societies, and 
trade unions such as the British Dental and British Medical Associations.   
The contractual arrangements and remuneration that general dental practitioners 
receive has a direct impact on the type of treatments carried out.  From 1951 until 
2006 the dental contract in England and Wales was based upon individual items of 
treatment (Chalkley et al., 2010; Hopper et al., 2011). The NHS General Dental 
Services (GDS) contract underwent radical changes in 2006, where patients were 
no longer ‘registered’ with one practice and items of treatment were banded 
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together with patients being charged depending upon the band of treatment 
provision (Health, 2005b).  
There is little high quality evidence to suggest that audit or external inspections 
improve compliance with standards or modify behaviour.  The responsibilities of 
clinical audit were ‘devolved’ away from the individual practices and back to 
primary care trusts in 2001 and the financial incentives for carrying them out were 
also removed (Cannell, 2012).  Following the Health and Social Care Act 
(Department of Health, 2008) all primary healthcare services are now under the 
scrutiny of the Care Quality Commission.   It is possible that the change in 
regulation may have also exerted an influence on the decisions made in every day 
practice.  
Qualitative studies have attempted to identify trends in dentists’ perceptions and 
use of research findings (Allison and Bedos, 2003; Watt et al., 2004; Dyer and 
Robinson, 2006; Hopper et al., 2011).  The most recent study to examine dentists’ 
perceptions of research was carried out in the North West of England, in a series of 
qualitative research interviews.  The authors concluded that more research was 
required to understand how best to incentivise an evidence-based culture in 
primary dental care (Hopper et al., 2011).  Other commentators have questioned 
the usefulness of continuing professional development and in particular validating 
the ‘verifiability’ of some sources of further education (Kelleher, 2012). If future 
qualitative research is to be undertaken, the consolidated criteria for reporting 
qualitative research (COREQ) framework should be used to help design, conduct 
and report qualitative research appropriately (Tong et al., 2007).   
Contractual and legislation changes along with the significant increase in emphasis 
to participate in continuing professional development may have an effect on how 
practitioners engage with evidence-based practice.  By trying to understand some 
of the problems and challenges facing primary care dentists and how they engage 
with the ever increasing amount of published research, it may be possible to 
design and implement effective strategies to translate research into dental practice 
(Grol and Grimshaw, 2003).  
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1.7 Aim of the thesis 
This aim of this thesis is to undertake translational studies that evaluate plaque 
control interventions.  This will be undertaken in three parts: 
1. A longitudinal clinical study, with two sequential plaque control 
interventions, to characterise and correlate clinical, microbial and host response 
parameters in subjects with mild to moderate gingivitis. 
2. A randomised controlled trial examining the effect of a personalised plaque 
control programme for patients with oral lichen planus-attributed desquamative 
gingivitis. 
3. A qualitative study to investigate the perceived barriers to implementing 
clinical research findings in general dental practice in North East England. 
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Chapter 2 
A longitudinal study to characterise and correlate clinical, 
microbial and host response parameters in subjects with mild to 
moderate gingivitis (Clinical Trial 1) 
2.1 Introduction 
Periodontal diseases are inflammatory conditions which affect tooth supporting 
tissues and can be divided into two basic categories: gingivitis and periodontitis 
(Armitage, 1999).  Gingivitis is a more superficial inflammation; it is confined to 
the gingival tissues, and is reversible with simple treatment to improve oral 
hygiene.  Periodontitis is destructive and results in the loss of tooth attachment 
and bony destruction.  Clinical trials usually evaluate the effectiveness of hygiene 
phase therapy and professional prophylaxis from a clinical, biochemical or a 
microbiological perspective; rarely do they correlate multiple outcomes 
(Hellstrom et al., 1996; Bogren et al., 2007; Teles et al., 2007; Lalic et al., 2012; 
Scott et al., 2012).  Previous interventions have assessed shifts in biomarker panels 
to evaluate the relationships between bacteria and their hosts in health and 
diseased subjects (Kumar et al., 2006; Offenbacher et al., 2007; Aspiras et al., 2008; 
Barros et al., 2008; Joshi et al., 2008; Offenbacher et al., 2010).  There has, 
however, been a focus to try and correlate the clinical picture with both biological 
markers and bacterial species (Offenbacher et al., 2007; Offenbacher et al., 2010; 
Salvi et al., 2010).  The aim of this study is to help characterise the context in which 
gingivitis resolves following treatment observing clinical changes as well as those 
at the biochemical and microbiological level (Kumar et al., 2006; Offenbacher et al., 
2007). 
2.2 Aim 
The primary aim of this study was to characterise clinical parameters with 
microbial and host-responses, following a formal oral hygiene programme and 
professional prophylaxis, in subjects with mild to moderate gingivitis. The 
secondary aim was to develop further understanding of hygiene phase therapy 
that could be utilised in further studies with more aggressive or symptomatic 
gingival inflammation. 
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2.3 Materials and methods 
This study had an open-label (non-blinded) longitudinal design; all subjects 
enrolled in the study received the same two sequential interventions (Figure 7).  
The first was instruction in brushing twice daily for two minutes with a powered 
toothbrush, Sonicare FlexCare+ HX6942/20 (Philips Oral Healthcare Inc. Bothell, 
WA, USA).  The second was a professional prophylaxis delivered by a dental 
hygienist.  Subjects were recalled at 2-week intervals from baseline for the 8-week 
duration of the study.  Clinical markers of health and disease were recorded and 
samples of gingival crevicular fluid and dental plaque taken to allow biomarker 
analysis. 
The clinical component of the study was carried out in the Department of 
Periodontics at Newcastle Dental Hospital, Newcastle upon Tyne, United Kingdom.  
The laboratory biomarker analysis was carried out at the Cytokine Analysis 
Facility, University of North Carolina, Chapel Hill, North Carolina, United States and 
the microbiological analysis at Ohio State University, Columbus, Ohio, United 
States.   
The study was conducted in accordance with ICH Good Clinical Practice (GCP) 
guidelines.  A favourable ethical opinion was provided by Sunderland Research 
Ethics Committee (REC), United Kingdom, on 29th January 2010 (ref. 
10/H0904/2).  The study was sponsored by Philips Oral Healthcare, Bothell, WA, 
United States.  Local approval was provided through Newcastle Upon Tyne NHS 
Foundation Trust’s Research and Development Office.  The study was insured by 
ACE Insurance and Chartis, Europe for all aspects of the study (policy numbers on 
file).  External audit was carried out during the study by Harrison Clinical Research 
Limited (UK) to ensure compliance with the approved protocol. 
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Figure 7.  Clinical Trial 1. Study overview. 
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2.3.1 Subjects 
Potential subjects were recruited from staff and students within Newcastle Dental 
Hospital and the School of Dental Sciences, Newcastle University, United Kingdom.  
Advertisements were placed around the Dental Hospital and Faculty of Medical 
Sciences to participate in a tooth-brushing study.  Potential subjects who contacted 
the study co-ordinator were provided with a Research Ethics Committee (REC) 
approved participant information sheet detailing information to further consider 
their voluntary participation (Appendix 2).  31 participants were identified and 
further appointments were made for a screening visit, where consent was obtained 
and the study inclusion and exclusion criteria applied.  If a subject did not meet the 
eligibility criteria for bleeding sites, they were withdrawn from the study. 
Inclusion criteria 
Subjects were included in the study if they fulfilled the following criteria: 
 Adults between 18-65 years; 
 In generally good health; 
 Have a minimum of 20 natural teeth; 
 Be a regular manual toothbrush user; 
 Able to comply with study protocols and procedures and be available at all 
times required for participation; 
 Gingival Index (Löe and Silness, 1967) ≥ 2 on at least 20 sites; 
 Non-smoker. 
Exclusion criteria 
Subjects were excluded from the study if they met any of the following criteria: 
 Infectious or systemic diseases that may be unduly affected by participation 
in this study; 
 Diabetes mellitus; 
 Insufficient capacity that may affect the participant’s ability to properly 
follow study instructions; 
 Pregnancy or nursing of infants at time of enrolment; 
 Undergoing or required extensive dental, periodontal, orthodontic or 
implant treatment; 
 A cardiac pacemaker or automatic implanted cardiac defibrillator; 
 Antimicrobials within 3 weeks of enrolment in the study; 
 Anti-inflammatory medication;  
 Taking anti-coagulant medication; 
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 Had severe gingivitis defined as whole mouth average Gingival Index (Löe 
and Silness, 1967) of ˃2.5; 
 Existence of periodontal pockets with concurrent attachment loss of 
˃1.0mm at ˃ 5 sites in any one quadrant; 
 Had heavy deposits of calculus, either supragingival and/or subgingival; 
 Extensive crown or bridge work and/or rampant decay at the discretion of 
the examiner; 
 Using bleaching trays or professional whitening treatment at time of 
enrolment; 
 Unwilling to abstain from using mouthrinses, dental floss, toothpastes 
(other than that provided for the project) or other toothbrushes for the 
duration of the study; 
 Had oral surgery within 6 months of enrolment; 
 Had orthodontic brackets; 
 Had received a dental prophylaxis within 1 month prior to enrolment; 
 Oral or extra-oral piercing with ornament or accessory in/or surrounding 
the oral cavity; 
 Had been a participant in a dental research study within the previous 20 
days prior to enrolment; 
 Were a current or regular user of an electronic/power/battery toothbrush 
(prior periodic use or in other studies permitted) at time of enrolment; 
 Were employed by a company that produces, distributes or markets dental 
products. 
Prior and Concomitant Therapy 
Subjects who were current, regular powered toothbrush users were excluded from 
the study.  At baseline the use of any additional oral hygiene treatments or aids 
other than those prescribed were prohibited.  These included but were not limited 
to: mouthwash, dental floss or other interproximal cleaning aids, chewing gum or 
whitening products.  The use of any dentifrice was prohibited other than Colgate 
Cavity Protection, which was provided to subjects during the study.  Any subject 
who was prescribed antimicrobials during the study was subsequently withdrawn.  
Extended, defined as over 3 days, or chronic use of anti-inflammatory or anti-
coagulant medication (over the counter or prescription) at any time whilst 
participating in the study was also prohibited. 
2.3.2 Power and sample size 
The primary endpoint was the change in Gingival Index (Löe and Silness, 1967), 
Plaque Index (Silness and Löe, 1964) and biomarkers from baseline after 
introduction of an oral hygiene programme and after professional prophylaxis.  
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The Gingival Index (Löe and Silness, 1967) was used for the purposes of 
calculating a sample size. 
The study was designed to have a high probability (statistical power) of detecting a 
moderate change in mean Gingival Index over time.  The assumption was made 
that a standard deviation of 0.2 was a reasonable estimate of the within-group 
standard deviation.  30 subjects would be required to detect with 90% power a 
mean Gingival Index change of 0.12 or greater.  
2.3.3 Clinical measures 
Plaque was measured on a four-point index of Silness and Löe (Silness and Löe, 
1964).  This Plaque Index (PI) scores plaque on the surface of teeth without the use 
of a disclosing solution on a scale of 0 to 3.  It is dependent upon a clinical 
examiner interpreting the difference between the following: 
Code Descriptor 
0 No plaque. 
1 A film of plaque that is only visible by running a dental probe along the 
gingival margin. 
2 A moderate level of plaque that is visible to the naked eye. 
3 An abundance of plaque on the tooth surface. 
 
A full mouth PI at 6 sites per tooth (distobuccal, buccal, mesiobuccal, distolingual, 
lingual, mesiolingual) was recorded. 
Inflammation of the gingival tissues was recorded using the Löe and Silness 
Gingival Index (GI) (Löe and Silness, 1963).  Full mouth GI at 6 sites per tooth 
(distobuccal, buccal, mesiobuccal, distolingual, lingual, mesiolingual), recorded on 
a scale of 0 to 3 where: 
Code Descriptor 
0 Normal gingivae. 
1 Mild inflammation, slight change in colour, slight oedema, no bleeding on 
probing. 
2 Moderate inflammation, redness, oedema and glazing, bleeding on probing.  
3 Severe inflammation, marked redness and oedema, ulceration, tendency to 
spontaneous bleeding. 
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Full mouth pocket probing depth (PPD) and clinical attachment loss (CAL) were 
recorded at 6 sites per tooth (distobuccal, buccal, mesiobuccal, distolingual, 
lingual, mesiolingual), excluding third molars, and recorded in millimetres using a 
UNC-15 probe (Hu-Friedy Manufacturing Co., Inc. Chicago, IL, USA). 
Biomarkers 
Gingival Crevicular Fluid (GCF) samples were collected and the volume recorded 
from each subject at specific intervals (visits 3-7) to determine local levels of 
inflammatory biomarkers.  The biomarkers analysed were: IL-1α, IL-1β, IL-8, MIP-
1α, MIP-1β, RANTES, MMP-1, MMP-3, MMP-8, MMP-9, MMP-13.  These were 
chosen because they are thought to mediate phases of the inflammatory response 
in periodontal disease, and are produced in response to the presence of an active 
biofilm and its products.  Supragingival and subgingival plaque samples were 
collected at visits 3, 5 and 7 to determine levels of pre-selected microorganisms. 
2.3.4 Examiner calibration  
In order to minimise bias, and ensure the validity of any conclusions drawn from 
the results of the study, a calibration exercise was undertaken on three clinical 
dental parameters: Plaque Index (PI), Gingival Index (GI), and Probing Depth (PD).  
Repeat measures were performed on subjects not involved in the main study.  An 
additional examiner was also calibrated in the event that the primary examiner 
was unable to carry out the clinical examinations. 
It was appropriate to employ a weighted Cohen’s Kappa statistic to assess the 
agreement between two raters after adjusting for chance (Cohen, 1968).  The use 
of weighting ensures that a disagreement of more than one unit arising between 
replicate 1 and replicate 2 is more heavily penalised than a disagreement of only 
one unit.  The weighted Cohen’s Kappa for three clinical parameters was: PI = 0.80 
[95% CI 0.75, 0.84]; GI = 0.77 [95% CI 0.70, 0.82]; PD = 0.84 [95% CI 0.78, 0.82].  
Although the guidance for interpreting the weighted Kappa statistic results varies, 
agreements above 0.7 are taken as implying very good-to-excellent agreement 
(Cohen, 1968; Viera and Garrett, 2005).   
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2.3.5 Study visits 
Subjects were asked to attend for a total of 7 study visits over 8 weeks, with visits 
1 and 2 permitted to be on the same day (Figure 7). 
Visit 1 Subject information and consent 
Written informed consent was obtained from each subject at the screening visit 
prior to enrolment and the initiation of any study related procedures (Appendix 3).  
Potential subjects were scheduled for a screening appointment and provided with 
a REC approved information leaflet and consent form to read.  They were then 
given the opportunity to ask any relevant questions about the study.  If they agreed 
to participate they signed the consent form and were offered a copy for their 
records.  If requested, subjects were given a further period of time (up to 24 hours) 
to consider their willingness to take part in the study.  The research team or 
Principal Investigator answered any questions that were raised by potential 
participants.  Original copies of the signed informed consent forms were retained 
on file at Newcastle University. 
Visit 2 Screening 
Those subjects who wished to participate were screened for their eligibility.  They 
were instructed to brush their teeth 2-6 hours before the next appointment.  A 
medical history was recorded and was reviewed by the investigator to assess 
eligibility.  Demographics (date of birth, age, gender, race, height, weight, BMI) 
were recorded for each subject. 
An intraoral soft tissue examination was performed noting particularly any 
gingival abrasions, irritation, lacerations or ulceration.  The GI was recorded at 6 
sites per tooth.  Subjects required a mean GI of at least 2.0 over at least 20 sites to 
continue in the study.  Full mouth periodontal probing depths were recorded using 
a UNC-15 periodontal probe at 6 sites per tooth rounded to the next lower whole 
millimetre.  Subjects with periodontitis, defined as recording periodontal pockets 
with concurrent loss of attachment greater than 1.0mm at greater than 5 sites in 
any one quadrant, were excluded.  Clinical attachment loss (CAL) was measured 
using a UNC-15 periodontal probe at 6 sites per tooth to measure the distance in 
millimetres from the cementoenamel junction (CEJ) to the base of the gingival 
sulcus.  Subjects who fulfilled all of the inclusion/exclusion criteria were then 
scheduled for baseline assessment. 
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Visit 3 Baseline 
Visit 3 took place within 14 days of visit 1.  As with visit 2, subjects had been 
instructed to brush their teeth within 2-6 hours prior to the appointment.  The 
subjects’ medical and dental histories were reviewed for any adverse events that 
may be attributed to participation in the study.  An intra-oral soft tissue 
examination and full mouth PI was performed.  GCF, supra- and sub-gingival 
plaque samples were collected from 2 sites per quadrant (Figure 8).  A full mouth 
GI was then recorded followed by full mouth periodontal pocket depths as 
described in Visit 2. 
The first of the two interventions (hygiene phase therapy) was provided at visit 3.  
All subjects received a Sonicare FlexCare HX6942/20 with ProResults brush head 
(Philips Oral Healthcare Inc. Bothell, WA, USA).  They were given comprehensive 
written and verbal instructions to brush their teeth twice daily for 2 minutes using 
standardised toothpaste Colgate Cavity Protection (Colgate-Palmolive, Guildford, 
Surrey, UK; active ingredient sodium monofluorophosphate 0.76%).  The Sonicare 
FlexCare toothbrush did not have the ‘easy start’ feature active and was used in its 
default-brushing mode ‘clean’. 
Subjects were asked to keep a brushing diary to aid with compliance and to brush 
2-6 hours prior to the next appointment.  No other interdental cleaning aids, 
mouthrinses or chewing gum were permitted during the study. Subsequent 
appointments were then scheduled for the remaining study visits. 
Visit 4 
Visit 4 took place 14 days after Visit 3 (+/- 3 days).  A compliance check was 
carried out with a verbal interview and review of the brushing diary to determine 
if the subject had followed the study instructions.  Soft tissue examination, medical 
and dental histories were recorded along with any reportable adverse events.  A 
full mouth PI was carried out prior to the collection of GCF at the same sites 
described in Visit 3.  A full mouth GI was then carried out; no plaque samples were 
collected at this visit. 
Visit 5 
Visit 5 took place 28 days after Visit 3 (+/- 3 days).  A compliance check was 
carried out with a verbal interview and review of the brushing diary.  Soft tissue  
 65 
 
 
 
 
 
 
 
 
Figure 8.  Clinical Trial 1. Sites sampled for plaque and GCF.   
All four quadrants were sampled using buccal surfaces from the mesial of the second 
molar (171, 271, 371, 471) and the distal of the first molar (163, 263, 363, 463). 
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examination, medical and dental histories were recorded along with any 
reportable adverse events.  Clinical records of PI, GI, PPDs along with supra and 
subgingival plaque samples and GCF were recorded as previously described.  A 
new brushing diary was also issued. 
The second of the two interventions was provided at this visit.  A full mouth 
prophylaxis was undertaken by a dental hygienist, this included scaling to remove 
supra and subgingival calculus deposits and a full mouth prophylaxis (Prophylaxis 
paste, Kemdent®, UK).   
Visit 6 
Visit 6 took place 42 days after Visit 3 (+/- 3 days).  A compliance check was 
carried out with a verbal interview and review of the brushing diary.  Soft tissue 
examination, medical and dental histories were recorded along with any 
reportable adverse events.  A full mouth PI was carried out prior to the collection 
of GCF at the same sites as described in Visit 3.  A full mouth GI was then carried 
out; no plaque samples were collected at this visit. 
Visit 7 
Visit 7 took place 56 days after Visit 3 (+/- 7 days).  A compliance check was 
carried out with a verbal interview and collection of the brushing diary.  Soft tissue 
examination, medical and dental histories were recorded along with any 
reportable adverse events.  Clinical records of PI, GI, PPDs along with supra and 
subgingival plaque samples and GCF were recorded as previously described.  
Subjects were compensated for participation in the study with £70 in gift vouchers 
before being dismissed from the study. 
2.3.6 Biomarker collection 
Gingival crevicular fluid samples 
GCF was collected at 2 weekly intervals from baseline (Visits 3,4,5,6 and 7) using 
the following method:  GCF was collected using Periopaper® collection strips 
(Oraflow, Smithtown, NY, USA) which were inserted gently into the gingival 
crevice.  The teeth were air dried and isolated with cotton rolls prior to placement 
of the Periopaper® strips to reduce saliva contamination.  Sufficient pressure was 
applied to allow the Periopaper® to be held just within the gingival crevice.  The 
Periopaper® was left in place for 30-60 seconds or until the paper visibly 
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dampened at the lower third.  The paper was then removed and the volume 
determined using a calibrated Periotron 8000 (Oraflow, Smithtown, NY, USA).  
This device had been allowed to warm up for at least 10 minutes prior to use.  In 
addition to the warm up time, dry Periopaper strips were used to adjust the 
reading on the Periotron to “0.” Two consecutive readings of zero were determined 
with a reading between 002 and -002 being acceptable tolerances.  After 
measuring the volumes of GCF the metal contacts of the Periotron were cleaned 
with alcohol and dry gauze to prevent cross contamination of samples and residual 
moisture affecting subsequent readings. 
Calibration of the Periotron was carried out according to the manufacturer’s 
protocol to determine the relationship between periotron readings and standard 
distilled water volumes (Oraflow, 2007).  The calibration data were then used to 
determine the concentrations of mediators in each of the samples of GCF taken 
from the subjects during analysis.  Comprehensive calibrations (12 volumes 
repeated three times) of the Periotron were carried out monthly for the duration 
of the study with smaller interim calibrations taking place weekly.  Records of the 
interim and comprehensive calibrations were retained in the main study file. 
GCF samples were taken from 2 sites per quadrant with the preferential sites being 
the mesiobuccal site of the second permanent molar and the distobuccal site of the 
first permanent molar.  If these teeth were absent then the sample was taken from 
the next available mesial tooth.  The quadrant tooth site (QTS) notation was used 
for site nomenclature and identification with the same sites being used for both 
GCF and plaque collection for microbial assessment: 171/163, 271/263, 371/363, 
471/463 (Figure 8).  
Plaque samples 
Supragingival plaque was collected from the target sites by sweeping a curette or 
scaler at the first site and wiping onto 2 paper points.  Subgingival plaque samples 
were collected by inserting 5 paper points into the gingival sulcus of the site for 10 
seconds.  Following removal of the paper points, the sulcus was swept with a scaler 
or curette and the plaque wiped onto the same points.  The paper points (Dentsply 
Maillefer, Ballaigues, Switzerland) were then placed into the prelabelled cryovial 
and the procedure repeated for the subsequent sites in the remaining quadrants.   
Samples were placed into barcoded (for subject number, site and visit) 2mL 
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Eppendorf microcentrifuge tubes and placed in a freezer at -80°C until shipment to 
Ohio State University, OH, USA for analysis. 
2.3.7 Biomarker analysis 
GCF analysis 
Analysis of the GCF samples took place at the University of North Carolina (UNC) 
Cytokine Analysis Facility, Chapel Hill, NC, USA.  The protocols for multiplex 
cytokine analysis have previously been published using the R&D Systems 
Fluorokine® MultiAnalyte Profiling kits (Offenbacher et al., 2007; Offenbacher et 
al., 2010).  Samples were collected onto filter paper strips (Periopaper®, Oraflow, 
Smithtown, NY, USA) and the volume determined using a Periotron 8000® as 
previously described (Oraflow, Smithtown, NY, USA). 
Following determination of the GCF volumes, the samples were then wrapped in 
autoclaved aluminium foil and placed into two barcoded 2mL Eppendorf 
microfuge tubes. The sample tubes were pre-labelled with unique identifiers for 
the study and specimen.  Samples were then flash frozen in liquid nitrogen (stored 
in a nearby Dewar flask) and placed in a temperature-controlled freezer (-80°C) 
until shipment on dry ice to UNC and then stored in liquid nitrogen (-180°C) until 
mediator analysis. 
Sample preparation 
Two samples per subject visit (463,471) were prepared and analysed separately 
for the following mediators IL-1α, IL-1β, IL-8, MIP-1α, MIP1β, RANTES, MMP-1, 
MMP-3, MMP-8, MMP-9, MMP-13.  Analysis was performed to quantify the levels of 
these inflammatory mediators using the Fluorokine® Profiling MAP cytokine 
multiplex kits (R&D Systems, MN, USA) and the Bio-Plex® 200 analyser system 
(Luminex Corporation, DeSoto, TX, USA) (Figure 9).  The cytokines (IL-1, IL-1, 
IL-2, MIP-1, MIP-1) were analysed using Fluorokine® MAP multi analyte 
profiling human base kit whereas the matrix metalloproteinases (MMP-1, MMP-3, 
MMP-8, MMP-9, MMP-13) were analysed using human MMP base kit (R&D 
systems, MN, USA). 
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Figure 9.  Clinical Trial 1.  Overview of the principle of the Bio-Plex® 200 multiplex assay 
(R&D Systems, MN, USA).   
  
Colour coded 
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with analyte specific  
capture antibody are 
added to the eluted 
analyte 
Analyte specific 
antibodies capture the 
analyte of interest.  
Biotinylated detection 
antibodies specific bind 
to analyte. 
Phycoerythrin (PE) 
conjugated streptavidin 
is added 
Microspheres are read 
using a dual laser 
detection instrument 
e.g. Bio-Plex 200 
One laser classifies the 
bead and the second 
determines magnitude 
of fluorescence 
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The GCF samples were eluted according to Luminex Corporation protocols for each 
of the base kits for human MMP and cytokines (R&D systems, MN, USA).  The 
samples were thawed and the Periopaper® strips eluted with 200 L phosphate 
buffered saline (PBS) into a 96-well vacuum manifold collection plate.  They were 
then placed on a microplate shaker at 450 rpm for 30 minutes at room 
temperature. The working standard curve, which allowed comparison with the 
samples, was made up.  100 L of the two standard cocktails of recombinant 
human cytokines in each base kit (R&D systems, MN, USA) were mixed then 
agitated, using a Vortex-Genie 2 mixer (Scientific Industries, Bohemia, NY, USA) for 
30 seconds.  The standard mixture was then diluted in serial as per the standard 
value cards supplied in the Fluorokine® MAP base kits.  Following dilution the 
standards were gently agitated at 450 rpm (VWR SignatureTM Microplate Shaker, 
Radnor, PA, USA) for 15-30 minutes. 
Analyte specific antibodies (to e.g. MMP-1) were pre-coated onto colour-coded 
microspheres supplied by the manufacturer in the form of a concentrate.  The 
concentrates were vortexed to resuspend the microspheres; 50 L of each 
microparticle concentrate was added to a mixing bottle with 5 mL of microparticle 
diluent before vortexing the mixture.   
The microplate was pre-wetted with 100 L wash buffer to stop the microspheres 
clumping together and errors occuring during analysis, the liquid was removed 
using a vacuum manifold designed to accommodate the microplate.  
The first two vertical columns of the plate were used for the serial dilution 
standards.  50 L of the microparticle mixture was then added to the microplate 
along with 50 L of sample or standard.  The plate was sealed and incubated for 3 
hours at room temperature on a microplate shaker at 450 rpm; the layout of the 
plate was recorded to record standards and samples to be assayed. 
The plate was then washed by removing the liquid with the vacuum manifold.  This 
was done by filling each well with 100 L wash buffer then removing the liquid 
again this process was repeated three times.  The biotin detection antibodies were 
prepared by centrifuging the antibody vial for 30 seconds followed by re-
suspending the concentrate using a vortex.  50 L of biotin antibody concentrate 
was then added to a vial of biotin antibody diluent and gently mixed.  50 L of 
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diluted antibody cocktail was added to each well of the microplate then covered 
and incubated for a further hour on a microplate shaker at 450 rpm. 
The streptavidin-phycoerythrin conjugate (Strepavidin-PE) was prepared in an 
amber polylpropylene bottle to prevent light contamination.  It was diluted by 100 
times by adding 55 L of Strepavidin-PE to 5.5 mL of wash buffer.  50 L of diluted 
Strepavidin-PE was added to each well of the microplate, covered with a foil plate 
sealer and incubated for 60 minutes on a microplate shaker at 450 rpm.  Following 
a final wash with wash buffer to remove unbound Streptavidin-PE, the 
microspheres were re-suspended in 100 L of wash buffer in each well and 
agitated for 2 minutes on the microplate shaker at 450 rpm. 
Detection 
The plate was then read using the Bio-Plex® 200 analyser; the microspheres were 
drawn up from the wells and read using two lasers.  The first identifies the bead 
type and determines the analyte being detected.  The second laser determines the 
magnitude of the fluorescence signal, which is in direct proportion to the amount 
of bound analyte.  All biomarker mediator values were then corrected for elution 
volume, assay dilution and GCF volume and expressed as a GCF concentration.   
Microbial analysis 
Analysis of the plaque samples was carried out at the College of Dentistry, Ohio 
State University, OH.  Analysis was carried out on pooled samples from one 
quadrant for each subject for each visit, as has previously been described 
(Shchipkova et al., 2010).  The Applied BioCode System (Applied Biocode Inc., CA, 
USA) has not been widely used for determination of oral bacteria, but the 
underlying chemistry is similar to the immunoassays performed with the GCF 
samples.  It uses small (25μm x 75μm x 5μm) carboxyl barcoded magnetic beads 
(BMBs) to simultaneously detect up to 32 different analytes within a single sample.  
The molecular reaction takes place on the surface of digital barcoded magnetic 
beads (Figure 10).  Target specific capture probes are covalently linked to a 
specific set of digital barcoded beads.  Biotin-labelled targets (single stranded 
DNA) are captured by the bead bound capture probes in a hybridisation 
suspension.  Streptavidin-phycoerythrin conjugate (SA-PE) is finally added to the 
samples to hybridise the targets and allow detection (Applied Biocode, 2013a).   
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Figure 10.  Clinical Trial 1.  Molecular bioassay protocol using Barcoded Magnetic Bead 
(BMB) Multiplex technology.   
The barcoded magnetic bead is formed by combining a biocompatible polymer with 
paramagnetic material, this allows for highly stable surface chemistry and the magnetic 
properties allow easy handling and washing of the beads when an external magnetic force 
is applied.  The carboxyl BMBs allow DNA probes for specific bacteria to bind the bead 
surface (Applied Biocode, 2013a). 
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Sample preparation 
200 μL phosphate-buffered-saline (PBS) were used to elute the bacteria from the 
paper points in the microcentrifuge tubes.  The samples were agitated at 450 rpm 
using a microplate shaker for 2 hours at room temperature followed by 
centrifuging.  The paper points were removed and the bacterial DNA was isolated 
with a Qiagen DNA MiniAmp kit (Qiagen, Valencia, CA, USA) using the tissue 
protocol according to the manufacturer’s instructions. The bacterial DNA was 
amplified using Polymerase Chain Reaction (PCR) and labelled using A17 (5’ GTT 
TGA TC TGG CTC AG 3’) and 317 (5’ AAG GAG GTG ATC CAG GC 3’) primers 
(Biosythesis, Lewisville, TX, USA) as previously described (Kumar et al., 2005). 
The products of the PCR reaction were then purified to remove impurities from the 
samples (e.g. primers, enzymes, mineral oils, salts) and pure DNA was eluted with 
small volumes of endotoxin specific (ES) buffer. A Qiaquick spin column (Qiagen, 
Valencia, CA, USA) was placed into a conventional 2mL collection tube.  The sample 
was added to the column and centrifuged for 30-60 seconds at 13,000 RPM in a 
conventional table-top microfuge at room temperature.  The flow through was 
discarded and the column was placed back into the same tube and washed with 
0.75mL PE buffer before being returned to the centrifuge for a further 30-60 
seconds.  Once the residual wash buffer was removed, the DNA was eluted in 50 μL 
of elution buffer and centrifuged for a further 1 minute.  Agarose gel 
electrophoresis was used to confirm successful amplification of the bacterial DNA 
to confirm validity of the samples as PCR can be sensitive to contamination. 
Barcoded magnetic bead- probe coupling and hybridisation 
The bacteria specific capture probes were then covalently coupled to the carboxyl 
barcoded magnetic beads as described in the manufacturer’s protocol.  Following 
this the beads were re-suspended in 200 μL PBS-T and stored at 2-8 °C prior to 
hybridisation with the sample (Applied Biocode, 2013b).  The bead-bound probes 
were then hybridised to the biotin labelled PCR product prior to the addition of 
Streptavidin-R-Phycoerythrin and detection buffer to hybridise the target and 
allow detection of the sample. 
Detection 
A 96 well microplate was placed into the BioCode 1000 analyser (Applied Biocode 
Inc., CA, USA) for detection.  A bright LED with a charged couple device (CCD) 
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camera to illuminate the beads was used to obtain a barcode image.  Secondarily 
the LED was used to obtain a fluorescent image.  The images were then decoded 
for each individual bead and the amount of fluorescence intensity, which directly 
related to the microbial levels in the sample.   
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2.4 Data management and confidentiality 
Study records, including each volunteer’s signed informed consent and other study 
related documents were kept in a secure area under the supervision of the 
Principal Investigator.  All study data (excluding laboratory data) were recorded 
on paper based clinical record forms.  Data were double-entered into an electronic, 
web-based data system (InForm Version 4.6) provided by the study sponsor, 
Philips Oral Healthcare.  All personal subject identifiers were removed from the 
data set and all enrolled subjects were assigned a specific study number.  Only the 
investigators at Newcastle University had access to information linking the 
subjects to the corresponding assigned study number. 
Access to the electronic data entry system was protected by login identification 
and passwords.  Data entry as well as all data modification, was documented by the 
system and available in an audit trail.  De-identified study data were also retained 
by the study sponsor.  Paper based records of enrolment metrics, safety 
information and concomitant medication were retained on file at Newcastle 
University. 
During data collection any modification to a written form or document was 
amended with a single line through the erroneous data.  The correction was legibly 
entered as well as the initials and date of the person making the correction.  The 
master list of participants was retained in the event that subjects needed to be 
contacted after study completion. After the conclusion of the clinical part of the 
study, electronic clinical record forms was completed and digitally signed, the 
clinical database was then electronically locked. 
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2.5 Statistical and analytical plan 
The population to be analysed comprised all enrolled subjects with available post-
baseline data.  Analysis were conducted using SAS/STAT® software.   Continuous 
variables were summarised using descriptive statistics: number of obervations, 
mean, standard deviation, median minimum and maximum.  The Plaque Index, 
Gingival Index and Pocket Probing Depths were analysed using analysis of 
variance (ANOVA), the following model was used: 
yij = μ+ αi + Wj + ԑij 
Where: 
yij Change from baseline for each subject (i) at week (j) (2,4,6,8); 
 μ overall effect; 
Wj extent to which change from baseline is attributable to week (j); 
αi  random subject effect; 
ԑij unexplained/residual variation for each subject (i) at week (j) (2,4,6,8). 
The biomarker data were summarised using descriptive statistics for the observed 
values and the changes from baseline.  Two sided t-tests, without adjustment for 
multiple comparisons were used to assess the statistical significance of changes 
from baseline. 
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2.6 Results 
A total of 31 subjects were screened.  All fulfilled the entry criteria and were 
consented to participate.  31 subjects were retained through the 7 visit protocol 
(217 study visits) to the completion of the study with no early terminations.  The 
subjects were mostly female (67%) and white (83.9%).  The mean age was 27 
years.  A summary of demographics is listed in Table 6. 
During the study there were 13 protocol deviations, 9 of which were due to the 
lack of availability of liquid nitrogen to snap freeze the GCF samples.  These 
samples were placed directly into the -80°C freezer.  The deviations were not 
expected to have a major impact on the overall study conclusions.   
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Demographic 
 
Age (years) Mean (SD) 27 (10.3) 
Median 21 
Min, Max 20, 54 
Gender (number of subjects) Female 21 
Male 10 
Race Asian 1 
Black 1 
White 26 
Mixed 2 
Chinese 1 
Height (cm) Mean (SD) 169.7 (9.2) 
Median 168 
Min, Max 154, 186 
Weight (Kg) Mean (SD) 68.3 (13.6) 
Median 65 
Min, Max 48, 102 
BMI Mean (SD) 23.6 (3.4) 
Median 22.4 
Min, Max 18.6, 32.6 
Smoking status Not current 31 
Never 27 
Former 4 
   
 
 
Table 6.  Clinical Trial 1.  Study demographics for the 31 participants. 
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2.6.1 Plaque Index 
The overall mean PI was calculated as an arithmetic average of all PI scores 
recorded at 6 sites per tooth as detailed in the protocol. Descriptive statistics are 
shown for PI in Table 7.  
4 weeks following Intervention 1, the reduction in PI from baseline with 95% CI 
was 0.56 (0.43, 0.69).  8 weeks following Intervention 1 and 4 weeks following 
Intervention 2 the mean reduction in PI with 95% CI was 0.7 (0.6, 0.9).  Analysis of 
variance (ANOVA) statistics (Table 8) examined the statistical difference from 
baseline to weeks 2,4,6 and 8 which indicated a significant reduction in PI from 
baseline at all weeks (ANOVA p<0.0001).  There was a consistent reduction in PI 
from baseline following each intervention which was sustained to the completion 
of the study.   
The combined effect of both interventions (PI reduction=0.70) was greater than 
that of one single intervention alone; a post hoc analysis which used the week 4 
(Intervention 1) observation as the baseline for Intervention 2 suggests that 
Intervention 2 has a smaller reduction in PI compared to intervention 1 
(p=0.0005).  All of the subjects received the same two sequential interventions in 
the same order; it was not possible to examine whether the same effect would have 
been observed had the professional prophylaxis been the first intervention.  
Box plots for change from baseline in overall PI by visit were generated and are 
presented in Figure 11.  A line graph shows the reduction in mean plaque at each 
visit (Figure 12).  Reference plots were produced that provide a visual 
representation of in mean PI change from baseline at weeks 4 (Figure 13) and 8 
weeks (Figure 14). 
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Visit n Mean PI (SD) Median PI Min, Max 95% CI 
      
Baseline 31 1.1 (0.4) 1.1 0.3, 1.8 (1.0, 1.2) 
Week 2  31 0.7 (0.4) 0.8 0.1, 1.4 (0.6, 0.9) 
Week 4  31 0.6 (0.3) 0.7 0.1, 1.2 (0.5, 0.8) 
Week 6 31 0.4 (0.3) 0.3 0.0, 0.9 (0.3, 0.5) 
Week 8 31 0.4 (0.2) 0.3 0.0, 0.8 (0.3, 0.4) 
 
Reduction 
Baseline to Week 2  31 0.4 (0.3) 0.4 -0.0, 1.1 (0.3, 0.5) 
Baseline to Week 4 31 0.5 (0.3) 0.4 -0.0, 1.1 (0.3, 0.6) 
Baseline to Week 6 31 0.7 (0.3) 0.7 0.1, 1.3 (0.6, 0.8) 
Baseline to Week 8 31 0.7 (0.3) 0.7 0.2, 1.3 (0.6, 0.9) 
      
 
 
 
 
Table 7.  Clinical Trial 1.  Descriptive statistics for Plaque Index (Silness and Löe, 1964) 
including reduction in Plaque Index from baseline. 
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Visit/ Contrast n Least squares 
mean reduction in 
PI (SE) 
95% CI ANOVA p-
value 
 
Week 2 
 
31  
 
0.56 (0.07)  
 
(0.43, 0.69)  
 
 
 
 
<0.0001 
 
Week 4  31  0.64 (0.07)  (0.51, 0.78)  
Week 6  31  0.87 (0.07)  (0.74, 1.00)  
Week 8  31  0.94 (0.07)  (0.81, 1.07)  
 
Intervention 2 (Weeks 6 and 8) vs 
Intervention 1 (Weeks 2 and 4)  
 
 
31 
 
0.30 (0.05)  
 
(0.20, 0.40)  
 
 
 
Table 8.  Clinical Trial 1.  Analysis of variance (ANOVA) statistics for Plaque Index (Silness 
and Löe, 1964) outlining reduction in PI from baseline. 
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Figure 11.  Clinical Trial 1.  Box plot for Plaque Index over time; 
interventions after clinical examinations at baseline and week 4.   
Mean values are represented by diamonds and medians by horizontal line 
though the box plot, error bars are also shown.  Statistical significant 
reductions were found at weeks 2,4,6 and 8 (ANOVA P<0.0001). 
 
 
Figure 12.  Clinical Trial 1.  Line graph to show reduction in Plaque Index 
over time study with corresponding error bars.   
Interventions took place at baseline (day = 0) and 4 weeks.  Statistical 
significant reductions were found at weeks 2,4,6 and 8 (ANOVA 
P<0.0001). 
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Figure 13.  Clinical Trial 1.  Reference plot for Plaque Index at week 4 
against baseline.   
Mean Plaque Index scores plotted above the diagonal line represent 
subjects that have improved following hygiene phase therapy.  
 
Figure 14.  Clinical Trial 1.  Reference plot for Plaque Index at week 8 
against baseline.   
Mean Plaque Index scores plotted above the diagonal line represent 
subjects that have improved from Baseline to follow-up, these scores 
represent the combined effects of Intervention 1 and Intervention 2.  
There are no scores below the line to indicate deterioration in Plaque 
Index scores from baseline for any subject. 
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2.6.2 Gingival Index  
The overall mean GI was calculated as an arithmetic mean of all GI scores recorded 
at 6 sites per tooth as detailed in the protocol.  Descriptive statistics are provided 
for GI in Table 9.  
4 weeks following Intervention 1 the mean reduction in GI from baseline with 95% 
CI was 0.30 (0.24,0.35).  Eight weeks following Intervention 1 and four weeks 
following Intervention 2, the mean reduction in GI from baseline with 95% CI was 
0.51 (0.46,0.56).  An analysis of variance (ANOVA) was carried out (Table 10) to 
examine the statistical difference from baseline to weeks 2, 4, 6 and 8 which 
indicated a significant reduction in GI from baseline at all weeks (ANOVA 
p<0.0001).  There was no statistical significance in GI between weeks 6 and 8; the 
95% CI included 0 and the mean reduction was 0.02 (-0.06,0.10).  The results 
demonstrate a consistent reduction in GI from baseline following each intervention 
which is sustained to the completion of the study.   
The combined effect of both interventions (mean GI reduction = 0.51) was greater 
than that of Intervention 1 alone.  Intervention 2 did not have a greater overall 
reduction in GI compared with Intervention 1 where week 4 was used as the 
baseline for Intervention 2 (p=0.2214).   
A line graph showing the reduction in GI from baseline is shown in Figure 15 , Box 
plots for change from baseline by visit are presented in Figure 16.  Reference plots 
provide a visual representation of in mean GI change from baseline at weeks 4 
(Figure 17) and 8 weeks (Figure 18). 
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Visit n Mean GI (SD) Median GI Min, Max 95% CI 
Baseline 31  1.0 (0.2) 1.0 0.6, 1.3 (0.9, 1.0) 
Week 2 31  0.8 (0.2) 0.8 0.4, 1.2 (0.7, 0.9) 
Week 4 31  0.7 (0.2) 0.7 0.4, 1.0 (0.6, 0.7) 
Week 6 31  0.5 (0.2) 0.5 0.2, 1.0 (0.4, 0.5) 
Week 8  31  0.4 (0.1) 0.4 0.2, 0.8 (0.4, 0.5) 
 
 
Reduction 
Baseline to Week 2 
 
 
31  
 
 
0.2 (0.2) 
 
 
0.2 
 
 
-0.1, 0.4 
 
 
(0.1, 0.2) 
Baseline to Week 4 31  0.3 (0.1) 0.3 0.0, 0.6 (0.2, 0.3) 
Baseline to Week 6 31  0.5 (0.2) 0.5 0.1, 0.9 (0.4, 0.6) 
Baseline to Week 8 31  0.5 (0.1) 0.5 0.2, 0.8 (0.5, 0.6) 
 
 
 
 
Table 9.  Clinical Trial 1. Descriptive statistics for Gingival Index (Löe and Silness, 1967) 
including reduction from baseline. 
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Visit/ Contrast  n Least square mean 
reduction in GI (SE) 
95% CI ANOVA p-
value 
Week 2 (Day 14)  31 0.17 ( 0.03)  0.11, 0.22  
<.0001 
Week 4 (Day 28)  31 0.30 ( 0.03)  0.24, 0.35 
Week 6 (Day 42)  31 0.49 ( 0.03) 0.43, 0.54 
Week 8 (Day 56)  
Intervention 2 (Weeks 6 and 8) vs 
Intervention 1 (Weeks 2 and 4)  
31 
31 
0.51 ( 0.03) 
0.27 ( 0.03) 
0.46, 0.56 
0.21, 0.32 
     
 
 
 
 
 
 
 
 
 
 
Table 10.  Clinical Trial 1.  Analysis of variance (ANOVA) for Gingival Index (Löe and 
Silness, 1967). 
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Figure 15.  Clinical Trial 1.  Line graph to show reduction in Gingival 
Index. 
Statistical significant reductions were found at weeks 2,4,6 and 8 (ANOVA 
P<0.0001). 
 
 
 
 
Figure 16.  Clinical Trial 1.  Box plot for Gingival Index over time: 
Interventions after the measurements at baseline (Intervention 1) and 
week 4 (Intervention 2). 
Mean values are represented by diamonds and medians by horizontal line 
though the box plot, error bars are also shown.  Statistical significant 
reductions were found at weeks 2,4,6 and 8 (ANOVA P<0.0001). 
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Figure 17.  Clinical Trial 1.  Reference plot for Gingival Index at week 4 
against baseline. 
Mean Gingival Index scores plotted above the diagonal line represent 
subjects that have improved from Baseline to follow up 4 weeks after 
Intervention 1 (hygiene phase therapy). 
 
 
Figure 18.  Clinical Trial 1.  Reference plot for Gingival Index at week 8 
against baseline.   
Mean Gingival Index scores plotted above the diagonal line represent 
subjects that have improved from Baseline to follow-up, these scores 
represent the combined effects of Intervention 1 and Intervention 2.  
There are no scores below the line to indicate deterioration in Plaque 
Index scores from baseline for any subject. 
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2.6.3 Pocket probing depth (PPD) 
Overall mean PPDs were calculated as the arithmetic average of all PPD values per 
subject.  There was little change in mean PPD throughout the study, which would 
be expected in subjects with gingivitis with no significant loss of attachment.  
Descriptive statistics are provided for PPD in Table 11.  After 4 weeks the 
reduction in mean PPD was not significantly greater than 0, the mean reduction in 
PPD with 95% CI was 0.02 (-0.38,0.42).  At 8 weeks the reduction in PPDs was not 
statistically greater than 0, the mean with 95% CI was 0.08 (-0.32,0.48).  An 
analysis of variance indicated no statistically significant difference (p=0.1266). 
A line graph showing the reduction in PPD from baseline is shown in Figure 19. 
Box plots for change from baseline in PPD by visit are presented in Figure 20.  
Reference plots were produced that provide a visual representation of mean PPD 
change from baseline at weeks 4 (Figure 21) and 8 weeks (Figure 22). 
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Visit n Mean PPD (SD) Median PPD Min, Max 95% CI 
Pre-screening 31 1.9 (0.2) 1.9 1.7, 2.6 (1.8, 2.0) 
Baseline (Day 0)  31 1.9 (0.2) 1.8 1.6, 2.6 (1.8, 2.0) 
Week 4 (Day 28)  31 1.9 (0.2) 1.9 1.6, 2.4 (1.8, 1.9) 
Week 8 (Day 56)  31 1.8 (0.2) 1.8 1.4, 2.4 (1.7, 1.9) 
 
 
Reduction  
Baseline to Week 4 
 
 
31 
 
 
0.0 (0.2) 
 
 
0.0 
 
 
-0.3, 0.4 
 
 
(-0.0, 0.1) 
Baseline to Week 8 31 0.1 (0.2) 0.1 -0.2, 0.4 (0.0, 0.1) 
 
 
 
 
 
 
 
 
Table 11.  Clinical Trial 1.  Descriptive statistics for pocket probing depths including 
reduction in pocket probing depth from baseline. 
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Figure 19.  Clinical Trial 1.  Line graph to show reduction in pocket 
probing depth over time with corresponding error bars.   
There were no significant reductions in PPDs from baseline for any visit 
(ANOVA p=0.1266)..  
 
 
 
Figure 20.  Clinical Trial 1.  Box plot for pocket probing depth over time. 
The interventions took place after the measurements were recorded at 
baseline (Intervention 1) and week 4 (Intervention 2).   Mean values are 
represented by diamonds and medians by horizontal line though the box 
plot, error bars are also shown.  There were no significant reductions in 
PPDs from baseline for any visit (ANOVA p=0.1266). 
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Figure 21.  Clinical Trial 1.  Reference plot for pocket probing depth at 
week 4 against baseline.   
Mean pocket probing depth scores plotted above the diagonal line 
represent subjects that have decreased from baseline to week 4, those 
that fall below the reference line have increased.  The plots generally fall 
either side and close to the reference line indicating little change over 
time. 
 
 
 
 
Figure 22. Clinical Trial 1.  Reference plot for pocket probing depth at 
week 8 against baseline.   
Mean pocket probing depth scores plotted above the diagonal line 
represent subjects that have decreased from baseline to week 4, those 
that fall below the reference line have increased.  The plots generally lie 
close to the reference line indicating little change over time. 
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2.6.4 Biomarkers 
All laboratory analysis was performed blinded to the sample, visit and patient 
identifiers. Descriptive statistics were produced for each mediator including mean 
values and standard deviations for each patient at each visit as follows: 
 IL-1α  (Table 12) 
 IL-1β   (Table 13) 
 IL-8   (Table 14) 
 MIP-1α (Table 15) 
 MIP-1β  (Table 16) 
 RANTES (Table 17) 
 MMP-1 (Table 18) 
 MMP-3 (Table 19) 
 MMP-8  (Table 20) 
 MMP-9  (Table 21) 
 MMP-13 (Table 22) 
Log mean values of mediator concentrations in picograms per millilitre were 
calculated for comparison as the mean values were not normally distributed. 
Whilst most biomarkers increased transiently post treatment: those that showed 
statistical significance at the 95% level were IL-1β, MMP-1, MMP-3, MMP-8, MMP-
9, from baseline to week 2, RANTES at week 4 and week 8; MIP-1α and MIP-1β at 
week 8.  Figure 23 is a spaghetti plot of the mean log-10 transformed biomarker 
levels.  There were transient changes following the interventions at baseline and 
week 4 for some mediators.  No mediators showed a sustained change from 
baseline.  When examining the collated data or when all biomarkers were 
considered together, no significant differences were detected over time (p>0.05).  
There were no correlations found with the clinical indices.  
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Biomarker Endpoint Visit n Mean (SD) Median Min, Max p-value 
IL-1α Observed Baseline 31 5.07 (0.64) 5.1 3.74, 6.11  
Week 2 31 5.16 (0.58) 5.3 3.61, 5.86 
Week 4 31 5.23 (0.58) 5.3 3.81,  6.29 
Week 6 30 5.12 (0.66) 5.3 3.84, 6.35 
Week 8 31 5.22 (0.63) 5.3 3.88, 6.41 
 Reduction 
from 
baseline 
Week 2  31 -0.09 (0.66) -0.0 -1.26, 1.44 0.434 
Week 4  31 -0.16 (0.74) -0.1 -2.20, 1.31 0.236 
Week 6  30 -0.06 (0.78) -0.1 -1.73, 1.69 0.676 
Week 8  31 -0.15 (0.87) -0.1 -1.83, 1.41 0.343 
 
 
 
 
 
Table 12.  Clinical Trial 1.  Mean observed log-10 transformed biomarker levels for IL-1α 
over the 8 weeks of the study.  
The lower portion of the table indicates reduction from baseline with negative values for 
mean reduction indicating a positive change in biomarkers, all biomarker concentrations 
are in pg/ml. 
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Biomarker Endpoint Visit n Mean (SD) Median Min, Max p-value 
IL-1β Observed Baseline  31 4.57 (0.63) 4.7 2.92, 5.75  
Week 2  31 4.81 (0.62) 4.9 3.24, 5.94  
Week 4  31 4.76 (0.66) 4.8 3.00, 6.17  
Week 6  30 4.81 (0.66) 5.0 3.48, 6.08 
Week 8  31 4.77 (0.70) 4.8 3.25, 5.87 
 
Reduction 
from 
baseline 
Week 2  31 -0.24 (0.66) -0.4 -1.53, 1.11 0.050 
Week 4  31 -0.19 (0.74) -0.1 -2.25, 1.19 0.152 
Week 6  30 -0.25 (0.80) -0.3 -1.94, 1.66 0.096 
Week 8 31 -0.20 (0.88) -0.1 -1.83, 1.93 0.211 
 
 
 
 
 
 
Table 13.  Clinical Trial 1.  Mean observed log-10 transformed biomarker levels for IL-1β 
over the 8 weeks of the study.  
The lower portion of the table indicates reduction from baseline with negative values for 
mean reduction indicating a positive change in biomarkers, all biomarker concentrations 
are in pg/ml. 
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Biomarker Endpoint Visit n Mean (SD) Median Min, Max p-value 
IL-8 Observed Baseline  31 5.38 (0.52) 5.4 3.96, 6.44  
Week 2  31 5.60 (0.61) 5.8 4.01, 6.87 
Week 4  31 5.56 (0.51) 5.6 4.31, 6.28 
Week 6  30 5.60 (0.64) 5.6 4.32, 6.75 
Week 8  31 5.58 (0.54) 5.6 4.60, 6.50 
 Reduction 
from 
baseline 
Week 2  31 -0.22 (0.72) -0.4 -1.57, 1.49 0.092 
Week 4  31 -0.18 (0.61) -0.2 -1.45, 1.04 0.115 
Week 6  30 -0.22 (0.89) -0.2 -2.10, 1.34 0.195 
Week 8  31 -0.20 (0.75) -0.4 -1.54, 0.95 0.146 
 
 
 
 
 
 
Table 14.  Clinical Trial 1.  Mean observed log-10 transformed biomarker levels for IL-8 
over the 8 weeks of the study.  
The lower portion of the table indicates reduction from baseline with negative values for 
mean reduction indicating a positive change in biomarkers, all biomarker concentrations 
are in pg/ml. 
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Biomarker Endpoint Visit n Mean (SD) Median Min, Max p-value 
MIP-1α Observed Baseline  31 3.83 (0.44) 3.8 2.93, 4.68  
Week 2  31 4.03 (0.53) 4.0 3.02, 5.18 
Week 4  31 4.03 (0.61) 4.0 2.90, 5.54 
Week 6  30 4.00 (0.46) 3.9 3.28, 4.88 
Week 8  31 4.07 (0.53) 4.1 3.16, 5.05 
 
Reduction 
from 
baseline 
Week 2 31 -0.20 (0.62) -0.1 -1.59, 1.03 0.086 
Week 4 31 -0.20 (0.66) -0.1 -1.81, 1.33 0.109 
Week 6  30 -0.17 (0.66) -0.1 -1.92, 1.07 0.161 
Week 8 31 -0.24 (0.57) -0.3 -1.07, 0.82 0.027 
 
 
 
 
 
 
 
Table 15.  Clinical Trial 1.  Mean observed log-10 transformed biomarker levels for MIP-1α 
over the 8 weeks of the study.  
The lower portion of the table indicates reduction from baseline with negative values for 
mean reduction indicating a positive change in biomarkers, all biomarker concentrations 
are in pg/ml. 
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Biomarker Endpoint Visit n Mean (SD) Median Min, Max p-value 
MIP-1β Observed Baseline  31 3.38 (0.59) 3.4 1.89, 4.64  
Week 2  31 3.66 (0.74) 3.6 2.42, 5.40 
Week 4  31 3.58 (0.69) 3.4 2.31, 4.82 
Week 6  30 3.60 (0.63) 3.3 2.89, 4.83 
Week 8  31 3.69 (0.68) 3.6 2.56, 5.05 
 Reduction 
from 
baseline 
Week 2  31 -0.27 (0.90) -0.3 -2.06, 1.72 0.101 
Week 4  31 -0.19 (0.72) -0.3 -1.63, 1.20 0.146 
Week 6  30 -0.23 (0.94) -0.0 -2.41, 1.63 0.196 
Week 8  31 -0.31 (0.74) -0.4 -1.35 - 1.27 0.028 
 
 
 
 
 
 
 
 
Table 16.  Clinical Trial 1.  Mean observed log-10 transformed biomarker levels for MIP-1β 
over the 8 weeks of the study.  
The lower portion of the table indicates reduction from baseline with negative values for 
mean reduction indicating a positive change in biomarkers, all biomarker concentrations 
are in pg/ml. 
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Biomarker Endpoint Visit n Mean (SD) Median Min, Max p-value 
RANTES Observed Baseline 31 3.58 (0.51) 3.6 2.55, 4.44  
Week 2  31 3.69 (0.42) 3.8 2.84, 4.67 
Week 4 31 3.92 (0.64) 3.8 2.97, 5.92 
Week 6 30 3.73 (0.36) 3.7 2.77, 4.65 
Week 8 31 3.87 (0.45) 3.8 2.98, 4.71 
 Reduction 
from 
baseline 
Week 2 31 -0.11 (0.55) -0.1 -0.98, 0.98 0.287 
Week 4 31 -0.34 (0.72) -0.2 -1.84, 1.16 0.014 
Week 6 30 -0.15 (0.62) -0.1 -1.65, 1.01 0.186 
Week 8 31 -0.29 (0.61) -0.3 -1.64, 1.32 0.014 
 
 
 
 
 
 
 
 
Table 17.  Clinical Trial 1.  Mean observed log-10 transformed biomarker levels for 
RANTES over the 8 weeks of the study.  
The lower portion of the table indicates reduction from baseline with negative values for 
mean reduction indicating a positive change in biomarkers, all biomarker concentrations 
are in pg/ml. 
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Biomarker Endpoint Visit n Mean (SD) Median Min, Max p-value 
MMP-1 Observed Baseline  31 4.56 (0.82) 4.5 2.70, 5.73  
Week 2  31 4.94 (0.66) 5.0 3.19, 6.24 
Week 4  31 4.53 (0.62) 4.5 3.13, 6.19 
Week 6  31 4.83 (0.82) 4.9 3.04, 6.18 
Week 8  31 4.73 (0.78) 4.9 3.17, 6.26 
 Reduction 
from 
baseline 
Week 2  31 -0.39 (0.89) -0.3 -2.90, 1.28 0.021 
Week 4  31 0.03 (1.07) 0.3 -2.90, 1.71 0.886 
Week 6  31 -0.27 (1.04) -0.2 -2.10, 2.67 0.156 
Week 8  31 -0.17 (1.02) -0.2 -2.97, 2.01 0.360 
 
 
 
 
 
 
Table 18.  Clinical Trial 1.  Mean observed log-10 transformed biomarker levels for MMP-1 
over the 8 weeks of the study.  
The lower portion of the table indicates reduction from baseline with negative values for 
mean reduction indicating a positive change in biomarkers, all biomarker concentrations 
are in pg/ml. 
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Table 19.  Clinical Trial 1.  Mean observed log-10 transformed biomarker levels for MMP-3 
over the 8 weeks of the study.  
The lower portion of the table indicates reduction from baseline with negative values for 
mean reduction indicating a positive change in biomarkers, all biomarker concentrations 
are in pg/ml. 
  
Biomarker Endpoint Visit n Mean (SD) Median Min, Max p-value 
MMP-3 Observed Baseline 31 4.26 (0.74) 4.4 2.47, 5.46  
Week 2 31 4.60 (0.67) 4.5 2.98, 5.99 
Week 4 31 4.24 (0.58) 4.3 3.16, 5.29 
Week 6 31 4.43 (0.73) 4.5 3.11, 6.04 
Week 8 31 4.30 (0.72) 4.3 2.72, 5.69 
 Reduction 
from 
baseline 
Week 2 31 -0.34 (0.81) -0.2 -2.97, 0.76 0.025 
Week 4 31 0.02 (0.81) 0.3 -2.14, 1.16 0.894 
Week 6 31 -0.18 (0.95) -0.0 -1.81, 2.08 0.312 
Week 8 31 -0.04 (0.90) 0.2 -2.06, 1.59 0.799 
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Biomarker Endpoint Visit n Mean (SD) Median Min - Max p-value 
MMP-8 Observed Baseline  31 7.11 (0.76) 7.3 5.77, 8.29  
Week 2 31 7.68 (0.54) 7.7 6.63, 8.71 
Week 4 31 7.10 (0.70) 7.3 5.67, 8.74 
Week 6 31 7.51 (0.81) 7.6 5.16, 8.86 
Week 8 31 7.16 (0.71) 7.2 5.84, 8.40 
 Reduction 
from 
baseline 
Week 2 31 -0.57 (0.88) -0.5 -2.27, 1.26 0.001 
Week 4 31 0.01 (0.94) 0.0 -1.56, 1.78 0.963 
Week 6 31 -0.40 (1.12) -0.4 -2.40, 2.96 0.057 
Week 8 31 -0.05 (0.96) -0.1 -1.94, 1.91 0.792 
 
 
 
 
 
 
Table 20.  Clinical Trial 1.  Mean observed log-10 transformed biomarker levels for MMP-8 
over the 8 weeks of the study.  
The lower portion of the table indicates reduction from baseline with negative values for 
mean reduction indicating a positive change in biomarkers, all biomarker concentrations 
are in pg/ml. 
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Biomarker Endpoint Visit n Mean (SD) Median Min, Max p-value 
MMP-9 Observed Baseline  31 7.67 (0.74) 7.7 6.41, 8.96  
Week 2 31 8.15 (0.54) 8.1 7.10, 9.64 
Week 4 31 7.68 (0.68) 7.8 6.01, 8.90 
Week 6 31 7.98 (0.81) 8.1 5.72, 9.27 
Week 8 31 7.74 (0.79) 7.9 6.13, 9.10 
 
Reduction 
from 
baseline 
Week 2 31 -0.49 (0.88) -0.3 -2.72, 0.69 0.005 
Week 4 31 -0.02 (0.96) -0.0 -1.91, 1.99 0.921 
Week 6 31 -0.32 (1.18) -0.2 -2.35, 3.24 0.145 
Week 8 31 -0.08 (0.95) -0.2 -2.18, 1.61 0.651 
 
 
 
 
 
 
Table 21.  Clinical Trial 1.  Mean observed log-10 transformed biomarker levels for MMP-9 
over the 8 weeks of the study. 
The lower portion of the table indicates reduction from baseline with negative values for 
mean reduction indicating a positive change in biomarkers, all biomarker concentrations 
are in pg/ml. 
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Biomarker Endpoint Visit n Mean (SD) Median Min, Max p-value 
MMP-13 Observed Baseline 31 5.23 (0.86) 5.3 3.01, 6.41  
Week 2 31 5.39 (0.90) 5.6 3.44, 7.16 
Week 4 31 5.26 (0.82) 5.4 2.74, 6.79 
Week 6 31 5.41 (0.91) 5.8 3.44, 6.50 
Week 8 31 5.44 (0.95) 5.5 3.45, 7.09 
 Reduction 
from 
baseline 
Week 2 31 -0.16 (0.84) -0.1 -1.65, 1.42 0.296 
Week 4 31 -0.03 (0.97) 0.1 -2.15, 1.82 0.851 
Week 6 31 -0.18 (1.02) -0.1 -1.67, 2.65 0.329 
Week 8 31 -0.21 (1.03) -0.2 -2.46, 1.91 0.264 
 
 
 
 
 
 
Table 22.  Clinical Trial 1.  Mean observed log-10 transformed biomarker levels for MMP-
13 over the 8 weeks of the study.  
The lower portion of the table indicates reduction from baseline with negative values for 
mean reduction indicating a positive change in biomarkers, all biomarker concentrations 
are in pg/ml.
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Figure 23.  Clinical Trial 1.  A spaghetti plot representing the mean log 10 transformed 
biomarker levels by visit. 
Vertical bars show standard error of the mean, all biomarker concentrations are in pg/ml. 
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2.6.5 Microbial biomarkers 
All laboratory analysis was performed blinded to the sample, visit and patient 
identifers.   Following examination of the distribution of the microbial data it was 
log 10 transformed prior to analysis. Descriptive statistics for mean microbial 
levels are presented along with t-test p-values showing change from baseline 
(Table 23 for subgingival species and Table 24 for supragingival species).  
Summary tables of those species with significant reductions from baseline are 
shown in Table 25 for the subgingival samples and Table 26 for the supragingival 
samples. Those species with significant increases from baseline are shown in Table 
27 for subgingival samples and Table 28 for the supragingival samples. 
Several organisms associated with disease significantly decreased post 
intervention (Table 25 and Table 26).  Some of the bacteria more commonly 
associated with oral health: Streptococcus mitis, Streptococcus sanguinis, Veillonella 
parvula increased significantly post treatment.  Three species that are associated 
with disease: Granulicatella adjacens, Neisseria mucosa, and Prevotella nigrescens 
increased significantly post treatment.  Species associated with deep pocketing, 
bleeding upon probing and periodontitis: Porphyromonas gingivalis, Tannerella 
forsynthesis, and Treponema denticola (Figure 24) were found in small numbers in 
all subjects with little change over time (Socransky et al., 1998).   
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Table 23.  Clinical Trial 1.  Descriptive summary of subgingival bacterial species including 
ANOVA statistical difference from baseline (log 10 transformed data).  
 
Microbe Visit n Mean (SD) Median Min, Max p-value 
change 
from 
baseline 
Actinomyces naeslundii  Baseline 27 0.14 (0.27) 0.0 0.00, 0.88 N/a 
Week 4 27 0.23 (0.33) 0.0 0.00, 0.99 0.151 
Week 8 27 0.08 (0.30) 0.0 -0.47,0.95 0.263 
Actinomyces 
odontolyticus  
Baseline 27 0.02 (0.07) 0.0 0.00, 0.27 N/a 
Week 4 27 0.04 (0.12) 0.0 0.00, 0.52 0.381 
Week 8  27 -0.03 (0.28) 0.0 -0.91, 0.64 0.375 
Actinomyces viscosus  Baseline 27 0.09 (0.21) 0.0 0.00, 0.71 N/a 
Week 4 27 0.02 (0.07) 0.0 0.00, 0.26 0.128 
Week 8  27 -0.04 (0.16) 0.0 -0.71, 0.00 0.010 
Aggregatibacter 
actinomycetemcomitans  
Baseline 27 -0.01 (0.06) 0.0 -0.28, 0.11 N/a 
Week 4 27 0.00 (0.00) 0.0 0.00, 0.00 0.597 
Week 8 27 0.00 (0.00) 0.0 0.00, 0.00 0.597 
Bifidobacterium 
infantis  
Baseline 27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Week 4 27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Week 8 27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Campylobacter gracilis  Baseline 27 0.46 (0.37) 0.5 0.00, 1.09 N/a 
Week 4 27 0.13 (0.24) 0.0 0.00, 0.79 <0.001 
Week 8 27 0.06 (0.23) 0.0 -0.47, 0.54 <0.001 
Capnocytophaga 
ochracea  
Baseline 27 0.24 (0.31) 0.2 0.00, 1.15 N/a 
Week 4  27 0.10 (0.18) 0.0 0.00, 0.56 0.062 
Week 8  27 -0.07 (0.26) 0.0 -0.92, 0.37 <0.001 
Catonella morbi  Baseline 27 0.03 (0.32) 0.0 -0.63, 0.81 N/a 
Week 4 27 0.05 (0.13) 0.0 0.00, 0.60 0.765 
Week 8 27 0.04 (0.09) 0.0 0.00, 0.27 0.875 
Dialister pneumosintes  
  
Baseline 27 0.87 (0.47) 0.9 0.00, 1.56 N/a 
Week 4 27 0.23 (0.37) 0.0 0.00, 1.09 <0.001 
Week 8 27 0.27 (0.30) 0.2 0.00, 0.88 <0.001 
Enterococcus faecalis  
 
Baseline 27 -0.00 (0.21) 0.0 -0.88, 0.58 N/a 
Week 4 27 0.00 (0.00) 0.0 0.00, 0.00 0.980 
Week 8 27 0.00 (0.00) 0.0 0.00, 0.00 0.980 
Eubacterium brachy  
 
Baseline 27 0.10 (0.23) 0.0 0.00, 0.93 N/a 
Week 4 27 0.02 (0.06) 0.0 0.00, 0.23 0.073 
Week 8 27 0.07 (0.15) 0.0 0.00, 0.63 0.543 
Eubacterium 
saburreum  
 
Baseline 27 0.30 (0.34) 0.2 0.00, 1.09 N/a 
Week 4 27 0.12 (0.24) 0.0 0.00, 0.75 0.026 
Week 8 27 0.10 (0.23) 0.0 -0.11, 0.79 0.014 
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Table 23.  (Continued)       
Fillifactor alocis  
 
Baseline 27 -0.02 (0.12) 0.0 -0.60, 0.00 N/a 
Week 4 27 0.00 (0.00) 0.0 0.00, 0.00 0.282 
Week 8 27 0.00 (0.00) 0.0 0.00, 0.00 0.282 
Fusobacterium 
nucleatum  
 
Baseline 27 -0.04 (0.22) 0.0 -0.96, 0.23 N/a 
Week 4 27 -0.03 (0.14) 0.0 -0.64, 0.08 0.957 
Week 8 27 -0.02 (0.18) 0.0 -0.49, 0.26 0.779 
Granulicatella adjacens  
 
Baseline 27 0.04 (0.22) 0.0 -0.64, 0.38 N/a 
Week 4 27 0.23 (0.28) 0.0 0.00, 0.92 <0.001 
Week 8 27 0.22 (0.28) 0.1 -0.19, 0.83 <0.001 
Lactobacillus gasseri Baseline 27 -0.02 (0.10) 0.0 -0.49, 0.00 N/a 
Week 4 27 0.00 (0.00) 0.0 0.00, 0.00 0.327 
Week 8 27 0.00 (0.00) 0.0 0.00, 0.00 0.327 
Lactobacillus reuteri  Baseline 27 -0.00 (0.00) 0.0 -0.01, 0.00 N/a 
Week 4 27 0.00 (0.00) 0.0 0.00, 0.00 0.327 
Week 8 27 0.00 (0.00) 0.0 0.00, 0.00 0.327 
Leptotrichia buccalis  Baseline  27 -0.04 (0.17) 0.0 -0.62, 0.30 N/a 
Week 4  27 0.06 (0.24) 0.0 0.00, 1.13 0.085 
Week 8  27 0.07 (0.19) 0.0 0.00, 0.78 0.057 
Neisseria mucosa  Baseline  27 0.02 (0.07) 0.0 0.00, 0.28 N/a 
Week 4  27 0.17 (0.30) 0.0 0.00, 1.02 0.020 
Week 8  27 0.18 (0.35) 0.0 -0.80, 0.83 0.020 
Parvimonas micra  Baseline  27 0.21 (0.37) 0.0 0.00, 1.11 N/a 
Week 4  27 0.02 (0.08) 0.0 -0.11, 0.24 0.016 
Week 8  27 0.02 (0.07) 0.0 -0.01, 0.25 0.009 
Porphyromonas 
gingivalis  
Baseline 27 0.01 (0.05) 0.0 0.00, 0.26 N/a 
Week 4  27 -0.07 (0.27) 0.0 -1.07, 0.00 0.154 
Week 8  27 -0.07 (0.28) 0.0 -1.14, 0.10 0.132 
Prevotella nigrescens  Baseline  27 -0.12 (0.29) 0.0 -0.88, 0.28 N/a 
Week 4  27 0.01 (0.06) 0.0 0.00, 0.29 0.031 
Week 8  27 0.00 (0.00) 0.0 0.00, 0.00 0.046 
Prevotella oris  Baseline  27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Week 4  27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Week 8  27 -0.03 (0.16) 0.0 -0.84, 0.00 0.327 
Propionibacterium 
propionicus  
Baseline  27 0.02 (0.10) 0.0 0.00, 0.52 N/a 
Week 4  27 0.03 (0.08) 0.0 0.00, 0.30 0.7909 
Week 8  27 0.03 (0.24) 0.0 -0.65, 0.58 0.911 
Pseudomonas 
aeruginosa  
Baseline  27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Week 4  27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Week 8  27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Selenomonas noxia  Baseline  27 0.41 (0.42) 0.5 0.00, 1.28 N/a 
Week 4  27 0.06 (0.15) 0.0 0.00, 0.61 <0.001 
Week 8  27 0.00 (0.11) 0.0 -0.43, 0.30 <0.001 
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Table 23.  (Continued)       
Selenomonas sputigena  Baseline  27 0.19 (0.33) 0.0 0.00, 1.00 N/a 
Week 4  27 0.06 (0.13) 0.0 0.00, 0.55 0.059 
Week 8  27 0.07 (0.16) 0.0 -0.01, 0.56 0.107 
Streptococcus mitis  Baseline  27 0.17 (0.29) 0.0 0.00, 1.10 N/a 
Week 4  27 0.47 (0.54) 0.0 0.00, 1.38 0.027 
Week 8  27 0.59 (0.49) 0.6 -0.35, 1.28 <0.001 
Streptococcus mutans  Baseline  27 -0.12 (0.42) 0.0 -2.08, 0.00 N/a 
Week 4  27 0.04 (0.12) 0.0 0.00, 0.54 0.066 
Week 8  27 -0.07 (0.21) 0.0 -0.91, 0.00 0.594 
Streptococcus sanguinis  Baseline  27 0.59 (0.42) 0.6 0.00, 1.38 N/a 
Week 4  27 0.90 (0.37) 1.0 0.00, 1.43 0.002 
Week 8  27 0.93 (0.40) 1.0 -0.70, 1.40 <0.001 
Tannerella forsynthesis  Baseline  27 0.03 (0.18) 0.0 0.00, 0.94 N/a 
Week 4  27 0.00 (0.00) 0.0 0.00, 0.00 0.327 
Week 8  27 -0.01 (0.04) 0.0 -0.23, 0.00 0.233 
Treponema denticola  Baseline  27 0.35 (0.35) 0.3 0.00, 1.05 N/a 
Week 4  27 0.10 (0.22) 0.0 0.00, 0.71 <0.001 
Week 8 27 -0.04 (0.29) 0.0 -0.66, 0.73 <0.001 
Veillonella parvula  Baseline 27 1.00 (0.34) 1.0 0.24, 1.58 N/a 
Week 4 27 1.31 (0.23) 1.3 0.52, 1.66 <0.001 
Week 8 27 1.35 (0.17) 1.4 1.09, 1.65 <0.001 
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Table 24.  Clinical Trial 1.  Descriptive summary of supragingival bacterial species 
including ANOVA statistical difference from baseline (log 10 transformed data). 
 
Microbe Visit n Mean (SD) Median Min, Max p-value 
change 
from 
baseline 
Actinomyces naeslundii  Baseline 27 0.40 (0.41) 0.3 0.00, 1.43 N/a 
Week 4 27 0.25 (0.27) 0.2 0.00, 0.83 0.164 
Week 8 27 0.26 (0.33) 0.1 0.00, 1.16 0.223 
Actinomyces 
odontolyticus  
Baseline 27 0.04 (0.17) 0.0 0.00, 0.84 N/a 
Week 4 27 0.01 (0.04) 0.0 0.00, 0.22 0.359 
Week 8 27 -0.08 (0.25) 0.0 -0.94, 0.00 0.041 
Actinomyces viscosus  Baseline  27 -0.01 (0.23) 0.0 -0.63, 0.55 N/a 
Week 4 27 0.03 (0.15) 0.0 -0.43, 0.54 0.483 
Week 8 27 0.06 (0.18) 0.0 -0.01, 0.71 0.184 
Aggregatibacter 
actinomycetemcomitans  
Baseline 27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Week 4 27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Week 8 27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Bifidobacterium 
infantis  
Baseline 27 0.02 (0.11) 0.0 0.00, 0.55 N/a 
Week 4 27 0.00 (0.00) 0.0 0.00, 0.00 0.327 
Week 8 27 0.00 (0.00) 0.0 0.00, 0.00 0.327 
Campylobacter gracilis  Baseline 27 0.25 (0.28) 0.2 0.00, 0.81 N/a 
Week 4 27 0.08 (0.20) 0.0 0.00, 0.84 0.017 
Week 8 27 0.04 (0.23) 0.0 -0.94, 0.34 0.004 
Capnocytophaga 
ochracea  
Baseline 27 0.33 (0.44) 0.2 0.00, 1.49 N/a 
Week 4 27 0.13 (0.20) 0.0 0.00, 0.83 0.039 
Week 8 27 0.21 (0.31) 0.0 -0.03,1.15 0.274 
Catonella morbi  Baseline 27 0.01 (0.06) 0.0 0.00, 0.34 N/a 
Week 4 27 0.00 (0.00) 0.0 0.00, 0.00 0.327 
Week 8 27 -0.03 (0.18) 0.0 -0.92,0.00 0.205 
Dialister pneumosintes  
 
Baseline  27 -0.08 (0.26) 0.0 -0.93, 0.18 N/a 
Week 4 27 0.00 (0.00) 0.0 0.00, 0.00 0.132 
Week 8 27 0.02 (0.07) 0.0 0.00, 0.29 0.066 
Enterococcus faecalis  Baseline 27 -0.05 (0.33) 0.0 -1.70, 0.24 N/a 
Week 4 27 0.00 (0.00) 0.0 0.00, 0.00 0.404 
Week 8 27 0.00 (0.00) 0.0 0.00, 0.00 0.404 
Eubacterium brachy  Baseline 27 0.21 (0.29) 0.0 0.00, 0.94 N/a 
Week 4 27 0.15 (0.26) 0.0 0.00, 0.85 0.487 
Week 8 27 0.03 (0.15) 0.0 -0.45, 0.27 0.014 
Eubacterium 
saburreum  
Baseline 27 0.06 (0.14) 0.0 0.00, 0.55 N/a 
Week 4 27 0.04 (0.12) 0.0 0.00, 0.54 0.607 
Week 8 27 -0.08 (0.33) 0.0 -0.92, 0.83 0.054 
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Table 24. (Continued)       
Fillifactor alocis  Baseline 27 -0.06 (0.26) 0.0 -0.93, 0.34 N/a 
Week 4 27 0.00 (0.00) 0.0 0.00, 0.00 0.271 
Week 8  27 0.01 (0.05) 0.0 0.00, 0.24 0.208 
Fusobacterium 
nucleatum  
Baseline 27 0.05 (0.15) 0.0 0.00, 0.71 N/a 
Week 4 27 0.00 (0.00) 0.0 0.00, 0.00 0.119 
Week 8 27 -0.03 (0.14) 0.0 -0.63, 0.25 0.126 
Granulicatella adjacens  Baseline 27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Week 4 27 0.06 (0.16) 0.0 0.00, 0.72 0.075 
Week 8 27 0.04 (0.14) 0.0 0.00, 0.74 0.185 
Lactobacillus gasseri  Baseline 27 0.16 (0.26) 0.0 0.00, 0.84 N/a 
Week 4 27 0.08 (0.15) 0.0 0.00, 0.62 0.052 
Week 8 27 -0.01 (0.21) 0.0 -0.63, 0.34 0.009 
Lactobacillus reuteri  Baseline 27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Week 4 27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Week 8 27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Leptotrichia buccalis  Baseline 27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Week 4 27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Week 8 27 0.01 (0.05) 0.0 0.00, 0.27 0.327 
Neisseria mucosa  Baseline 27 0.03 (0.14) 0.0 0.00, 0.71 N/a 
Week 4 27 0.10 (0.22) 0.0 0.00, 0.82 0.026 
Week 8 27 0.01 (0.30) 0.0 -0.62, 0.83 0.774 
Parvimonas micra  Baseline 27 0.04 (0.19) 0.0 0.00, 0.97 N/a 
Week 4 27 0.02 (0.06) 0.0 0.00, 0.24 0.495 
Week 8 27 0.03 (0.08) 0.0 0.00, 0.26 0.664 
Porphyromonas 
gingivalis  
Baseline 27 0.03 (0.11) 0.0 0.00, 0.53 N/a 
Week 4 27 0.03 (0.09) 0.0 0.00, 0.34 0.963 
Week 8 27 0.01 (0.05) 0.0 0.00, 0.27 0.440 
Prevotella nigrescens  Baseline 27 0.09 (0.21) 0.0 0.00, 0.89 N/a 
Week 4 27 0.00 (0.00) 0.0 0.00, 0.00 0.037 
Week 8 27 0.02 (0.07) 0.0 0.00, 0.26 0.044 
Prevotella oris  Baseline 27 -0.03 (0.18) 0.0 -0.92, 0.00 N/a 
Week 4 27 0.01 (0.05) 0.0 0.00, 0.24 0.230 
Week 8 27 0.00 (0.00) 0.0 0.00, 0.00 0.327 
Propionibacterium 
propionicus  
Baseline 27 0.05 (0.33) 0.0 -0.63, 0.95 N/a 
Week 4 27 0.02 (0.06) 0.0 0.00, 0.24 0.581 
Week 8 27 0.02 (0.06) 0.0 0.00, 0.24 0.625 
Pseudomonas 
aeruginosa  
Baseline 27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Week 4 27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Week 8 27 0.00 (0.00) 0.0 0.00, 0.00 N/a 
Selenomonas noxia  
 
Baseline 27 0.20 (0.43) 0.0 -0.63, 1.24 N/a 
Week 4 27 0.02 (0.10) 0.0 0.00, 0.54 0.041 
Week 8 27 0.04 (0.09) 0.0 0.00, 0.27 0.056 
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Table 24. (Continued)       
Selenomonas sputigena  
 
Baseline  27 0.74 (0.57) 0.8 0.00, 1.56 N/a 
Week 4  27 0.31 (0.39) 0.2 0.00, 1.24 <0.001 
Week 8  27 0.25 (0.31) 0.0 0.00, 0.95 <0.001 
Streptococcus mitis  
 
Baseline  27 0.44 (0.40) 0.5 0.00, 1.26 N/a 
Week 4 27 0.65 (0.51) 0.7 0.00, 1.56 0.013 
Week 8 27 0.63 (0.54) 0.7 0.00, 1.46 0.035 
Streptococcus mutans  
 
Baseline 27 0.02 (0.07) 0.0 0.00, 0.27 N/a 
Week 4 27 0.03 (0.11) 0.0 0.00, 0.54 0.702 
Week 8 27 -0.08 (0.24) 0.0 -0.92, 0.00 0.041 
Streptococcus sanguinis  
 
Baseline 27 0.56 (0.41) 0.6 0.00, 1.11 N/a 
Week 4 27 0.95 (0.45) 1.1 0.00, 1.47 <0.001 
Week 8 27 0.96 (0.43) 1.1 0.00, 1.52 <0.001 
Tannerella forsynthesis  
 
Baseline 27 0.01 (0.05) 0.0 0.00, 0.24 N/a 
Week 4 27 0.01 (0.05) 0.0 0.00, 0.24 1.000 
Week 8 27 -0.07 (0.25) 0.0 -0.93, 0.00 0.118 
Treponema denticola  
 
Baseline 27 -0.03 (0.29) 0.0 -0.94, 0.34 N/a 
Week 4 27 0.01 (0.05) 0.0 0.00, 0.24 0.480 
Week 8 27 0.00 (0.00) 0.0 0.00, 0.00 0.577 
Veillonella parvula  
 
Baseline 27 0.59 (0.34) 0.6 0.00, 1.31 N/a 
Week 4 27 0.81 (0.37) 0.8 0.00, 1.48 0.028 
Week 8 27 0.79 (0.35) 0.8 0.00, 1.30 0.038 
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Microbe Visit n Mean (SD) Median Min, Max p-value 
change 
from 
baseline 
Dialister pneumonistes  Week 4 27 0.63 (0.58) 0.8 -1.09, 1.55 <0.001 
Week 8 27 0.59 (0.61) 0.7 -0.57, 1.56 <0.001 
Campylobacter gracilis  Week 4 27 0.34 (0.41) 0.2 -0.22, 1.09 <0.001 
Week 8 27 0.41 (0.44) 0.3 -0.37, 1.26 <0.001 
Selenomonas noxia  Week 4 27 0.35 (0.42) 0.1 -0.26, 1.22 <0.001 
Week 8 27 0.41 (0.46) 0.5 -0.30, 1.28 <0.001 
Treponema denticola  Week 4 27 0.25 (0.35) 0.2 -0.56, 1.05 <0.001 
Week 8 27 0.39 (0.48) 0.3 0.00, 1.61 <0.001 
Capnocytophaga 
ochracea  
Week 4 27 0.14 (0.38) 0.0 -0.56, 1.15 0.062 
Week 8 27 0.31 (0.41) 0.3 -0.37, 1.58 <0.001 
Eubacterium 
saburreum  
Week 4 27 0.18 (0.39) 0.0 -0.61, 0.90 0.026 
Week 8 27 0.20 (0.39) 0.0 -0.59, 0.94 0.014 
Parvimonas micra  Week 4 27 0.19 (0.37) 0.0 -0.24, 1.11 0.016 
Week 8 27 0.19 (0.34) 0.0 0.00, 1.11 0.009 
Actinomyces viscosus  Week 4 27 0.07 (0.22) 0.0 -0.26, 0.71 0.128 
Week 8 27 0.13 (0.24) 0.0 0.00, 0.71 0.010 
 
 
 
 
 
 
 
 
Table 25.  Clinical Trial 1.  Subgingival species with statistically significant reductions at 
respective weeks (log 10 transformed data). 
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Microbe Visit n Mean (SD) Median Min, Max p-value 
change 
from 
baseline 
Selenomonas sputigena  Week 4 27 0.44 (0.59) 0.5 -0.88 ,1.38 <0.001 
Week 8 27 0.50 (0.63) 0.5 -0.74, 1.56 <0.001 
Campylobacter gracilis  Week 4 27 0.17 (0.36) 0.0 -0.84, 0.81 0.017 
Week 8 27 0.21 (0.36) 0.0 -0.26, 0.94 0.004 
Capnocytophaga 
ochracea  
Week 4 27 0.20 (0.47) 0.0 -0.83, 1.15 0.039 
Week 8 27 0.12 (0.55) 0.0 -1.15, 1.49 0.274 
Eubacterium brachy  Week 4 27 0.06 (0.44) 0.0 -0.85, 0.94 0.487 
Week 8 27 0.18 (0.36) 0.0 -0.27, 0.94 0.014 
Selenomonas noxia  Week 4 27 0.18 (0.42) 0.0 -0.63, 1.24 0.041 
Week 8 27 0.16 (0.41) 0.0 -0.63, 1.00 0.056 
Lactobacillus gasseri  Week 4 27 0.09 (0.22) 0.0 -0.24, 0.68 0.052 
Week 8 27 0.17 (0.31) 0.0 -0.34, 0.63 0.009 
Actinomyces 
odontolyticus 
Week 4 27 0.03 (0.17) 0.0 -0.22, 0.84 0.359 
Week 8 27 0.12 (0.29) 0.0 0.00, 0.94 0.041 
Streptococcus mutans  Week 8 27 0.10 (0.24) 0.0 0.00, 0.92 0.041 
Prevotella nigrescens  Week 4 27 0.09 (0.21) 0.0 0.00, 0.89 0.037 
Week 8 27 0.07 (0.17) 0.0 -0.02, 0.63 0.044 
Neisseria mucosa  Week 8 27 0.02 (0.32) 0.0 -0.83, 0.71 0.774 
 
 
 
 
Table 26.  Clinical Trial 1.  Supragingival species with statistically significant reductions at 
respective weeks (log 10 transformed data).  
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Microbe Visit n Mean (SD) Median Min, Max p-value 
change 
from 
baseline 
Streptococcus mitis  Week 4 27 -0.30 (0.67) 0.0 -1.38, 1.10 0.027 
Week 8 27 -0.42 (0.50) -0.2 -1.28, 0.35 <0.001 
Veillonella parvula  Week 4 27 -0.31 (0.36) -0.3 -1.21, 0.56 <0.001 
Week 8 27 -0.35 (0.32) -0.3 -1.30, 0.04 <0.001 
Streptococcus sanguinis  Week 4 27 -0.31 (0.46) -0.2 -1.29, 0.52 0.002 
Week 8 27 -0.34 (0.46) -0.2 -1.16, 0.70 <0.001 
Granulicatella  
adjacens  
Week 4 27 -0.19 (0.23) -0.1 -0.68, 0.11 <0.001 
Week 8 27 -0.19 (0.24) -0.2 -0.64, 0.30 <0.001 
Neisseria mucosa  Week 4 27 -0.15 (0.31) 0.0 -1.02, 0.28 0.020 
Week 8 27 -0.16 (0.33) 0.0 -0.83, 0.80 0.020 
Prevotella nigrescens  Week 4 27 -0.13 (0.29) 0.0 -0.88, 0.28 0.031 
Week 8 27 -0.12 (0.29) 0.0 -0.88, 0.28 0.046 
 
 
 
 
Table 27.  Clinical Trial 1.  Subgingival species with statistically significant increases at 
respective weeks (log 10 transformed data). 
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Microbe Visit n Mean (SD) Median Min, Max p-value 
change 
from 
baseline 
Streptococcus sanguinis  Week 4 27 -0.39 (0.47) -0.4 -1.19, 0.88 <0.001 
Week 8 27 -0.40 (0.46) -0.4 -1.22, 0.88 <0.001 
Veillonella parvula  Week 4 27 -0.23 (0.51) -0.3 -1.09, 1.09 0.028 
Week 8 27 -0.20 (0.47) -0.1 -1.00, 0.54 0.038 
Streptococcus mitis  Week 4 27 -0.21 (0.40) -0.2 -0.70, 0.85 0.013 
Week 8 27 -0.19 (0.45) -0.2 -0.84, 0.85 0.035 
Streptococcus mutans  Week 4 27 -0.01 (0.13) 0.0 -0.54, 0.27 0.702 
Neisseria mucosa  Week 4 27 -0.07 (0.16) 0.0 -0.68, 0.00 0.026 
 
 
 
 
 
 
 
 
 
 
 
Table 28.  Clinical Trial 1.  Supragingival species with statistically significant increases at 
respective weeks (log 10 transformed data). 
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Figure 24.  Diagrammatic representation of the relationships within and between 
microbial complexes (Socransky et al., 1998). 
The species to the left of the schematic being representative of commensal species and 
those associated with health moving to the right of the diagram representing those 
organisms that were particularly associated with progressive periodontal attachment loss. 
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2.7 Discussion 
The changes in microbial populations following hygiene phase treatment either 
brushing alone or with adjunctive professional prophylaxis are consistent with 
previous studies (Aspiras et al., 2008; Barros et al., 2008; Offenbacher et al., 2010; 
Salvi et al., 2010).  These indicate a progressive increase in the proportion of 
bacteria associated with disease to those associated with health in both 
supragingival and subgingival plaque (Kumar et al., 2006).  These microbial shifts 
generally precede changes in clinical manifestations that are indicative of disease 
development or resolution. In this study, this is apparent post intervention with 
significant increases observed with ‘health-associated’ bacteria (Streptococcus 
mitis, Streptococcus sanguinis and Veillonella parvula) and significant decreases in 
disease associated bacteria. Reductions in levels are observed for Dialister 
pneumosintes and Selenomonas noxia associated with gingivitis as well as for 
Treponema denticola of the ‘red complex’ of subgingival bacteria.  The latter reside 
in the subgingival periodontal pocket and are typically associated with advanced 
periodontal disease.  
As with many microbial ecosystems, bacterial interactions occur both chemically 
and physically. These interactions in turn drive cellular spatial arrangements 
within bacterial communities in plaque biofilm. Mechanically disrupting the 
biofilm by tooth brushing or professional prophylaxis disrupts the arrangements 
of a commensal or pathogenic bacterial biofilm. The effect of these interventions 
results in the creation of a favourable environment for non-pathogenic bacteria.  
Removal of the upper layers of subgingival plaque and associated endotoxins will 
‘expose’ the predominantly pathogenic anaerobic species embedded deeper in the 
biofilm; potentially exposing subgingival species to a more hostile environment of 
high redox potential (Smulow et al., 1983; Katsanoulas et al., 1992).  This favours a 
change in the composition of plaque in favour of those species associated with 
health that are aerobic and enhance the antagonistic relationship that exists 
between pathogenic and non-pathogenic species (Smulow et al., 1983; Dahlen et 
al., 1992; Socransky et al., 1998).  The effect of compliance with an oral hygiene 
regimen and supplemented by professional prophylaxis may account for the 
increased levels of beneficial bacteria, decrease in disease associated species, and 
concomitant clinical observations of plaque reduction and improved gingival 
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health.  (Haffajee et al., 2001a; Haffajee et al., 2001b).  The findings of this study are 
in keeping with previous evidence that optimal supragingival plaque control 
affects the quantity of plaque biofilm and also its composition (Teles et al., 2006). 
Techniques using DNA probes for microbiological analysis allow the potential for a 
vast number of bacterial species to be identified; with this ever-increasing number 
of species identifying those species that are predictive of progressive disease may 
become more difficult, and care must be taken when drawing conclusions about 
the pathogenicity of specific species.  The aim of treatment of gingivitis should be 
to reduce the quantity of bacterial pathogens to a level that is tolerated by the host 
and can be maintained by self-performed plaque control and more infrequent 
professional intervention (Teles et al., 2006).  There is evidence to suggest that the 
risk of developing periodontitis increases when red complex bacteria are present 
at greater numbers at deeper sites with clinical attachment loss (Haffajee and 
Socransky, 1994; Teles et al., 2006).  There is, however, no measurable bacterial 
threshold over which gingivitis will progress to periodontitis, the response of each 
individual to pathogenic organisms will vary and cause-related therapy should 
continue to be initiated to reduce the numbers of key pathogenic species (Chapple, 
2009). 
Inflammation occurs in gingival tissue in response to adjacent plaque bacterial 
biofilm and the accumulation of endotoxins.  At the tissue and cellular level, clinical 
changes in gingivitis are caused by an initial increase in blood flow and enhanced 
vascular permeability.  This results from the influx of cells (neutrophils and 
macrophages) from the peripheral blood to the gingival crevice.  The cytokines (IL-
1α, IL-1β and IL-8) and chemokines (MIP-1α, MIP-1β, RANTES) investigated in this 
study play a major role in activating and recruiting these inflammatory cells to the 
site of infection (Offenbacher et al., 2010).  The MMPs are molecules (enzymes) 
involved in the destruction of periodontal tissue and are often associated with 
more advanced stages of periodontal disease and overt clinical signs (Birkedal-
Hansen, 1993).  Bleeding and inflammation resulting from these events form the 
basis of the gingival indices currently used to monitor and diagnose gingivitis. 
During hygiene phase therapy for treatment of clinical signs of inflammation, the a 
priori hypothesis would be that reductions in clinical indices, particularly GI would 
be concomitant with reductions in subclinical levels of cytokine, chemokine and 
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MMP biomarkers.  In this study there were clinical improvements following each 
intervention but no significant reductions in GCF inflammatory mediators.  The 
absence of statistically significant differences in levels of specific inflammatory 
biomarkers may be due to high biological variance in subjects’ genetic disposition 
(better or poorer responders to treatment than others), microbial flora in inflamed 
sites and the magnitude of the host inflammatory response, all of which reduce the 
power to detect treatment effects.   
The bacterial content of the pocket is an important factor in gene expression in the 
gingival tissues and therefore, can influence the clinical phenotype and 
inflammatory response.  Pathogenic bacteria may directly up-regulate only a few 
genes responsible for a generalised non-specific inflammatory response while 
regulating a larger set of genes responsible for localised cellular responses unique 
to each bacterium in the biofilm. The variation in the microbial-host gene 
regulation could explain why a small change in biomarker activity for one 
individual may not translate to an equivalent degree of clinical change in another. 
It also reinforces the challenges of ascribing predictable trends of some biomarker 
behaviours to specific periodontal disease states or indeed generally to 
inflammatory disease. 
In this study there was a general, although statistically insignificant, trend for a 
number of biomarkers to increase at week 2 (following the first intervention), 
decrease at week 4 and then a repeat in this trend at weeks 6 and 8 (following the 
second intervention). There were some reductions of individual IL cytokines and 
chemokine biomarkers from baseline, but these were not sustained reductions 
throughout the study.  A previous study by Honda et al. found that pro-
inflammatory cytokines such as IL-1β and TNF- α (not investigated in this study) 
may play a role in gingivitis that may differ from the role they play in more 
advanced periodontitis (Honda et al., 2006).  IL-1β is known to up-regulate tissue 
turnover, it may not necessarily induce tissue destruction in gingivitis lesions, but 
may stimulate MMPs at the same time (Lark et al., 1990).  Inflammatory 
biomarkers are not necessarily always pathogenic and exhibit different functions; 
MMPs being involved in tissue remodelling however in excess can exacerbate 
inflammation driven tissue damage. 
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It is possible that the type and severity of the host response is dependent upon the 
stage of the periodontal lesion.  In this study, subjects with a diagnosis of mild to 
moderate gingivitis were recruited.  It is possible that a transient increase in IL-1β 
and other cytokine levels at the 2 week sampling time point may have been 
sufficient to stimulate collagen synthesis for tissue repair; any further increase 
may have been counterproductive to the host and levels then decrease.  The same 
biomarker might behave differently in advanced periodontal disease perhaps by 
being unregulated, ultimately leading to irreversible tissue damage.  It is also 
possible that other biomarkers play contradictory roles in the inflammatory 
cascade, where they may help initially with normal tissue turnover (or regulation 
of strictly inflammatory biomarkers) in the early stages of inflammation they then 
may acquire a pathogenic role if unregulated.  This transient beneficial role may 
explain why some of these biomarkers appear to increase at the 2-week time point 
while clinically gingival health continues to improve. 
Implementation of a sustained oral regimen and/or professional cleaning may 
have helped prevent continued accumulation of some of these biomarkers to 
pathogenic inflammatory levels.  Inflammatory mediators and biofilm 
accumulating in the gingival crevice was removed at regular intervals.  This could 
account for why most of the biomarker improvements were seen at the maximum 
time point (e.g. 4 or 8 weeks) after the onset of each intervention of tooth brushing 
or professional cleaning.  
Previous work has suggested that changes in levels of microbial and chemical 
biomarkers are indicative of future clinical patterns in health and disease (Teles et 
al., 2006; Offenbacher et al., 2010).  A longer study beyond 8 weeks post 
intervention could provide further evidence to support these observed 
correlations between the clinical and subclinical metrics but would bring the 
associated risks of non-compliance with study protocols.  The study subjects had 
mild-moderate gingivitis (overall mean GI at baseline = 1.0) and it must be 
recognised that they may not necessarily exhibit the most severe and profound 
inflammation at the test sites for chemical biomarker analysis.   
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2.8 Conclusion 
The provision of sequential interventions, oral hygiene instruction with Sonicare 
FlexCare+ HX6942/20 (Philips Oral Healthcare Inc. Bothell, WA, USA) and 
subsequent professional prophylaxis brought about significant improvements in 
the clinical signs of mild to moderate gingivitis.  A shift in the microbiological flora 
towards those species associated with health was observed following the 
interventions however there were no significant difference in local levels of 
biological markers of inflammation (cytokines, MMPs).  The greatest change in 
clinical signs resulted from the instruction in self-performed plaque control with a 
powered toothbrush.  This intervention was effective in plaque removal and 
therefore can be used to evaluate the effect that plaque control may have in a 
patient group with symptomatic gingival disease. 
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Chapter 3 
A personalised plaque control programme for managing the 
gingival manifestations of oral lichen planus (Clinical Trial 2) 
3.1 Introduction 
Gingival manifestations are most commonly seen in the erosive, ulcerative and 
atrophic forms of oral lichen planus (Jadinski and Shklar, 1976, Scully and Porter, 
1997, Stoopler et al., 2003, Leao et al., 2008, Lo Russo et al., 2009).  The lesions are 
often symptomatic with the extent of gingival involvement varying from chronic 
epithelial desquamation, erythema, and erosion to blistering of the attached and 
marginal gingiva (Prinz, 1932, Scully and Porter, 1997, Guiglia et al., 2007). 
Symptomatic ulcerative or erosive gingival lesions have the potential to 
compromise effective plaque control (Lo Russo et al., 2009).  It is recognised that 
whilst good plaque control does not bring about complete resolution, it may 
reduce the frequency of the symptoms of oral lichen planus (Erpenstein, 1985; 
Holmstrup et al., 1990; Guiglia et al., 2007; Lopez-Jornet and Camacho-Alonso, 
2010a).  Further, most guidelines and reviews have recommended that as part of 
the initial treatment, the optimisation of plaque control may also prevent 
periodontal damage (Lo Russo et al., 2008). 
Current evidence suggests that topical corticosteroids should be the first line 
treatment, but there is no universally agreed second line treatment such as short 
courses of systemic corticosteroids (Cribier et al., 1998; Carrozzo and Gandolfo, 
1999; Eisen, 2002; Eisen et al., 2005; Lodi et al., 2005b; Al-Hashimi et al., 2007; 
Scully and Carrozzo, 2008; Carrozzo and Thorpe, 2009; BSOM, 2010; Cheng et al., 
2012).  Factors that have been found to expedite improvement of symptomatic 
lesions include reassurance, avoidance of exacerbating factors such as certain 
foods, avoidance of smoking, alcohol and improving plaque control (Ramon-Fluixa 
et al., 1999; Thongprasom et al., 2003; Thongprasom et al., 2011).  The outcomes of 
the two most recent systematic reviews of interventions for treating oral lichen 
planus have recommended an evaluation of cost-effectiveness of treatments 
should also take place (Zakrzewska et al., 2005; Lodi et al., 2012). 
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3.2 Primary aim 
The primary aim of this study was to evaluate the impact of a tailored oral hygiene 
programme for patients with gingival manifestations of oral lichen planus. 
3.3 Secondary objectives 
 To investigate the association in clinical outcome and oral health related 
quality of life following the intervention of a tailored hygiene programme. 
 To investigate the change in the visual extent of the lesions (i.e. site and 
severity) following the intervention. 
 To undertake a cost-benefit analysis of providing a personalised plaque 
control programme to patients with gingival manifestations of oral lichen 
planus. 
 To compare the change in levels of biomarkers from baseline between the 
intervention and the control groups in a subset of the sampled cohort. 
3.4 Materials and methods 
This was a parallel group, longitudinal, randomised controlled trial (RCT).  The 
intervention comprised an oral hygiene programme consisting of personalised 
advice using a powered toothbrush (Sonicare FlexCare HX6942/20, Philips Oral 
Healthcare, Bothell, WA, USA) and interdental cleaning aids.  Study participants 
were evaluated at 4-weeks and 20-weeks following baseline and randomisation 
(Figure 25). 
The study was conducted in accordance with ICH Good Clinical Practice (GCP) and 
a favourable ethical opinion was provided for the study by Sunderland Research 
Ethics Committee (REC), UK on September 27th 2010 (Ref. 10/H0904/48).  The 
study was sponsored by the Joint Research and Development office, Newcastle 
upon Tyne NHS Foundation Trust.  The study design was insured and risk assessed 
through Newcastle University with Zurich Municipal. In addition, Caldicott 
guardian approval was obtained from Newcastle upon Tyne NHS Foundation 
Trust. 
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Figure 25.  Clinical Trial 2.  Study overview showing study and conventional treatment pathways and the timeline for appointments. 
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3.4.1 Subjects 
Patients were recruited from consultant led oral medicine and periodontal clinics 
at Newcastle Dental Hospital between February 2011 and June 2012. Patients 
were provided with a REC approved information sheet (Appendix 4), and a further 
appointment was made or further time given to consider their involvement.  All 
subjects whose diagnosis of oral lichen planus was not previously confirmed by 
biopsy or histopathological analysis had this performed, along with direct 
immunofluorescence and blood tests where appropriate (BSOM, 2010).  
Participation in the study was designed to fit within the patients’ standard clinical 
care pathway (Figure 25).  
The following inclusion and exclusion criteria were applied: 
Inclusion criteria 
 Adult patients aged 18 years and above; 
 Willing and able to complete questionnaires; 
 Able to provide informed consent to participate in the study; 
 Patients newly referred to, or who are under review at Newcastle Dental 
Hospital with a desquamative gingivitis and a provisional diagnosis of oral 
lichen planus; 
Exclusion criteria 
 Unable to attend for the additional appointments prior to their biopsy; 
 Unable to complete questionnaires; large print questionnaires were made 
available for those with visual impairment. Alternatively the questionnaire 
was read to the subject; 
 Potential subjects that have been a participant in a research study within 
the previous 28 days; 
 Potential subjects who were involved in other research studies at the time 
of recruitment. 
3.4.2. Power and Sample Size 
Sample size was determined using the OHIP as the primary outcome measure, with 
pain, clinical indices and cost-effectiveness being secondary outcomes.  The 
minimally important difference, the smallest difference between groups of an 
outcome that patients perceive as having a beneficial effect, was used to calculate 
the standard deviation and subsequently the number of subjects required in the 
study (Allen et al., 2009; John et al., 2009).  Powering the study at 80% using a 
standard deviation of 10.49, 49 subjects in each group were required to detect a 
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difference with confidence at the 95% level (Allen et al., 2009; John et al., 2009). 
The attrition rate was expected to be high (Hewitt et al., 2010).  To allow for 20% 
dropout rate (non-compliance with the protocol and loss to follow up) the a priori 
estimate of subjects to be recruited was 118.  This calculation was independently 
verified. 
This estimate uses figures from other oral conditions; the minimally important 
(clinical) difference for OHIP in patients with oral lichen planus is likely to be 
different.  Therefore a post hoc calculation was planned to attain whether the 
study was appropriately powered. 
3.4.3 Randomisation 
Randomisation using sealed opaque envelopes was carried out in blocks of 10 to 
ensure roughly similar numbers of subjects in each group (Dallal, 2008; Suresh, 
2011).  These envelopes were opened in front of the subject by the researcher 
following consent and enrolment into the study and after the baseline records had 
been recorded. 
3.4.4 Calibration of examiners 
Calibration of the clinical examiner was undertaken using repeated measurements 
on subjects not involved with the study.  A weighted Cohen’s Kappa statistic was 
used to assess the agreement between two ratings after adjusting for chance 
(Cohen, 1968).  The weighted Cohen’s Kappa attained were:  Plaque Index = 0.80 
[95% CI 0.75, 0.84]; Escudier Index site score 0.96 [95%CI 0.83, 1.00] and activity 
score 0.78 [95%CI 0.63, 0.91]. 
3.4.5 Study visits 
Visit 1  
Written informed consent was obtained from each participant (Appendix 5).  
Subjects were asked to self-complete the OHIP questionnaire and 100mm VAS 
scale for pain.  Clinical examination took place and Plaque Index (Silness and Löe, 
1964) and Escudier oro-mucosal disease scores (Escudier et al., 2007) were 
recorded along with clinical photographs.   
At baseline, the intervention group received an oral hygiene programme 
comprising personalised oral hygiene advice using a powered toothbrush, Sonicare 
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FlexCare+ HX6942/20 (Philips Oral Healthcare Inc. Bothell, WA, USA) with 
instructions to brush for 2 minutes.  They were also provided with interdental 
cleaning aids, either appropriately sized TePe® extra soft interdental brushes 
(TePe Munhygienprodukter, Sweden) ranging from ISO size 1-6 or Oral-B Dental 
Floss (Procter & Gamble, UK).  Intervention group subjects were provided with all 
products required for the full duration of the study.  
All subjects (control and intervention) received a prophylaxis at baseline (which 
did not include scaling or root planing) and were provided with standardised 
toothpaste (Pronamel®, GlaxoSmithKline, UK).  Subjects were provided with 
sufficient products to last for the duration of the study. 
For a small subgroup (n=12), GCF and unstimulated saliva samples were obtained 
to assess local levels of inflammatory biomarkers.   
Saliva was collected by asking subjects to sit upright with their head inclined 
forwards.  They were asked not to swallow any saliva or cough up any mucus 
during this collection period.  Saliva was allowed to pool in a sterile polypropylene 
graduated collection tube until at least 3 ml was collected.  The unstimulated saliva 
samples were centrifuged for 10 minutes at 3000g.  After centrifugation, the 
resulting saliva supernatant was separated into 4 aliquot tubes with roughly equal 
volumes (approximately 0.5-0.9ml each). 
Four gingival crevicular fluid samples were collected per participant at each visit 
(171/163/471/463) (Figure 8) using the same protocols and methods described 
in Chapter 2.  Volumes were determined using a Periotron 8000 (Oraflow, 
Planview, New York, USA).  All samples were snap-frozen and stored at -80°C 
before shipment by international courier in dry ice to the University of North 
Carolina (UNC) cytokine analysis facility. 
Visit 2 
Visit 2 took place 4 weeks +/- 1 week after baseline.  Subjects were asked to self-
complete the OHIP questionnaire, VAS scale for pain and a global change score 
(improved a lot, improved slightly, stayed the same, become slightly worse, 
become a lot worse).  Clinical assessment using the Plaque Index (Silness and Löe, 
1964), Escudier oro-mucosal disease score (Escudier et al., 2007) and clinical 
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photographs were recorded.  For the subgroup (n=12) GCF and saliva samples 
were also taken. 
Visit 3  
Visit 3 took place 20 weeks +/- 1 week after baseline.  Subjects were asked to self-
complete the OHIP questionnaire, VAS scale for pain and a global change score.  
Clinical assessment using the Plaque Index (Silness and Löe, 1964), Escudier oro-
mucosal disease score (Escudier et al., 2007) and clinical photographs were 
recorded. 
At this visit recruits to the intervention group were asked to complete a short 
questionnaire, which recorded out of pocket payments and lost work time relating 
to the care provided during the study.  They were also asked to state the maximum 
amount they would be willing to pay to purchase the powered toothbrush and 
advice in an open-ended valuation exercise.  The valuation was preceded by the 
patients being given cards representing a range of prices [£1 to £2000] and asked 
to consider whether they would pay the amount listed on each card.  This exercise 
is frequently undertaken as an aid to the valuation of health services in contingent 
valuation studies. 
3.4.6 Biomarker analysis 
Testing of the saliva and GCF samples was performed using multiplex (BioPlex 
200) analysis using kits from R&D Systems (Minneapolis, MN), according to the 
manufacturer’s instructions, previously detailed in Chapter 2.  On completion of all 
study sample collections and shipping to the UNC facility, the samples were 
readied for analysis by thawing and again centrifuging the thawed materials, as 
recommended by Salimetrics, Inc. for optimal preparation of samples for analysis 
of salivary analytes. Tests to be performed included subsets of the Cytokine Panel 
A by R&D systems (Minneapolis, MN): IL-1, IL-2, MIP-1 MIP-1 and RANTES and 
the MMP panel (MMP-1, MMP-3, MMP-8, MMP-9, MMP-13). 
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3.5 Data management and confidentiality 
The study records, including each participant’s signed informed consent and other 
documents pertaining to the conduct of the study were retained and kept in a 
secure area.  Participant information was kept confidential and individual subject 
records contained sufficient data only to allow identification of the participants 
throughout the study.  Clinical record forms were coded and anonymised, and each 
participant was assigned a study number.  The master list with subject identifiers 
was retained. 
3.6 Reimbursement 
The oral hygiene aids including the powered toothbrush were provided to the 
intervention group to keep; control patients received the same powered 
toothbrush at the end of the study.  Reasonable travel expenses were reimbursed 
to participants attending visits above their routine care pathway upon production 
of receipts.   
3.7 Substantial amendments  
Two substantial amendments were applied for to Sunderland REC.  These were 
given favourable opinions by a sub-committee of the Sunderland REC on 4th 
February 2011 and 30th September 2011.  The first amendment was to increase 
the time from recruitment to Visit 1 for review patients (not new patients) from 1 
week to 3 weeks in order to maximise recruitment.  The second amendment was to 
collect GCF and saliva samples from a subgroup of intervention and control 
subjects.  
3.8 Statistical and analytic plan 
Unless otherwise noted, continuous variables were summarized using the number 
of observations, mean, standard deviation, median, minimum, and maximum.  
Categorical variables were summarized using the frequency count and the 
percentage of subjects in each category.  Subjects were grouped according to the 
treatment received. 
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3.8.1 Analysis Populations 
The population to be analysed was the modified-intention-to-treat (MITT) 
population.  This comprised all randomized subjects with a baseline and at least 
one post-baseline OHIP evaluation.  Subject 80 in the intervention group, Subjects 
7 and 56 in control group only had baseline OHIP, so they were not included in the 
MITT population.  79 out of the 82 participants recruited were analysed. 
 
 Intervention 
(N=39) 
Control 
(N=43) 
Cohort 
(N=82) 
Randomized 39 (100%) 43 (100%) 82 (100%) 
Modified-Intent-to-Treat (MITT) 38 (97%) 41 (95%) 79 (96%) 
 
 
Table 29.  Clinical Trial 2. Populations included in analysis.   
 
3.8.2 Analysis of demographic and baseline characteristics  
Standard subject demographics (e.g., age and gender) and baseline characteristics 
were summarized for all subjects randomized and for MITT subjects.  For 
continuous subject characteristics, means were compared using one-way analysis 
of variance (ANOVA).  The incidence of the categorical variables was compared 
using the Chi-square test or Fisher’s exact test as appropriate. All summaries were 
presented by treatment group and overall. 
3.8.3 Primary outcome analysis 
The primary outcome measure for this study was overall sum OHIP score and by 
domain.  The primary outcome measure was treated as a continuous variable.  
Analysis of OHIP score was performed on increase, decrease and net change from 
baseline at week 4 and week 20. 
Increase was defined as the number of impacts reported at follow-up that were not 
reported at baseline. It was calculated as the sum of change from baseline for the 
questions with increased score. Increase quantifies only deterioration in quality of 
life, ignoring any decreases (Slade, 1998).  
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Decrease was defined as the number of impacts reported at baseline that were not 
reported at follow-up.  It was calculated as the sum of reduction from baseline for 
the questions with decreased score. Decrease quantifies only improvements in 
quality of life, ignoring any increases (Slade, 1998).   
Net change was defined as the number of impacts reported at follow-up minus the 
number of impacts at baseline.  It was calculated as the sum of change from 
baseline for all questions.  Arithmetically, this was equivalent to the increase minus 
decrease (Slade, 1998). 
Statistical analysis of the data including parameter and confidence interval (CI) 
estimation was accomplished using SAS and STATA software.  Comparisons 
between the treatment groups were performed using the F-Test.  The following 
model was used: 
yij = μ+ αi + Wj + ԑij 
Where: 
yij Post baseline measurement for subject (i) and treatment (j); 
μ  Overall mean; 
αi Random subject effect; 
Wj  Extent to which change from baseline is attributable to treatment; 
ԑi Unexplained/residual variation for each subject (i) and treatment (j). 
Analysis was performed for increase, decrease, and net change of OHIP scores 
(ordinal and dichotomous) by domain and visit.  
The biomarker data were summarised using descriptive statistics for the observed 
values and the changes from baseline.  Two sided t-tests, without adjustment for 
multiple comparisons were used to assess the statistical significance of changes 
from baseline. 
Finally, effect size (Cohen’s d) was calculated from the mean pre and post-
treatment scores for each group for each outcome measure.  The purpose of this 
descriptive statistic is to measure the strength of a treatment effect and to 
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complement the comparisons made using the ANOVA statistics.  It also allows 
comparisons between studies and meta-analyses to be more easily conducted. 
Cohen’s   
       
 
 
xi = mean pre-treatment. 
xii = mean post-treatment. 
S = standard deviation of pre-treatment. 
3.8.4 Secondary efficacy analysis 
Analyses similar to the primary analysis were performed for change from baseline 
in VAS (pain), Plaque Index, Mucosal Disease Score (i.e. total site score, severity 
score and activity score), GCF and saliva sample biomarker concentration at Week 
4 and Week 20. 
For biomarkers, the concentration was measured multiple times from subsamples.  
The mean concentration among subsamples was used for analysis. Log 
transformation was applied to biomarkers due to deviation from normality. 
Spearman correlation coefficient was calculated between the OHIP and VAS, 
Plaque Index, Mucosal Disease Score and biomarkers.  The analysis was applied to 
the results and change from baseline (net change for OHIP).  
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3.9 Results 
Recruitment for the study ran from February 2011 to June 2012.  120 patients who 
attended oral medicine consultant diagnostic clinics were invited to participate.  
82 accepted and were enrolled (39 intervention and 43 control subjects).  It was 
not possible to recruit 98 subjects without extending the recruitment phase to 
beyond 17 months and allowing for the 20-week follow-up period. 
3 intervention subjects and 2 control subjects were lost to follow-up.  One subject 
failed to attend Visit 2 but was retained through to Visit 3. 
The age of the participants ranged from 31 to 83 years at the time of enrolment, 
descriptive statistics are provided in Table 30.  There were no significant 
differences in the treatment groups for demographic characteristics and baseline 
characteristics. The mean age for all randomized subjects was 61.4 years. The 
study included 15 (18.3%) males and 67 (81.7%) females reflecting the greater 
number of females with oral lichen planus in the wider population.  Recruitment 
selection bias was not considered to be significant: the gender demographics of 
subjects that declined participation or were unable to fulfil the inclusion and 
exclusion criteria were similar to the study participants with 5 (15.6%) males and 
27 (84.3%) females.   
A summary of the baseline characteristics for the clinical and self-reported 
outcome measures are detailed in Table 31.  There were no significant differences 
between intervention and control groups at baseline (p>0.05). 
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Outcome Category Group P-valuea 
  Intervention 
(N=39) 
Control 
(N=43) 
Cohort 
(N=82) 
 
Age (years) Mean (SD) 61.2 (9.90) 61.6 (11.80) 61.4 (10.90) 0.986 
95% CI (58, 64.4) (58, 65.2) (59, 63.8) 
Median 63 63 63 
Min, Max (39, 83) (31, 83) (31, 83) 
Gender Gender 1 6 (15.4%) 9 (20.9%) 15 (18.3%) 0.810 
Gender 2 33 (84.6%) 34 (79.1%) 67 (81.7%) 
 
 
 
 
 
Table 30.  Clinical Trial 2.  Descriptive statistics showing the age demographics for the 
Intervention and Control groups.   
aP-value is calculated by T-test for continuous variables, and Chi-squared test for 
categorical variables. 
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Outcome Category Group P-valuea 
  Intervention 
(N=39) 
Control 
(N=43) 
Cohort 
(N=82) 
 
OHIP Sum, 
Ordinal 
Mean (SD) 49.5 (24.60) 48.7 (29.30) 49.1 (27.00) 0.991 
95% CI 41.5, 57.4 39.6, 57.7 43.1, 55.0 
Median 44 45 44.5 
Min, Max 3, 92 8, 158 3, 158 
OHIP Sum, 
Dichotomous 
Mean (SD) 6.6 (4.90) 6.5 (6.90) 6.6 (6.00) 0.995 
95% CI 5.1, 8.2 4.4, 8.6 5.3, 7.9 
Median 6 4 5.5 
Min, Max 0, 20 0, 37 0, 37 
VAS 
Mean (SD) 3.3 (2.10) 3.4 (2.20) 3.4 (2.10) 0.999 
95% CI 2.7,4.0 2.7, 4.0 2.9, 3.8 
Median 3.0 2.9 2.9 
Min, Max 0, 7.2 0, 8.1 0, 8.1 
Plaque Index 
Mean (SD) 1.4 (0.40) 1.4 (0.30) 1.4 (0.30) 0.938 
95% CI 1.3, 1.5 1.3, 1.6 1.4, 1.5 
Median 1.4 1.4 1.4 
Min, Max 0.7, 2.4 0.9, 2.2 0.7, 2.4 
Mucosal Disease 
Score:  
Site Score 
Mean (SD) 10.9 (2.50) 10.3 (2.20) 10.6  (2.40) 0.611 
95% CI 10.1, 11.7 9.7, 11.0 10.1, 11.1 
Median 11 10 10 
Min, Max 7, 17 7, 15 7, 17 
Mucosal Disease 
Score:  
Severity Score 
Mean (SD) 14.9 (5.60) 12.9 (4.30) 13.8 (5.10) 0.181 
95% CI 13.1, 16.7 11.5, 14.2 12.7, 15.0 
Median 13 13 13 
Min, Max 6, 29 3, 21 3, 29 
Mucosal Disease 
Score:  
Activity Score 
Mean (SD) 16.8 (7.10) 14 (5.30) 15.3 (6.30) 0.123 
95% CI 14.5, 19.1 12.4, 15.6 13.9, 16.7 
Median 15 14 14 
Min, Max 6, 35 3, 27 3, 35 
 
 
 
 
 
Table 31.  Clinical Trial 2.  Summary of baseline characteristics for all randomised subjects. 
 aP-value is calculated by T-test for continuous variables, and Chi-squared test for 
categorical variables. 
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3.9.1 Oral health impact profile 
The two groups, intervention and control had a similar distribution of scores at 
baseline.  Descriptive statistics for the sum ordinal scores are presented in Table 
32 and dichotomous sum scores are presented in Table 33.   
The groups had similar baseline mean OHIP ordinal sum scores 49.66 (ordinal) 
and 6.55 (dichotomous) for the intervention group and 49.39 (ordinal) and 6.71 
(dichotomous) for the control group.  The relationship between baseline and post-
baseline for overall sum OHIP ordinal scores is presented in Figure 26 and overall 
sum dichotomous scores in Figure 27.  In these reference plots, scores plotted 
below the reference line indicate an increase post-baseline compared to baseline.  
Values above the reference line indicate a decrease compared to baseline.  Box 
plots were also produced for the ordinal sum scores (Figure 28) and for the 
dichotomous sum score (Figure 29).  At week 4 and week 20 the distributions shift 
with both groups showing a reduction in OHIP ordinal scores overall.  The shift for 
the intervention group was more than the control group. 
Least square (LS) mean and statistical analysis are presented in Table 34 for the 
sum ordinal scores and Table 35 for the sum dichotomous scores. 
Both treatment groups contained subjects who experienced an increase in OHIP 
ordinal and dichotomous scores.  The increase in ordinal scores indicates subjects 
experiencing deterioration to some questions (impact started or happened more 
frequently from baseline ignoring the questions with improvement).  The increase 
in dichotomous scores indicates some impacts happened “fairly often” or “very 
often” at post-baseline, which did not happen at such frequency at baseline 
(ignoring any improvement). The intervention group experienced less increase in 
both ordinal and dichotomous scores in overall domain. In each domain, the 
increase for the intervention group is similar or less than the control group.   
Both treatment groups contained subjects who experienced a decrease in OHIP 
ordinal and dichotomous scores.  The decrease in ordinal scores indicates subjects 
experiencing improvement to some questions (impact stopped or happened less 
frequently from baseline ignoring the questions with deterioration).  The decrease 
in dichotomous scores indicates some impacts happened “fairly often” or “very 
often” at baseline did not happen at such frequency post-baseline. The intervention 
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group experienced greater decrease in both ordinal and dichotomous scores 
overall.  In each domain, the decrease for intervention group is similar or more 
than the control group.   
Both treatment groups experienced negative net change (post-baseline minus 
baseline) in OHIP ordinal and dichotomous scores.  The negative net change in 
ordinal scores indicates subjects experiencing an overall improvement in given 
domain, taking into account both the improvement and deterioration to individual 
questions.  The negative net change in dichotomous scores indicates an overall 
decrease in the impacts that happened “fairly often” or “very often” from baseline 
to post-baseline, taking into account some impacts happened more frequently, and 
some happened less frequently.  The intervention group experienced greater 
negative net change in both ordinal and dichotomous scores in overall domain, 
indicating improvements in oral health related quality of life. 
Examination of the individual domain scores provides further insight into the 
range of impacts that oral lichen planus has on a subject’s quality of life.  Statistical 
output for each domain was undertaken using ordinal coding and presented as 
follows: 
 Functional limitation Table 36 
 Physical pain   Table 37 
 Psychological discomfort Table 38 
 Physical disability  Table 39 
 Psychological disability Table 40 
 Social disability  Table 41 
 Handicap   Table 42 
Graphical representation using bar charts of the domain scores are presented in 
Figure 30 and for net change from baseline at 4 and 20 weeks in Figure 31.  Those 
domains with significant differences between groups at 4 and 20 weeks were 
functional limitation (p=0.0216, p=0.0137), psychological discomfort (p=0.007, 
p=0.0016) and physical disability (p=0.0137, p=0.0035).  The psychological 
disability domain showed significant differences at the 20-week (p=0.003) but not 
the 4-week follow up (p=0.435).  There were no significant correlations in the 
social disability (p=0.7628, 0.8106) and handicap domains (p=0.8575, p=0.2239) 
and a constant although not statistically significant association (p=0.0594, 
p=0.0522) in the physical pain domain. 
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Visit Outcome Treatment n Mean (SD) Median Min, Max 
Baseline Result Intervention 38 49.66 (24.86) 45.5 3, 92 
Control 41 49.39 (29.82) 48 8, 158 
Week 4 Result Intervention 38 34.55 (23.84) 30 2, 84 
Control 40 42.25 (31.03) 36 3, 159 
Increase Intervention 32 6.34 (5.28) 5 1, 21 
Control 37 7.54 (5.32) 7 1, 19 
Decrease Intervention 38 20.45 (13.90) 17.5 1, 62 
Control 38 15.29 (9.61) 13 2, 49 
Net Change Intervention 38 -15.11 (16.31) -14 -60, 6 
Control 40 -7.55 (12.87) -7 -47,14 
Week 20 Result Intervention 36 31.64 (23.86) 27.5 1, 88 
Control 41 41.66 (28.87) 40 4, 162 
Increase Intervention 28 6.54 (5.36) 5.5 1, 24 
Control 37 10.30 (7.75) 9 1, 34 
Decrease Intervention 36 24.56 (15.90) 23 1, 71 
Control 40 17.45 (12.24) 16 1, 57 
Net Change Intervention 36 -19.47 (18.84) -15.5 -70, 11 
Control 41 -7.73 (17.39) -7 -47, 32 
 
 
 
 
Table 32.  Clinical Trial 2.  Oral Health Impact Profile (OHIP) scores.  Descriptive summary 
all domains, ordinal coding, MITT Subjects. 
The intervention and control groups were comparable at baseline exhibiting similar 
impacts recorded by OHIP.  Both groups showed both increases and decreases in OHIP 
ordinal sum score at follow-up visits with the net result being a decrease in OHIP ordinal 
sum score overall for both groups. 
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Visit Outcome Treatment n Mean (SD) Median Min, Max 
Baseline Result Intervention 38 6.55 (4.91) 6 0, 20 
Control 41 6.71 (6.97) 5 0, 37 
Week 4 Result Intervention 38 3.03 (3.28) 2 0, 11 
Control 40 5.30 (7.53) 3 0, 41 
Increase Intervention 11 1.73 (1.56) 1 1, 6 
Control 23 1.96 (1.52) 1 1, 6 
Decrease Intervention 35 4.37 (3.28) 4 1, 17 
Control 31 3.39 (2.11) 3 1, 9 
Net Change Intervention 38 -3.53 (3.56) -3 -17, 3 
Control 40 -1.50 (3.02) -1.5 -9, 6 
Week 20 Result Intervention 36 2.56 (3.32) 1 0, 12 
Control 41 4.90 (7.17) 3 0, 41 
Increase Intervention 11 2.09 (1.38) 2 1, 5 
Control 22 2.45 (1.63) 2 1, 6 
Decrease Intervention 33 5.36 (3.95) 5 1, 20 
Control 32 4.00 (3.45) 3 1, 16 
Net Change Intervention 36 -4.28 (4.28) -3.5 -19, 2 
Control 41 -1.80 (4.24) -1 -14, 6 
 
 
 
 
Table 33.  Clinical Trial 2.  Oral Health Impact Profile (OHIP) scores.  Descriptive summary 
all domains, dichotomous coding, MITT Subjects. 
The intervention and control groups were comparable at baseline exhibiting similar 
impacts recorded by OHIP.  Both groups showed both increases and decreases in OHIP 
dichotomous sum score at follow-up visits with the net result being a decrease in OHIP 
dichotomous sum score overall for both groups. 
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Figure 26.  Clinical Trial 2.  Reference Plot: Oral Health Impact Profile 
(OHIP) ordinal coding, all domains.  MITT Subjects. 
 
Figure 27.  Clinical Trial 2.  Reference plot: Oral Health Impact Profile 
(OHIP) dichotomous coding, all domains.  MITT subjects. 
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Figure 28.  Clinical Trial 2.  Box Plot: Oral Health Impact Profile Questionnaire (OHIP) 
scores.  All domains, ordinal coding, MITT Subjects.   
Ordinal is based on the sum of scores of each question original category (never =0, hardly 
ever=1, occasionally=2, fairly often=3, very often=4).  At the 4- and20-week  follow-up, 
both groups show improvement in OHIP ordinal scores.  The differences between the 
group means were statistically significant at follow-up (ANOVA p=0.9657 at baseline; 
p=0.0215 at week 4; p=0.0044 at week 20). 
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Figure 29.  Clinical Trial 2.  Box Plot: Oral Health Impact Profile (OHIP) scores.  All 
domains, dichotomous coding, MITT Subjects.  
Dichotomous is based on the sum of score where each question is rated as 0 or 1 
(occasionally, hardly ever, or never=0; fairly often or very often=1).  At the 4- and20-week  
follow-up, both groups show improvement in OHIP dichotomous scores.  The differences 
between the group means were statistically significant at follow-up (ANOVA p=0.9101 at 
baseline; p=0.0045 at week 4; p=0.0072 at week 20). 
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Visit Outcome Statistic Treatment Differenceb P-valuea 
   Intervention Control   
Baseline Result n 38 41   
LS Mean (SE) 49.66 (4.47) 49.39 (4.30) 0.27 (6.20) 0.9657 
95% CI 40.76, 58.56 40.82, 57.96 -12.09, 12.62  
Week 4 Result n 38 40   
LS Mean (SE) 34.62 (2.31) 42.19 (2.25) -7.57 (3.23) 0.0215 
95% CI 30.01, 39.22 37.70, 46.68 -14.00, -1.15  
Increase n 38 40   
LS Mean (SE) 6.35 (0.92) 7.53 (0.86) -1.18 (1.26) 0.3517 
95% CI 4.50, 8.20 5.82, 9.25 -3.71, 1.34  
Decrease n 38 40   
LS Mean (SE) 20.65 (1.79) 15.09 (1.79) 5.56 (2.54) 0.0315 
95% CI 17.08, 24.22 11.51, 18.66 0.51, 10.62  
Net 
Change 
n 38 40   
LS Mean (SE) -15.12 (2.31) -7.54 (2.25) -7.57 (3.23) 0.0215 
95% CI -19.72, -10.51 -12.03, -3.05 -14.00, -1.15  
Week 20 Result n 36 41   
LS Mean (SE) 30.95 (2.81) 42.26 (2.63) -11.31 (3.85) 0.0044 
95% CI 25.35, 36.55 37.02, 47.51 -18.99, -3.64  
Increase n 36 41   
LS Mean (SE) 6.53 (1.30) 10.30 (1.13) -3.77 (1.72) 0.0319 
95% CI 3.94, 9.12 8.05, 12.56 -7.21, -0.34  
Decrease n 36 41   
LS Mean (SE) 24.46 (2.05) 17.54 (1.94) 6.92 (2.82) 0.0165 
95% CI 20.38, 28.54 13.67, 21.40 1.30, 12.54  
Net 
Change 
n 36 41   
LS Mean (SE) -19.25 (2.81) -7.93 (2.63) -11.31 (3.85) 0.0044 
95% CI -24.84, 13.65 -13.18, -2.69 -18.99, -3.64  
 
 
Table 34.  Clinical Trial 2.  Oral Health Impact Profile (OHIP) scores.  Least squares means 
of all domains, ordinal coding, MITT subjects.   
Ordinal is based on the sum of scores of each question (never =0, hardly ever=1, 
occasionally=2, fairly often=3, very often=4).  ANOVA Model for baseline: 
Result=Treatment + error.  ANOVA Model for post-baseline: Result=Treatment + Baseline 
+ Error.   
aP-value is based on a mixed model F-test (Ho: Both treatments equal).  b Diff = Mean (SD) 
of the treatment difference (Intervention - Control). 
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Visit Outcome Statistic Treatment Differenceb P-valuea 
   Intervention Control   
Baseline Result n 38 41   
LS Mean (SE) 6.55 (0.98) 6.71 (0.95) -0.15 (1.37) 0.9101 
95% CI 4.59, 8.51 4.82, 8.59 -2.87, 2.57  
Week 4 Result n 38 40   
LS Mean (SE) 3.13 (0.51) 5.20 (0.49) -2.07 (0.71) 0.0045 
95% CI 2.12, 4.14 4.22, 6.18 -3.48, -0.66  
Increase n 38 40   
LS Mean (SE) 1.73 (0.45) 1.96 (0.31) -0.23 (0.55) 0.6822 
95% CI 0.81, 2.65 1.32, 2.59 -1.35, 0.90  
Decrease n 38 40   
LS Mean (SE) 4.47 (0.43) 3.28 (0.45) 1.18 (0.62) 0.0621 
95% CI 3.61, 5.32 2.38, 4.19 -0.06, 2.43  
Net 
Change 
n 38 40   
LS Mean (SE) -3.55 (0.51) -1.48 (0.49) -2.07 (0.71) 0.0045 
95% CI -4.56, -2.54 -2.46, -0.49 -3.48, -0.66  
Week 
20 
Result n 36 41   
LS Mean (SE) 2.51 (0.64) 4.94 (0.60) -2.43 (0.88) 0.0072 
95% CI 1.23, 3.79 3.74, 6.14 -4.19, -0.68  
Increase n 36 41   
LS Mean (SE) 2.01 (0.45) 2.50 (0.32) -0.49 (0.55) 0.3869 
95% CI 1.09, 2.93 1.85, 3.15 -1.62, 0.64  
Decrease n 36 41   
LS Mean (SE) 5.40 (0.53) 3.96 (0.54) 1.45 (0.75) 0.0600 
95% CI 4.35, 6.46 2.88, 5.03 -0.06, 2.96  
Net 
Change 
n 36 41   
LS Mean (SE) -4.26 (0.64) -1.82 (0.60) -2.43 (0.88) 0.0072 
95% CI -5.54, -2.98 -3.02, -0.62 -4.19, -0.68  
 
 
Table 35.  Clinical Trial 2.  Oral Health Impact Profile (OHIP) scores.  Least squares means 
of all domains, dichotomous coding, MITT subjects. 
Dichotomous is based on the sum of score where each question is rated as 0 or 1 
(occasionally, hardly ever, or never=0; fairly often or very often=1).  ANOVA Model for 
baseline: Result=Treatment + error. ANOVA Model for post-baseline: Result=Treatment + 
Baseline + Error.  aP-value is based on a mixed model F-test (Ho: Both treatments equal).  b 
Diff = Mean (SD) of the treatment difference (Intervention - Control).  
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Visit Outcome Statistic Treatment Differenceb P-valuea 
   Intervention Control   
Baseline Result n 38 41   
LS Mean (SE) 10.53 (0.87) 9.80 (0.83) 0.72 (1.20) 0.5503 
95% CI 8.80, 12.25 8.14,11.47 -1.67, 3.12  
Week 4 Result n 38 40   
LS Mean (SE) 7.71 (0.52) 9.40 (0.50) -1.69 (0.72) 0.0216 
95% CI 6.68. 8.74 8.40, 10.40 -3.12, -0.25  
Week 20 Result n 36 41   
LS Mean (SE) 6.95 (0.55) 8.85 (0.51) -1.89 (0.75) 0.0137 
95% CI 5.87. 8.04 7.83, 9.87 -3.39, -0.40  
 
 
 
 
 
 
Table 36.  Clinical Trial 2.  Functional limitation domain. OHIP ordinal sum scores, MITT 
subjects.   
 
This domain contains the OHIP questions relating to: difficulty chewing, trouble 
pronouncing words, teeth that don’t look right, appearance affected, stale breath, taste, 
food catching, digestion, and dentures not fitting.   
ANOVA Model for baseline: Result=Treatment + error. ANOVA Model for post-baseline: 
Result=Treatment + Baseline + Error.  aP-value is based on a mixed model F-test (Ho: Both 
treatments equal).   b Diff = Mean (SD) of the treatment difference (Intervention - Control). 
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Visit Outcome Statistic Treatment Differenceb P-valuea 
   Intervention Control   
Baseline Result n 38 41   
LS Mean (SE) 13.68 (0.88) 14.34 (0.85) -0.66 (1.23) 0.5934 
95% CI 11.93, 15.44 12.65, 16.03 -3.10, 1.78  
Week 4 Result n 38 40   
LS Mean (SE) 9.63 (0.65) 11.38 (0.64) -1.75 (0.91) 0.0594 
95% CI 8.33, 10.93 10.11, 12.64 -3.56, 0.07  
Week 20 Result n 36 41   
LS Mean (SE) 9.68 (0.77) 11.77 (0.72) -2.09 (1.06) 0.0522 
95% CI 8.14, 11.22 10.33, 13.21 -4.20, 0.02  
 
 
 
 
 
 
Table 37.  Clinical Trial 2.  Physical pain domain. OHIP ordinal sum scores, MITT subjects.   
 
This contains the OHIP questions relating to: painful aching, sore jaw, headaches, sensitive 
teeth, toothache, painful gums, eating comfort, sore spots, discomfort (dentures). 
ANOVA Model for baseline: Result=Treatment + error. ANOVA Model for post-baseline: 
Result=Treatment + Baseline + Error.  aP-value is based on a mixed model F-test (Ho: Both 
treatments equal).   b Difference = Mean (SD) of the treatment difference (Intervention - 
Control). 
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Visit Outcome Statistic Treatment Differenceb P-valuea 
   Intervention Control   
Baseline Result n 38 41   
LS Mean (SE) 7.79 (0.83) 7.93 (0.80) -0.14 (1.15) 0.9054 
95% CI 6.14, 9.44 6.34, 9.52 -2.43, 2.16  
Week 4 Result n 38 40   
LS Mean (SE) 4.84 (0.48) 6.68 (0.46) -1.84 (0.66) 0.0070 
95% CI 3.89, 5.79 5.76, 7.60 -3.17, -0.52  
Week 20 Result n 36 41   
LS Mean (SE) 4.12 (0.56) 6.63 (0.52) -2.51 (0.77) 0.0016 
95% CI 3.01, 5.23 5.58, 7.67 -4.04, -0.98  
 
 
 
 
 
 
 
Table 38.  Clinical Trial 2.  Psychological discomfort domain.  OHIP ordinal sum scores, 
MITT subjects.   
 
This contains the OHIP questions relating to: being worried, self-conscious, miserable, 
appearance and tension.  ANOVA Model for baseline: Result=Treatment + error. ANOVA 
Model for post-baseline: Result=Treatment + Baseline + Error.  aP-value is based on a 
mixed model F-test (Ho: Both treatments equal).   b Difference = Mean (SD) of the 
treatment difference (Intervention - Control). 
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Visit Outcome Statistic Treatment Differenceb P-valuea 
   Intervention Control   
Baseline Result n 38 41   
LS Mean (SE) 7.97 (0.91) 7.51 (0.88) 0.46 (1.27) 0.7163 
95% CI 6.16, 9.79 5.76, 9.26 -2.06, 2.98  
Week 4 Result n 38 40   
LS Mean (SE) 5.36 (0.57) 7.38 (0.56) -2.03 (0.80) 0.0137 
95% CI 4.21, 6.50 6.27, 8.50 -3.63, -0.43  
Week 20 Result n 36 41   
LS Mean (SE) 4.65 (0.61) 7.18 (0.57) -2.53 (0.84) 0.0035 
95% CI 3.44, 5.87 6.04, 8.32 -4.20, -0.86  
 
 
 
 
 
 
 
Table 39.  Clinical Trial 2.  Physical disability domain.  OHIP ordinal sum, MITT subjects.   
 
This contains the OHIP questions relating to: clarity of speech, being misunderstood, 
flavour in food, ability to brush teeth, avoidance of eating, diet, inability to eat (dentures), 
avoidance of smiling, interruption of meals. 
ANOVA Model for baseline: Result=Treatment + error. ANOVA Model for post-baseline: 
Result=Treatment + Baseline + Error.  aP-value is based on a mixed model F-test (Ho: Both 
treatments equal).   b Difference = Mean (SD) of the treatment difference (Intervention - 
Control). 
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Visit Outcome Statistic Treatment Differenceb P-valuea 
   Intervention Control   
Baseline Result n 38 41   
LS Mean (SE) 5.76 (0.79) 5.68 (0.76) 0.08 (1.10) 0.9418 
95% CI 4.19, 7.33 4.17, 7.20 -2.10, 2.26  
Week 4 Result n 38 40   
LS Mean (SE) 3.99 (0.44) 4.48 (0.43) -0.49 (0.62) 0.4349 
95% CI 3.11, 4.88 3.62, 5.34 -1.71, 0.75  
Week 20 Result n 36 41   
LS Mean (SE) 3.21 (0.56) 4.89 (0.53) -1.68 (0.77) 0.0324 
95% CI 2.08, 4.33 3.84, 5.94 -3.22, -0.15  
 
 
 
 
 
Table 40.  Clinical Trial 2.  Psychological disability domain.  OHIP ordinal sum scores, 
MITT subjects. 
 
This contains the OHIP questions relating to: interruption of sleep, being upset, difficulty 
in relaxing, depressed, concentration being affected and embarrasment. 
ANOVA Model for baseline: Result=Treatment + error. ANOVA Model for post-baseline: 
Result=Treatment + Baseline + Error.  aP-value is based on a mixed model F-test (Ho: Both 
treatments equal).   b Difference = Mean (SD) of the treatment difference (Intervention - 
Control). 
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Visit Outcome Statistic Treatment Differenceb P-valuea 
   Intervention Control   
Baseline Result n 38 41   
LS Mean (SE) 1.39 (0.49) 1.90 (0.47) -0.51 (0.68) 0.4584 
95% CI 0.42, 2.37 0.96, 2.84 -1.86, 0.85  
Week 4 Result n 38 40   
LS Mean (SE) 1.41 (0.24) 1.31 (0.23) 0.10 (0.33) 0.7628 
95% CI 0.94, 1.89 0.85, 1.77 -0.56, 0.77  
Week 20 Result n 36 41   
LS Mean (SE) 1.26 (0.29) 1.16 (0.27) 0.10 (0.40) 0.8106 
95% CI 0.68, 1.83 0.62, 1.70 -0.69, 0.89  
 
 
 
 
 
Table 41.  Clinical Trial 2.  Social disability domain.  OHIP ordinal sum scores, MITT 
subjects.   
 
This contains the OHIP questions relating to: avoid going out, being less tolerant of others, 
trouble getting on with others, Irritability with others, difficulty doing jobs. 
ANOVA Model for baseline: Result=Treatment + error. ANOVA Model for post-baseline: 
Result=Treatment + Baseline + Error.  aP-value is based on a mixed model F-test (Ho: Both 
treatments equal).   b Difference = Mean (SD) of the treatment difference (Intervention - 
Control). 
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Visit Outcome Statistic Treatment Differenceb P-valuea 
   Intervention Control   
Baseline Result n 38 41   
LS Mean (SE) 2.53 (0.58) 2.22 (0.56) 0.31 (0.81) 0.7045 
95% CI 1.37, 3.68 1.11, 3.33 -1.30, 1.91  
Week 4 Result n 38 40   
LS Mean (SE) 1.65 (0.29) 1.58 (0.28) 0.07 (0.40) 0.8575 
95% CI 1.08, 2.22 1.02, 2.14 -0.72, 0.87  
Week 20 Result N 36 41   
LS Mean (SE) 1.17 (0.32) 1.70 (0.30) -0.53 (0.43) 0.2239 
95% CI 0.54, 1.80 1.11, 2.29 -1.39, 0.33  
 
 
 
 
 
Table 42.  Clinical Trial 2.  Handicap domain.  OHIP ordinal sum scores, MITT subjects.   
 
This contains the OHIP questions relating to: health worsened, financial loss, inability to 
enjoy people’s company, unsatisfying life, inability to function, inability to work. 
ANOVA Model for baseline: Result=Treatment + error. ANOVA Model for post-baseline: 
Result=Treatment + Baseline + Error.  aP-value is based on a mixed model F-test (Ho: Both 
treatments equal).   b Difference = Mean (SD) of the treatment difference (Intervention - 
Control). 
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Figure 30.  Clinical Trial 2.  Bar Chart: Oral Health Impact (OHIP) scores for ordinal coding, MITT Subjects.  
Domains: A=Functional Limitation, B=Physical Pain, C=Psychological Discomfort, D=Physical Disability, E=Psychological Disability, F=Social Disability, 
G=Handicap.  Bars represent least square means. Vertical lines represent standard error of the LS means. 
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Figure 31.  Clinical trial 2.  Bar Chart: Oral Health Impact (OHIP) net change scores for ordinal coding MITT Subjects.  
OHIP Domains: A=Functional Limitation, B=Physical Pain, C=Psychological Discomfort, D=Physical Disability, E=Psychological Disability, F=Social 
Disability, G=Handicap. Bars represent least square means. Vertical lines represent standard error of the LS means.  
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3.9.2 Visual Analogue Scale (VAS) 
Descriptive statistics are presented in Table 43.  The treatment groups were 
similar at baseline with mean VAS 3.34 for intervention group and 3.36 for control 
group.  The median at baseline was 3.00 for intervention group and 2.90 for 
control indicating that the data were not skewed.   
The relationship between baseline and post-baseline is presented by box plots 
(Figure 32) and reference plots (Figure 33).  In these reference plots, scores below 
the reference line indicate increase at post-baseline compared to baseline, whilst 
values above the reference line indicate a decrease at post baseline. At week 4 and 
week 20, both groups’ distributions shift with a reduction in VAS pain.  The shift 
for the intervention group was slightly more than the control group. 
Least squares (LS) means and statistical output are presented in Table 44.  The 
overall LS mean VAS for pain reduction was 1.11 at week 4 and 1.62 at week 20 for 
the intervention group.  The overall LS mean VAS for pain reduction was 0.44 at 
week 4 and 0.90 at week 20 for the control group.  The LS mean treatment 
difference (Intervention – Control) and 95% CI was 0.67 (-0.04, 1.39) at week 4 
and 0.72 (-0.06, 1.50) at week 20.  The reduction in pain in the intervention group 
was more than in the control group, although the difference was not statistically 
significant (p=0.064, p=0.069) it was maintained at week 4 and week 20. 
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Visit Outcome Treatment n Mean (SD) Median Min, Max 95% CI 
Baseline Result Intervention 39 3.34 (2.07) 3.00 0.00, 7.20 2.67, 4.01 
Control 43 3.36 (2.23) 2.90 0.00, 8.10 2.67, 4.05 
Week 4 Result Intervention 38 2.27 (1.66) 2.05 0.00, 7.20 1.73, 2.82 
Control 40 2.95 (2.06) 2.55 0.00, 7.60 2.29, 3.61 
Reduction 
from 
Baseline 
Intervention 38 1.11 (1.80) 1.30 -2.20, 4.60 0.52, 1.70 
Control 40 0.44 (2.11) 0.20 -4.40, 5.80 -0.24, 1.11 
Week 20 Result Intervention 36 1.85 (1.72) 1.43 0.00, 6.80 1.27, 2.43 
Control 41 2.49 (2.04) 2.60 0.00, 9.20 1.85, 3.14 
Reduction 
from 
Baseline 
Intervention 36 1.68 (2.07) 1.50 -2.30, 5.40 0.98, 2.38 
Control 41 0.84 (2.21) 0.40 -7.10, 5.90 0.14, 1.54 
 
 
 
 
 
Table 43.  Clinical Trial 2.  Visual Analogue Scale (VAS) for pain. Descriptive summary, 
MITT Subjects.  10cm VAS scale responses were rounded to the nearest mm. 
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Figure 32.  Clinical Trial 2.  Box Plot of Visual Analogue Scale (cm) over time, MITT 
subjects. 
At the 4- and 20-week  follow-up, both groups show improvement in VAS score.  The 
differences between the group means were however not statistically significant at follow-
up (ANOVA p=0.9191 at baseline; p=0.0646 at week 4; p=0.0693 at week 20).  
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Figure 33.  Clinical Trial 2.  Reference Plot: Visual Analogue Scale (cm), MITT Subjects.   
Plots above the reference line indicate lower pain symptoms from baseline and those 
below the reference point indicate subjects with increases in pain. 
There are general improvements in both intervention and control subjects.  More 
Intervention subjects improve overall than control subjects 
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Visit Outcome Statistic Treatment Differenceb P-valuea 
   Intervention Control   
Baseline Result n 38 41  
0.9191 LS Mean (SE) 3.38 (0.35) 3.33 (0.34) 0.05 (0.49) 
95% CI 2.68, 4.09 2.66, 4.01 -0.93, 1.03 
Week 4 Result n 38 41  
0.0646 LS Mean (SE) 2.27 (0.26) 2.95 (0.25) -0.67 (0.36) 
95% CI 1.76, 2.79 2.45, 3.45 -1.39, 0.04 
Reduction 
from 
Baseline 
n 38 40  
0.0646 LS Mean (SE) 1.11 (0.26) 0.44 (0.25) 0.67 (0.36) 
95% CI 0.60, 1.62 -0.06, 0.94 -0.04, 1.39 
Week 20 Result n 38 41  
0.0693 LS Mean (SE) 1.81 (0.29) 2.53 (0.27) -0.72 (0.39) 
95% CI 1.24, 2.38 2.00, 3.06 -1.50, 0.06 
Reduction 
from 
Baseline 
n 36 41  
0.0693 LS Mean (SE) 1.62 (0.29) 0.90 (0.27) 0.72 (0.39) 
95% CI 1.05, 2.19 0.37, 1.43 -0.06, 1.50 
 
 
 
 
Table 44.  Clinical Trial 2.  Visual Analogue Scale (VAS) for pain.  Least squares means, 
MITT subjects. 
ANOVA Model for baseline: Result=Treatment + error. ANOVA Model for post-baseline: 
Result=Treatment + Baseline + Error. aP-value is based on a mixed model F-test (Ho: Both 
treatments equal). b Diff = Mean (SD) of the treatment difference (Intervention - Control). 
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3.9.3 Plaque Index (PI) (Silness and Löe, 1964) 
The two groups were similar at baseline (p=0.6928) with mean PI 1.42 for the 
intervention group and 1.45 for the control group.  Descriptive statistics are 
presented for PI in Table 45 and box plots for PI are presented in Figure 34.  The 
relationship between baseline and post-baseline for PI is presented in Figure 35.   
In this reference plot scores below the reference line indicate an increase post-
baseline compared to baseline, whilst values above the reference line indicate a 
decrease post-baseline. 
At weeks 4 and 20, only the intervention group showed distribution shift.  The 
overall mean PI was calculated as an arithmetic mean of all PI scores recorded at 6 
sites per tooth as detailed in the methods.   
The overall unadjusted PI reduction was 0.54 (36.32%) at week 4 and 0.57 
(39.45%) at week 20 for the intervention group.  The overall unadjusted PI 
reduction was -0.01 (-0.59%) at week 4 and -0.03 (-4.04%) at week 20 for the 
control group. 
The overall least squares mean PI reductions are presented in Table 46 and were 
0.53 (36.55%) at week 4 and 0.57 (39.56%) at week 20 for the intervention group.  
The overall LS mean PI reductions were 0.00 (0.81%) at week 4 and -0.03 (-4.13%) 
at week 20 for the control group.  The LS mean treatment difference (Intervention 
– Control) and 95% CI reduction was 0.53 (0.42, 0.64) at week 4 and 0.60 (0.48, 
0.73) at week 20.  The difference in reduction in PI between intervention and 
control groups was statistically significant (p<0.0001) at both follow-up visits. 
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Visit Outcome Treatment n Mean (SD) Median Min, Max 95% CI 
Baseline Result Intervention 39 1.42 (0.36) 1.35 0.70, 2.40 1.30, 1.54 
Control 43 1.45 (0.34) 1.41 0.85, 2.17 1.34, 1.55 
Week 4 Result Intervention 38 0.89 (0.33) 0.84 0.38, 2.04 0.78, 0.99 
Control 40 1.44 (0.34) 1.49 0.68, 2.05 1.33, 1.55 
Reduction 
from 
Baseline 
Intervention 38 0.53 (0.33) 0.49 -0.44, 1.36 0.42, 0.63 
Control 40 0.01 (0.22) 0.03 -0.46, 0.49 -0.06, 0.08 
% 
Reduction 
from 
Baseline 
Intervention 38 36 (21) 37 -50, 67 29, 43 
Control 40 -1 (18) 2 -53, 42 -6, 5 
Week 
20 
Result Intervention 36 0.86 (0.34) 0.88 0.22, 1.54 0.75, 0.98 
Control 41 1.47 (0.32) 1.42 0.86, 2.43 1.37, 1.57 
Reduction 
from 
Baseline 
Intervention 36 0.57 (0.36) 0.56 -0.12, 1.48 0.45, 0.69 
Control 41 -0.03 (0.27) -0.08 -0.49, 0.75 -0.11, 0.06 
% 
Reduction 
from 
Baseline 
Intervention 36 39 (22) 42 -9, 86 32, 47 
Control 41 -4 (20) -6 -58, 35 -10, 2 
 
 
 
 
 
Table 45.  Clinical Trial 2.  Plaque Index (Silness and Löe, 1964), descriptive summary, 
MITT subjects. 
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Figure 34.  Clinical Trial 2.  Box Plot:  Plaque Index (Silness and Löe, 1964), MITT Subjects. 
At the 4- and 20-week follow-up, both groups show improvement in Plaque Index.  The 
differences between the group means were statistically significant at follow-up (ANOVA 
p=0.6928 at baseline; p<0.0001 at week 4; p=<0.0001 at week 20). 
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Figure 35.  Clinical Trial 2.  Reference Plot: Plaque Index (Silness and Löe, 1964), MITT 
Subjects. 
Plots above the reference line indicate lower plaque indices from baseline and those below 
the reference point indicate subjects with increases in plaque. 
Generally there is a higher concentration of intervention subjects with plots above the 
reference lines at weeks 4 and 20 indicating an improvement in plaque control.  
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Visit Variable Statistic Treatment Differenceb P-valuea 
   Intervention Control   
Baseline Result n 38 41   
LS Mean (SE) 1.41 (0.06) 1.44 (0.05) -0.03 (0.08) 0.6928 
95% CI 1.30, 1.53 1.34, 1.55 -0.19, 0.13  
Week 4 Result n 38 41   
LS Mean (SE) 0.90 (0.04) 1.43 (0.04) -0.53 (0.06) <0.0001 
95% CI 0.82, 0.98 1.35, 1.51 -0.64, -0.42  
Reduction 
from 
Baseline 
n 38 40   
LS Mean (SE) 0.53 (0.04) 0.00 (0.04) 0.53 (0.06) <0.0001 
95% CI 0.45, 0.61 -0.07, 0.08 0.42, 0.64  
% 
Reduction 
from 
Baseline 
n 38 40   
LS Mean (SE) 37 (3) -1 (3) 37 (4) <0.0001 
95% CI 30, 43 -7, 6 29, 46  
Week 20 Result n 38 41   
LS Mean (SE) 0.87 (0.05) 1.47 (0.04) -0.60 (0.06) <0.0001 
95% CI 0.77, 0.96 1.38, 1.55 -0.73,-0.48  
Reduction 
from 
Baseline 
n 36 41   
LS Mean (SE) 0.57 (0.05) -0.03 (0.04) 0.60 (0.06) <0.0001 
95% CI 0.48, 0.67 -0.11, 0.06 0.48, 0.73  
% 
Reduction 
from 
Baseline 
n 36 41   
LS Mean (SE) 40 -4 (3) 44 (5) <0.0001 
95% CI 33, 46 -10, 2 35, 53  
 
 
 
 
Table 46.  Clinical Trial 2.  Plaque Index (Silness and Löe, 1964), overall least squares 
means, MITT subjects. 
ANOVA Model for baseline: Result=Treatment + error. ANOVA Model for post-baseline: 
Result=Treatment + Baseline + Error. 
aP-value is based on a mixed model F-test (Ho: Both treatments equal). 
b Diff = Mean (SD) of the treatment difference (Intervention - Control). 
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3.9.4 Oro-mucosal disease score (Escudier et al., 2007) 
The individual components that comprise the Escudier oro-mucosal disease score 
(site, severity and activity) were assessed along with the weighted overall score 
that included the subjective assessment of pain.  The scores from the VAS 10cm 
scale were used to complete the weighted score. Descriptive statistics for the 
individual components of the Oro-Mucosal Disease Scores are presented in Table 
47 for site score, Table 48 for severity score and Table 49 for activity score.  For 
the site, severity and activity scores, the medians at baseline were similar 
indicating that the data were not skewed.  The mean baseline severity and activity 
scores were slightly higher in the intervention group at baseline.   
The two groups had a similar distributions at baseline.  At week 4 and week 20 
both groups showed a distribution shift, and a reduction in site, severity and 
activity scores compared to baseline.  The shift in intervention group was greater 
than the control.  Box plots for change in site, severity and activity scores are 
presented in Figure 36.  The relationships between baseline and post-baseline are 
presented in reference plot form in Figure 37.  The plot scores below the reference 
line indicate an increase post-baseline compared to baseline, while scores above 
the reference line indicate a decrease post-baseline compared with baseline.  Bar 
charts showing the reduction from baseline for the site, severity and activity scores 
are presented in Figure 38. 
The LS means statistical output for oro-mucosal disease scores are presented in 
Table 50 (site), Table 51 (severity), Table 52 (activity) along with descriptive 
statistics and LS means for the weighted overall scores (Table 53).  At baseline 
there were no statistical differences between the two groups (p>0.05). At follow up 
the LS mean reduction was statistically different between the two groups 
(p<0.001) for site, severity and activity scores.  The LS mean treatment difference 
(intervention – control) and 95% CI in reduction in the oro-mucosal disease 
individual component scores were all statistically significant (p<0.01).  Graphical 
representation of the overall weighted score from baseline is presented in Figure 
39. 
When combined with pain scores to give the weighted score there was no 
difference between the groups at baseline (p=0.128) but a statistically significant 
difference in weighted score at week 4 (p=0.027) and week 20 (p=0.026).  The 
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overall reduction in weighted oro-mucosal disease score in the intervention group 
was more than the control group at weeks 4 and 20 (p<0.001). 
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Visit Outcome Treatment n Mean (SD) Median Min, Max 95% CI 
Baseline Result Intervention 39 10.87 (2.52) 11.0 7.0, 17.0 10.06, 11.69 
Control 43 10.35 (2.25) 10.0 7.0, 15.0 9.66, 11.04 
Week 4 Result Intervention 38 9.45 (2.65) 9.0 5.0,16.0 8.58, 10.32 
Control 40 10.63 (2.20) 10.0 7.0, 15.0 9.92, 11.33 
Reduction 
from 
Baseline 
Intervention 38 1.32 (1.74) 1.0 -3.0, 5.00 0.74, 1.89 
Control 40 -0.15 (1.31) 0.0 -3.0, 2.0 -0.57, 0.27 
% 
Reduction 
from 
Baseline 
Intervention 38 12 (17) 13 -27, 45 6, 17 
Control 40 -2 (13) 0.0 -30, 22 -7, 2 
Week 20 Result Intervention 36 9.14 (2.55) 9.0 4.0, 15.0 8.27, 10.00 
Control 40 10.50 (2.06) 10.5 7.0, 14.0 9.84, 11.16 
Reduction 
from 
Baseline 
Intervention 36 1.72 (1.77) 1.5 -2.0, 6.0 1.12, 2.32 
Control 40 -0.05 (1.71) 0.0 -7.0, 2.0 -0.60, 0.50 
% 
Reduction 
from 
Baseline 
Intervention 36 15 (17) 12.5 -29, 60 9, 21 
Control 40 -2 (21) 0.0 -100, 22 -9, 4 
 
 
 
 
 
 
Table 47.  Clinical Trial 2.  Escudier oro-mucosal disease score descriptive summary for 
the site score, MITT subjects. 
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Visit Variable Treatment n Mean (SD) Median Min, Max 95% CI 
Baseline Result Intervention 39 14.92 (5.64) 13.0 6.0, 29.0 13.10, 16.75 
Control 43 12.86 (4.30) 13.0 3.0, 21.0 11.54, 14.18 
Week 4 Result Intervention 38 10.79 (5.04) 10.0 3.0, 22.0 9.13, 12.45 
Control 40 13.53 (4.46) 13.5 5.0, 22.0 12.10, 14.95 
Reduction 
from 
Baseline 
Intervention 38 3.89 (4.07) 4.0 -4.0, 13.0 2.56, 5.23 
Control 40 -0.53 (3.37) -1.0 -7.0, 8.0 -1.60, 0.55 
% 
Reduction 
from 
Baseline 
Intervention 38 25 (28) 25 -50, 68 15, 34 
Control 40 -8 (27) -7 -67, 38 -17, 1 
Week 20 Result Intervention 36 9.67 (5.17) 9.0 1.0, 20.0 7.92, 11.42 
Control 40 11.98 (3.69) 12.0 6.0, 19.0 10.79, 13.16 
Reduction 
from 
Baseline 
Intervention 36 5.19 (4.47) 5.5 -4.0, 14.0 3.68, 6.71 
Control 40 1.03 (3.91) 0.0 -8.0, 12.0 -0.23, 2.28 
% 
Reduction 
from 
Baseline 
Intervention 36 34 (30) 39 -33, 89 24, 44 
Control 40 -1 (50) 0 -267, 63 -17, 15 
 
 
 
 
 
Table 48.  Clinical Trial 2.  Escudier oro-mucosal disease score descriptive summary for 
the severity score, MITT Subjects. 
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Visit Variable Treatment n Mean (SD) Median Min, Max 95% CI 
Baseline Result Intervention 39 16.82 (7.06) 15.0 6.0, 35.0 14.53, 19.11 
Control 43 13.98 (5.25) 14.0 3.0, 27.0 12.36, 15.59 
Week 4 Result Intervention 38 11.66 (6.04) 10.0 4.0, 28.0 9.67, 13.64 
Control 40 15.03 (5.95) 15.0 5.0, 28.0 13.12, 16.93 
Reduction 
from 
Baseline 
Intervention 38 4.87 (4.77) 4.5 -3.0, 17.0 3.30, 6.43 
Control 40 -0.88 (3.76) -1.0 -9.0, 8.0 -2.08, 0.33 
% 
Reduction 
from 
Baseline 
Intervention 38 27 (28) 28 -50, 69 18, 36 
Control 40 -10 (28) -6 -67, 41 -19, -1 
Week 20 Result Intervention 36 10.31 (6.06) 8.0 1.0, 22.0 8.25, 12.36 
Control 40 12.75 (4.63) 12.0 6.0, 25.0 11.27, 14.23 
Reduction 
from 
Baseline 
Intervention 36 6.36 (5.20) 7.0 -5.0, 15.0 4.60, 8.12 
Control 40 1.25 (4.44) 1.0 -8.0, 12.0 -0.17, 2.67 
% 
Reduction 
from 
Baseline 
Intervention 36 37 (31) 44 -38, 89 27, 48 
Control 40 -0 (51) 7 -267, 63 -16, 16 
 
 
 
 
 
Table 49.  Clinical Trial 2.  Escudier oro-mucosal disease score descriptive summary for 
the activity score, MITT Subjects. 
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Figure 36.  Clinical Trial 2.  Box Plots: Escudier oro-mucosal disease scores for site, severity and activity over time. 
 
The site score showed no significant difference between the means at baseline (ANOVA p=0.5409); at follow-up significant differences were observed 
between the means (ANOVA p<0.0001 at week 4, p<0.0001 at week 20). 
The severity score showed no significant difference between the means at baseline (ANOVA p=0.1340); at follow up significant differences were observed 
between the means (ANOVA p<0.0001 at week 4, p<0.0001 at week 20). 
The activity score showed small but not statistically significant difference at baseline (ANOVA p=0.086); at follow up significant differences were observed 
between the means (ANOVA p<0.0001 at week 4, p<0.0001 at week 20).
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Figure 37.  Clinical Trial 2.  Reference plots: Escudier oro-mucosal disease score for site, severity, and activity over time, MITT Subjects.   
The upper row of reference plots show plots at week-4 against baseline and the lower row at 20-weeks against baseline.  Plots above the reference line 
indicate subjects with improvements from baseline whilst those below the reference line indicate subjects who deteriorated from baseline.  
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Figure 38.  Clinical Trial 2.  Bar chart:  Escudier oro-mucosal disease site, severity and 
activity scores showing reduction from baseline, MITT subjects. 
Bars represent least square means. Vertical lines represent standard error of the LS 
means. 
At week 4, mean reductions in site, severity and activity score components were all 
significantly different between groups (ANOVA p<0.0001).  At week 20, mean reductions 
in site severity and activity score components were all significantly different between 
groups (ANOVA p<0.0001 for site score, p=0.0001 for severity score; p<0.0001 for activity 
score). 
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Visit Variable Statistic Treatment Differenceb P-valuea 
   Intervention Control   
Baseline Result n 38 41   
LS Mean (SE) 10.76 (0.38) 10.44 (0.37) 0.32 (0.53) 0.5409 
95% CI 10.01, 11.52 9.71, 11.17 -0.73, 1.38  
Week 4 Result n 38 41   
LS Mean (SE) 9.33 (0.24) 10.74 (0.24) -1.41 (0.34) <0.0001 
95% CI 8.85, 9.81 10.27, 11.21 -2.09, -0.74  
Reduction 
from 
Baseline 
n 38 40   
LS Mean (SE) 1.29 (0.24) -0.12 (0.24) 1.41 (0.34) <0.0001 
95% CI 0.81, 1.77 -0.59, 0.34 0.74, 2.09  
% Reduction 
from 
Baseline 
n 38 40   
LS Mean (SE) 12 (2) -2 (2) 14 (3) <0.0001 
95% CI 7, 16 -7, 2 7, 20  
Week 20 Result n 38 41   
LS Mean (SE) 8.99 (0.27) 10.64 (0.25) -1.65 (0.37) <0.0001 
95% CI 8.45, 9.52 10.13, 11.14 -2.39, -0.92  
Reduction 
from 
Baseline 
n 36 40   
LS Mean (SE) 1.66 (0.27) 0.01 (0.25) 1.65 (0.37) <0.0001 
95% CI 1.13, 2.19 -0.50, 0.51 0.92, 2.39  
% Reduction 
from 
Baseline 
n 36 40   
LS Mean (SE) 15 (3) -2 (3) 17 (4) 0.0002 
95% CI 9, 21 -8, 4 8, 25  
 
 
 
 
Table 50.  Clinical Trial 2.  Escudier oro-mucosal disease site score, least squares means, 
MITT subjects  
ANOVA Model for baseline: Result=Treatment + error.  
ANOVA Model for post-baseline: Result=Treatment + Baseline + Error. 
aP-value is based on a mixed model F-test (Ho: Both treatments equal). 
b Difference = Mean (SD) of the treatment difference (Intervention - Control). 
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Visit Variable Statistic Treatment Differenceb P-valuea 
   Intervention Control   
Baseline Result N 38 41   
LS Mean (SE) 14.68 (0.80) 13.00 (0.77) 1.68 (1.11) 0.1340 
95% CI 13.09, 16.28 11.46, 14.54 -0.53, 3.90  
Week 4 Result N 38 41   
LS Mean (SE) 10.21 (0.55) 14.08 (0.54) -3.87 (0.78) <0.0001 
95% CI 9.10, 11.31 13.01, 15.15 -5.42, -2.33  
Reduction 
from 
Baseline 
N 38 40   
LS Mean (SE) 3.61 (0.55) -0.26 (0.54) 3.87 (0.78) <0.0001 
95% CI 2.51, 4.72 -1.33, 0.81 2.33, 5.42  
% 
Reduction 
from 
Baseline 
N 38 40   
LS Mean (SE) 23 (4) -7 (4) 30(6) <0.0001 
95% CI 15, 32 -15, 2 18, 42  
Week 20 Result N 38 41   
LS Mean (SE) 9.13 (0.60) 12.46 (0.56) -3.32 (0.83) 0.0001 
95% CI 7.95, 10.32 11.33, 13.58 -4.97, -1.68  
Reduction 
from 
Baseline 
N 36 40   
LS Mean (SE) 4.75 (0.60) 1.43 (0.56) 3.32 (0.83) 0.0001 
95% CI 3.56, 5.94 0.30, 2.55 1.68, 4.97  
% 
Reduction 
from 
Baseline 
N 36 40   
LS Mean (SE) 31 (7) 1 (6) 30 (9) 0.0021 
95% CI 18, 44 -11, 14 11, 48  
 
 
 
 
Table 51.  Clinical Trial 2.  Escudier oro-mucosal disease severity score, least squares 
means, MITT subjects. 
ANOVA Model for baseline: Result=Treatment + error.  
ANOVA Model for post-baseline: Result=Treatment + Baseline + Error. 
aP-value is based on a mixed model F-test (Ho: Both treatments equal). 
b Difference = Mean (SD) of the treatment difference (Intervention - Control). 
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Visit Variable Statistic Treatment Differenceb P-valuea 
   Intervention Control   
Baseline Result N 38 41   
LS Mean (SE) 16.53 (1.00) 14.12 (0.96) 2.40 (1.38) 0.0861 
95% CI 14.54, 18.51 12.21, 16.03 -0.35, 5.16  
Week 4 Result N 38 41   
LS Mean (SE) 10.77 (0.65) 15.87 (0.63) -5.10 (0.92) <0.0001 
95% CI 9.47, 12.06 14.61, 17.13 -6.93, -3.28  
Reduction 
from 
Baseline 
N 38 40   
LS Mean (SE) 4.54 (0.65) -0.56 (0.63) 5.10 (0.92) <0.0001 
95% CI 3.24, 5.84 -1.83, 0.70 3.28, 6.93  
% 
Reduction 
from 
Baseline 
N 38 40   
LS Mean (SE) 26 (4) -8 (4) 34 (6) <0.0001 
95% CI 17, 35 -17, 0 22, 47  
Week 20 Result N 38 41   
LS Mean (SE) 9.50 (0.68) 13.47 (0.65) -3.97 (0.95) <0.0001 
95% CI 8.14, 10.86 12.18, 14.76 -5.86, -2.07  
Reduction 
from 
Baseline 
N 36 40   
LS Mean (SE) 5.76 (0.68) 1.79 (0.65) 3.97 (0.95) <0.0001 
95% CI 4.40, 7.12 0.50, 3.08 2.07, 5.86  
% 
Reduction 
from 
Baseline 
N 36 40   
LS Mean (SE) 35 (7) 2 (6) 32 (10) 0.0012 
95% CI 21, 48 -11, 15 13, 51  
 
 
 
 
 
Table 52.  Clinical Trial 2.  Escudier oro-mucosal disease activity score, least squares 
means, MITT subjects.  
ANOVA Model for baseline: Result=Treatment + error.  
ANOVA Model for post-baseline: Result=Treatment + Baseline + Error. 
aP-value is based on a mixed model F-test (Ho: Both treatments equal). 
b Difference = Mean (SD) of the treatment difference (Intervention - Control).  
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Visit Outcome Treatment n Mean (SD) Median Min, Max 95% CI Mean difference (SD)b P-valuea 
Baseline Result Intervention 39 31.12 (9.62) 30.90 16.30, 57.80 27.87, 34.37 
3.14 (-0.93, 7.22) 0.128 
Control 43 27.97 (8.07) 28.00 14.00, 46.90 25.28, 30.52 
Week 4 Result Intervention 38 23.93 (8.53) 20.85 12.50, 45.90 21.05, 26.81 
-4.53 (-8.53, -0.53) 0.027 
Control 40 28.46 (8.82) 28.30 14.00, 49.40 25.60, 31.32 
Reduction from 
Baseline 
Intervention 38 7.18 (6.24) 6.95 -3.50, 22.00 5.07, 9.29 
7.67 (5.05, 10.31) <0.001 
Control 40 -0.49 (5.18) -0.70 -12.40, 11.60 -2.17, 3.36 
% Reduction 
from Baseline 
Intervention 38 22 (18) 22 -19, 50 16, 28 
24.46 (16.32, 32.62) <0.001 
Control 40 -3 (17) -4 -35, 31 -8, 3 
Week 20 Result Intervention 36 21.40 (8.87) 18.70 5.00, 37.60 18.40, 24.40 
-4.25 (-7.97, -0.52) 0.026 
Control 40 25.65 (7.31) 25.40 14.50, 47.20 23.28, 28.02 
Reduction from 
Baseline 
Intervention 36 9.71 (6.42) 9.71 -4.50, 21.00 7.53, 11.89 
7.39 (4.49, 10.30) <0.001 
Control 40 2.32 (6.18) 2.40 -12.10, 17.80 0.32, 4.32 
% Reduction 
from Baseline 
Intervention 36 31 (20) 30 -19, 78 24, 38 
25.40 (15.56, 35.24) <0.001 
Control 40 6 (22) 9 -80, 46 -2, 13 
 
Table 53.  Clinical Trial 2.  Escudier oro-mucosal disease index weighted scores (site, activity and pain), least squares mean treatment difference, MITT 
subjects. 
ANOVA Model for baseline: Result=Treatment + error.  ANOVA Model for post-baseline: Result=Treatment + Baseline + Error. 
aP-value is based on a mixed model F-test (Ho: Both treatments equal). 
b Difference = Mean (SD) of the treatment difference (Intervention - Control). 
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Figure 39.  Clinical Trial 2.  Bar chart: Escudier oro-mucosal disease index weighted 
scores reduction from baseline. 
These represent the least squares mean sum of the site score, activity score and pain 
scores.  Vertical lines represent standard deviation of the least square means.  There were 
significant differences between groups at week 4 and week 20 (ANOVA p<0.001). 
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3.9.5 Biomarkers 
Samples of saliva and GCF were obtained from a subset of the population (n=12) at 
baseline and week 4 to determine the local levels of inflammatory biomarkers.  
Both GCF and saliva were analysed as previously described (Chapter 2) for the 
following biomarkers: IL-1, IL-2, MIP-1, MIP-1, RANTES, MMP-1, MMP-3, MMP-
8, MMP-9 MMP-13.  Descriptive statistics, and analysis of least squares means 
using analysis of variance are presented for the GCF samples in Table 54 for 
cytokines and Table 55 for MMPs.  The data for saliva samples are presented in 
Table 56 for cytokines and Table 57 for MMPs. 
Levels of all inflammatory biomarkers in both groups were similar at baseline in 
saliva (p>0.05) and GCF samples (p>0.05) although different levels of 
concentrations were identified in each fluid.  Generally, higher concentrations of 
inflammatory mediators were present in GCF in comparison with saliva.  
In the GCF samples, levels of MMP-1 and MMP-13 were detected below the 
minimum concentration threshold to have confidence in the result; in the saliva 
samples levels of IL-2, RANTES, MMP-1, MMP-13 were also not detected in high 
enough concentrations.  The difference in RANTES in particular was at 
undetectable levels in the saliva samples yet found in comparatively high 
concentrations in GCF. 
The mean biomarker concentrations were similar at the 4-week follow up for all 
observed biomarkers and no significant differences were observed following 
treatment (p>0.05).  
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Biomarker Visit Variable Treatment n Mean (SD)c Median Min, Max 95% CI Mean difference (SD)b P-valuea 
IL-1β Baseline Result Intervention 4 10.80 (0.39) 10.70 10.46, 11.34 10.17, 11.43 
-0.55 (0.42) 0.2220 
  
Control 7 11.35 (0.77) 11.25 10.44, 12.90 10.64, 12.07 
Week 4 Result Intervention 4 11.44 (0.69) 11.35 10.75, 12.32 10.34, 12.54 
-0.03 (0.48) 0.9443 
  
Control 7 11.53 (0.66) 11.31 10.45, 12.29 10.92, 12.14 
 
Change from Baseline Intervention 4 0.64 (0.75) 0.29 0.23, 1.76 -0.55, 1.83 
-0.03 (0.48) 0.9443 
  
Control 7 0.18 (0.97) 0.07 -1.06, 1.84 -0.72, 1.07 
IL-2 Baseline Result Intervention 4 1.22 (2.44) 0.00 0.00, 4.88 -2.66, 5.11 
0.50 (1.32) 0.7151 
  
Control 7 0.72 (1.91) 0.00 0.00, 5.07 -1.05, 2.49 
Week 4 Result Intervention 4 0.00 (0.00) 0.00 0.00, 0.00 N/a 
-0.63 (0.97) 0.5325 
  
Control 7 0.67 (1.78) 0.00 0.00, 4.70 -0.97, 2.32 
 
Change from Baseline Intervention 4 -1.22 (2.44) 0.00 -4.88, 0.00 -5.11, 2.66 
-0.63 (0.97) 0.5325 
  
Control 7 -0.05 (2.82) 0.00 -5.07, 4.70 -2.66, 2.56 
MIP-1α Baseline Result Intervention 4 8.60 (0.99) 9.07 7.12, 9.15 7.03, 10.18 
-0.09 (0.65) 0.8876 
  
Control 7 8.70 (1.05) 8.74 7.48, 10.23 7.72, 9.67 
Week 4 Result Intervention 4 9.48 (1.30) 10.04 7.55, 10.29 7.41, 11.55 
0.34 (0.38) 0.3871 
  
Control 7 9.20 (0.65) 9.23 8.21, 10.25 8.60, 9.80 
 
Change from Baseline Intervention 4 0.88 (0.38) 0.91 0.43, 1.26 0.28, 1.47 
0.34 (0.38) 0.3871 
  
Control 7 0.51 (0.74) 0.73 -0.81, 1.50 -0.18, 1.19 
MIP-1β Baseline Result Intervention 4 6.64 (3.52) 8.20 1.41, 8.75 1.05, 12.23 
-1.38 (1.42) 0.3581 
  
Control 7 8.02 (1.23) 7.76 6.08, 9.91 6.87, 9.16 
Week 4 Result Intervention 4 8.67 (1.43) 9.34 6.54, 9.48 6.40, 10.94 
2.41 (1.61) 0.1746 
  
Control 7 7.33 (3.41) 8.41 0.00, 10.31 4.18, 10.48 
 
Change from Baseline Intervention 4 2.03 (2.10) 1.13 0.73, 5.13 -1.31, 5.37 
2.41 (1.61) 0.1746 
  
Control 7 -0.69 (2.49) 0.20 -6.08, 1.35 -2.99, 1.62 
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Biomarker Visit Variable Treatment n Mean (SD)c Median Min, Max 95% CI Mean difference (SD)b P-valuea 
RANTES Baseline Result Intervention 4 5.64 (4.05) 6.60 0.00, 9.38 -0.79, 12.08 
0.48 (2.39) 0.8459 
  
Control 7 5.17 (3.68) 6.17 0.00, 9.15 1.76, 8.57 
Week 4 Result Intervention 4 7.67 (1.26) 7.88 6.12, 8.82 5.67, 9.68 
0.22 (1.02) 0.8345 
  Control 7 7.49 (1.69) 7.55 4.45, 9.26 5.93, 9.06 
 Change from Baseline Intervention 4 2.03 (3.50) 0.75 -0.55, 7.18 -3.54, 7.60 
0.22 (1.02) 0.8345 
  Control 7 2.33 (4.77) 0.45 -3.05, 9.26 -2.08, 6.74 
 
 
 
 
 
 
 
Table 54.  Clinical Trial 2.  Descriptive summary: Biomarker GCF samples cytokine panel, log scale, MITT subjects.   
Biomarkers concentration is calculated as the average of repeated measurements. Log transformation is applied to the average concentration. Change from 
baseline is calculated from the log-transformed concentration.  
ANOVA Model for baseline: Result=Treatment + error.  
ANOVA Model for post-baseline: Result=Treatment + Baseline + Error. 
aP-value F-test (Ho: Both treatments equal). 
b Difference = Mean (SD) of the treatment difference (Intervention - Control). 
c Mean biomarker concentration in pg/ml. 
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Biomarker Visit Variable Treatment n Mean (SD)c Median Min, Max 95% CI Mean difference (SD)b P-valuea 
MMP-1 Baseline Result Intervention 4 0.00 (0.00) 0.00 0.00, 0.00 N/a 
-1.28 (1.73) 0.4790 
  Control 7 1.28 (3.38) 0.00 0.00, 8.95 -1.85, 4.41 
Week 4 Result Intervention 4 0.00 (0.00) 0.00 0.00, 0.00 N/a 
-1.14 (1.42) 0.4468 
  Control 7 2.08 (3.56) 0.00 0.00, 7.72 -1.21, 5.37 
 Change from Baseline Intervention 4 0.00 (0.00) 0.00 0.00, 0.00 N/a 
-1.14 (1.42) 0.4468 
  Control 7 0.80 (2.70) 0.00 -1.23, 6.83 -1.69, 3.29 
MMP-3 Baseline Result Intervention 4 4.83 (5.59) 4.66 0.00, 10.01 -4.06, 13.72 
1.78 (3.35) 0.6092 
  Control 7 3.05 (5.23) 0.00 0.00, 11.37 -1.78, 7.89 
Week 4 Result Intervention 4 2.50 (5.00) 0.00 0.00, 9.99 -5.45, 10.45 
-0.36 (3.28) 0.9145 
  Control 7 2.80 (4.80) 0.00 0.00, 10.26 -1.63, 7.24 
 Change from Baseline Intervention 4 -2.33 (9.40) -4.66 -10.01, 9.99 -17.29, 12.63 
-0.36 (3.28) 0.9145 
  Control 7 -0.25 (5.61) 0.00 -19.38 -5.44, 4.94 
MMP-8 Baseline Result Intervention 4 16.14 (0.26) 16.09 15.88, 16.50 15.72, 16.56 
-0.77 (0.31) 0.0334 
  Control 7 16.90 (0.57) 16.73 16.29, 17.78 16.38, 17.43 
Week 4 Result Intervention 4 16.49 (0.46) 16.59 15.89, 16.87 15.75, 17.22 
-0.23 (0.30) 0.4789 
  Control 7 16.90 (0.32) 16.93 16.35, 17.29 16.61, 17.20 
 Change from Baseline Intervention 4 0.35 (0.29) 0.32 0.02, 0.73 -0.12, 0.81 
-0.23 (0.30) 0.4789 
  Control 7 -0.00 (0.58) 0.08 -1.71 -0.54, 0.54 
MMP-9 Baseline Result Intervention 4 16.89 (0.19) 16.89 16.69, 17.08 16.59, 17.19 
-0.61 (0.36) 0.1222 
  Control 7 17.50 (0.69) 17.80 16.49, 18.23 16.87, 18.13 
Week 4 Result Intervention 4 17.25 (0.37) 17.30 16.76, 17.64 16.66, 17.83 
-0.11 (0.30) 0.7197 
  Control 7 17.51 (0.44) 17.30 17.05, 18.20 17.11, 17.91 
 Change from Baseline Intervention 4 0.36 (0.28) 0.41 -0.62 -0.08, 0.80 
-0.11 (0.30) 0.7197 
  Control 7 0.01 (0.68) -0.04 -1.90 -0.62, 0.64 
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Biomarker Visit Variable Treatment n Mean (SD)c Median Min, Max 95% CI Mean difference (SD)b P-valuea 
MMP-13 Baseline Result Intervention 4 0.00 (0.00) 0.00 0.00, 0.00 N/a 
0.00 N/a 
  Control 7 0.00 (0.00) 0.00 0.00, 0.00 N/a 
Week 4 Result Intervention 4 0.00 (0.00) 0.00 0.00, 0.00 N/a 
1.39 (1.88) 0.4790 
  Control 7 1.39 (3.67) 0.00 0.00, 9.72 -2.01, 4.79 
 Change from Baseline Intervention 4 0.00 (0.00) 0.00 0.00, 0.00 N/a 
1.39 (1.88) 0.4790 
  Control 7 1.39 (3.67) 0.00 0.00, 9.72 -2.01, 4.79 
 
 
 
 
 
 
 
Table 55.  Clinical Trial 2.  Descriptive summary: Biomarker GCF samples – MMP panel, log scale, MITT subjects.   
Biomarkers concentration is calculated as the average of repeated measurement.  Log transformation is applied to the average concentration. Change from 
baseline is calculated from the log-transformed concentration. 
ANOVA Model for baseline: Result=Treatment + error.  
ANOVA Model for post-baseline: Result=Treatment + Baseline + Error. 
aP-value F-test (Ho: Both treatments equal). 
b Difference = Mean (SD) of the treatment difference (Intervention - Control). 
c Mean biomarker concentration in pg/ml. 
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Biomarker Visit Variable Treatment n Mean (SD)c Median Min, Max 95% CI Mean difference (SD)b P-valuea 
IL-1β Baseline Result Intervention 4 5.60 (1.10) 5.32 4.67, 7.09 3.84, 7.36 
-0.88 (0.57) 0.1597 
  Control 7 6.48 (0.80) 6.60 5.14, 7.74 5.74, 7.22 
Week 4 Result Intervention 4 6.10 (0.85) 6.11 5.09, 7.08 4.75, 7.45 
0.18 (0.41) 0.6706 
  Control 7 6.66 (1.00) 6.60 5.47, 8.47 5.74, 7.59 
 Change from Baseline Intervention 4 0.50 (0.40) 0.53 -0.01, 0.95 -0.14, 1.14 
0.18 (0.41) 0.6706 
  Control 7 0.18 (0.63) 0.01 -0.47, 1.26 -0.40, 0.77 
IL-2 Baseline Result Intervention 4 0.50 (0.14) 0.45 0.40, 0.69 0.28, 0.72 
0.07 (0.10) 0.4967 
  Control 7 0.42 (0.18) 0.40 0.15, 0.64 0.26, 0.58 
Week 4 Result Intervention 4 0.59 (0.08) 0.58 0.50, 0.69 0.46, 0.71 
0.02 (0.07) 0.8048 
  Control 7 0.53 (0.16) 0.55 0.28, 0.77 0.38, 0.67 
 Change from Baseline Intervention 4 0.09 (0.17) 0.08 -0.09, 0.29 -0.18, 0.36 
0.02 (0.07) 0.8048 
  Control 7 0.10 (0.10) 0.13 -0.1, 0.2 0.01, 0.20 
MIP-1α Baseline Result Intervention 4 4.56 (0.47) 4.50 4.16, 5.10 3.81, 5.32 
0.56 (0.32) 0.0268 
  Control 7 4.01 (0.24) 4.03 3.53, 4.30 3.78, 4.23 
Week 4 Result Intervention 4 4.60 (0.57) 4.45 4.16, 5.35 3.70, 5.50 
0.15 (0.32) 0.6541 
  Control 7 4.19 (0.26) 4.16 3.97, 4.73 3.95, 4.44 
 Change from Baseline Intervention 4 0.04 (0.15) 0.00 -0.1, 0.25 -0.20, 0.28 
0.15 (0.32) 0.6541 
 Control 7 0.19 (0.48) 0.10 -0.33, 1.2 -0.26, 0.63 
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Biomarker Visit Variable Treatment n Mean (SD)c Median Min, Max 95% CI Mean difference (SD)b P-valuea 
MIP-1β Baseline Result Intervention 4 1.95 (1.67) 2.20 0.00, 3.42 -0.71, 4.62 
0.75 (0.85) 0.4035 
  Control 7 1.21 (1.17) 0.71 0.00, 3.62 0.13, 2.29 
Week 4 Result Intervention 4 2.18 (1.80) 2.18 0.00, 4.36 -0.69, 5.05 
0.57 (0.93) 0.5580 
  Control 7 1.29 (1.25) 1.51 0.00, 3.42 0.13, 2.45 
 Change from Baseline Intervention 4 0.23 (0.87) 0.36 -0.89, 1.09 -1.16, 1.62 
0.57 (0.93) 0.5580 
  Control 7 0.09 (1.79) 0.67 -3.62, 1.81 -1.57, 1.74 
RANTES Baseline Result Intervention 4 0.00 (0.00) 0.00 0.00, 0.00 N/a 
-0.23 (0.31) 0.4790 
  Control 7 0.23 (0.60) 0.00 0.00, 1.59 -0.33, 0.78 
Week 4 Result Intervention 4 0.70 (1.40) 0.00 0.00, 2.79 -1.52, 2.92 
-0.70 (0.55) 0.2415 
  Control 7 0.00 (0.00) 0.00 0.00, 0.00 N/a 
 Change from Baseline Intervention 4 0.70 (1.40) 0.00 0.00, 2.79 -1.52, 2.92 
-0.70 (0.55) 0.2415 
  Control 7 -0.23 (0.60) 0.00 -1.59, 0.00 -0.78, 0.33 
 
Table 56.  Clinical Trial 2. Descriptive summary: Biomarker saliva samples cytokine panel, log scale, MITT subjects.  
Note: Biomarkers concentration is calculated as the average of repeated measurement. Log transformation is applied to the average concentration. Change 
from baseline is calculated from the log-transformed concentration. 
ANOVA Model for baseline: Result=Treatment + error.  
ANOVA Model for post-baseline: Result=Treatment + Baseline + Error. 
aP-value F-test (Ho: Both treatments equal). 
b Difference = Mean (SD) of the treatment difference (Intervention - Control). 
c Mean biomarker concentration in pg/ml. 
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Biomarker Visit Variable Treatment n Mean (SD)c Median Min, Max 95% CI Mean difference (SD)b P-valuea 
MMP-1 Baseline Result Intervention 4 2.77 (3.22) 2.54 0.00, 6.00 -2.36, 7.90 
0.14 (1.74) 0.9395 
Control 7 2.63 (2.53) 3.52 0.00, 5.35 0.29, 4.98 
Week 4 Result Intervention 4 2.29 (2.77) 1.78 0.00, 5.60 -2.12, 6.71 
-0.65 (1.23) 0.6096 
Control 7 2.85 (2.68) 4.44 0.00, 5.42 0.37, 5.33 
Change from Baseline Intervention 4 -0.48 (0.72) -0.20 -1.52, 0.00 -1.62, 0.66 
-0.65 (1.23) 0.6096 
Control 7 0.21 (2.41) 0.00 -3.52, 4.76 -2.02, 2.44 
MMP-3 Baseline Result Intervention 4 6.50 (1.37) 6.96 4.54, 7.52 4.31, 8.68 
-0.41 (0.63) 0.5374 
Control 7 6.90 (0.77) 6.82 5.40, 7.65 6.19, 7.62 
Week 4 Result Intervention 4 7.12 (0.84) 7.14 6.23, 7.99 5.79, 8.46 
0.30 (0.82) 0.7247 
Control 7 7.02 (1.49) 6.84 4.91, 9.34 5.64, 8.40 
Change from Baseline Intervention 4 0.62 (1.02) 0.38 -0.32, 2.07 -1.00, 2.25 
0.30 (0.82) 0.7247 
Control 7 0.12 (1.44) 0.17 -2.60, 1.87 -1.22, 1.45 
MMP-8 Baseline Result Intervention 4 11.32 (1.24) 11.40 9.97, 12.53 9.36, 13.29 
-1.15 (0.65) 0.1117 
Control 7 12.47 (0.92) 12.54 10.92, 13.73 11.62, 13.32 
Week 4 Result Intervention 4 11.76 (1.05) 11.74 10.54, 13.03 10.09, 13.43 
-0.36 (0.56) 0.5382 
Control 7 12.83 (0.93) 12.81 11.29, 14.05 11.97, 13.69 
Change from Baseline Intervention 4 0.44 (0.64) 0.70 -0.51, 0.85 -0.58, 1.46 
-0.36 (0.56) 0.5382 
Control 7 0.36 (0.91) 0.30 -0.95, 1.73 -0.48, 1.20 
MMP-9 Baseline Result Intervention 4 12.52 (0.87) 12.49 11.63, 13.46 11.14, 13.90 
-0.65 (0.36) 0.1068 
Control 7 13.17 (0.36) 13.10 12.73, 13.67 12.84, 13.51 
Week 4 Result Intervention 4 12.73 (0.76) 12.75 11.95, 13.48 11.52, 13.94 
-0.01 (0.34) 0.9859 
Control 7 13.17 (0.48) 13.22 12.45, 13.68 12.73, 13.62 
Change from Baseline Intervention 4 0.21 (0.28) 0.29 -0.19, 0.45 -0.23, 0.65 
-0.01 (0.34) 0.9859 
Control 7 -0.00 (0.56) 0.06 -1.09, 0.76 -0.52, 0.52 
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Biomarker Visit Variable Treatment n Mean (SD)c Median Min, Max 95% CI Mean difference (SD)b P-valuea 
MMP-13 Baseline Result Intervention 4 1.19 (2.39) 0.00 0.00, 4.78 -2.61, 4.99 
0.02 (1.81) 0.9914 
Control 7 1.17 (3.11) 0.00 0.00, 8.22 -1.70, 4.05 
Week 4 Result Intervention 4 0.00 (0.00) 0.00 0.00, 0.00 N/a 
0.00 N/a 
Control 7 0.00 (0.00) 0.00 0.00, 0.00 N/a 
Change from Baseline Intervention 4 -1.19 (2.39) 0.00 -4.78, 0.00 -4.99, 2.61 
0.00 N/a 
Control 7 -1.17 (3.11) 0.00 -8.22, 0.00 -4.05, 1.70 
 
 
 
 
 
Table 57.  Clinical Trial 2.  Descriptive summary: Biomarker saliva samples MMPs, log scale, MITT subjects. 
Biomarkers concentration is calculated as the average of repeated measurement. Log transformation is applied to the average concentration. Change from 
baseline is calculated from the log-transformed concentration. 
ANOVA Model for baseline: Result=Treatment + error.  
ANOVA Model for post-baseline: Result=Treatment + Baseline + Error. 
aP-value F-test (Ho: Both treatments equal). 
b Difference = Mean (SD) of the treatment difference (Intervention - Control). 
c Mean biomarker concentration in pg/ml. 
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3.9.6 Global change scores 
Symptoms were globally assessed at each follow-up visit to provide some overall 
context to the subjects’ symptoms and also to provide validity to the OHIP data.  
Global change scores were recorded on a 5-point scale, responses were coded 
positively for improvements and negatively for deteriorations in symptoms where:   
 Improved a lot (+2);  
 Improved slightly (+1); 
 Stayed the same 0; 
 Become slightly worse (-1) 
 Become a lot worse (-2). 
Descriptive statistics were produced for each group at each follow up appointment 
listed in Table 58.  At week 4 the mean global change with 95% CI was 1.03 (0.86, 
1.38) for the intervention group indicating that the subjects in that groups felt that 
their symptoms improved slightly.  The control group still showed a positive mean 
global change score but the confidence interval included zero at 0.26 (-0.02, 0.53) 
and therefore their symptoms may not have changed significantly from baseline.  
There were statistically significant differences between the two groups (p<0.001) 
at the 4-week follow up. 
At week 20 the participants also reported improvement from week 4 in both 
groups, with greater improvement in the intervention group.  The intervention 
group mean global score was 0.94 (0.56, 1.33) and the control group mean score 
0.44 (0.07, 0.81). There were no statistical differences between groups at the 20-
week follow-up (p=0.067).  
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Visit Treatment n Mean (SD) Median Min, Max 95% CI p-value 
Week 4 Intervention 38 1.03 (1.03) 1 -1.00-2.00 0.86, 1.38 
<0.001 
Control 40 0.26 (0.85) 0 -2.00-2.00 -0.02, 0.53 
Week 20 Intervention 36 0.94 (1.15) 1 -1.00-2.00 0.56, 1.33 
0.067 
Control 40 0.44 (1.14) 0 -2.00-2.00 0.07, 0.81 
 
 
 
 
 
 
 
Table 58.  Clinical Trial 2.  Descriptive statistics produced for global change scores.   
Respondents were asked to consider their symptoms since the previous visit and indicate 
if they had improved a lot, improved slightly, stayed the same, become slightly worse or 
become a lot worse.  Positive values indicate treatment improvement and negative values 
indicate deterioration in symptoms. Statistical analysis was carried out with MITT subjects 
using Mann Whitney U statistic, as the data were not normally distributed. 
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3.9.7 Effect sizes 
The effect of treatment was examined using Cohen’s d (Table 59).  Interpretation of 
effect sizes differs but it is generally agreed that those values above 0.2 are seen to 
be having a small treatment effect, above 0.5 to have a moderate effect and above 
0.8 to have a large effect.   
Moderate treatment effects were seen in the intervention group for OHIP ordinal 
scores at week 4 (0.608) and week 20 (0.725).  Moderate treatment effects were 
also observed in the intervention group for pain (VAS) both at the 4-week (0.517) 
and 20 weeks (0.700).  Large effect sizes were observed in the intervention group 
for PI at week 4 (1.470) and week 20 (1.559).  A moderate effect was seen in 
Escudier oro-mucosal disease index at week 4 (0.75) and a large effect observed at 
week 20 (1.01).  Small changes were observed for the control group in OHIP scores 
and VAS scores at 4 and 20 weeks.  No effect was observed in PI for the control 
group at any week.  The effect sizes can be used alongside the surrogate measures 
of health (clinical indices) and subjective measures of health (OHIP) in an attempt 
to provide a comprehensive assessment of the effect of the intervention. 
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Outcome 
measure 
Follow up  Group Mean pre-
treatment (SD) 
Mean post-
treatment 
Effect size 
OHIP-ordinal Week 4 Intervention 49.66 (24.86) 34.55 0.61 
Control 49.39 (29.82) 42.25 0.24 
Week 20 Intervention 49.66 (24.86) 31.64 0.74 
Control 49.39 (29.82) 41.66 0.26 
OHIP-
dichotomous 
Week 4 Intervention 6.55 (4.91) 3.03 0.72 
Control 6.71 (6.97) 5.30 0.20 
Week 20 Intervention 6.55 (4.91) 2.56 0.74 
Control 6.71 (6.97) 4.90 0.26 
VAS Week 4 Intervention 3.34 (2.07) 2.27 0.52 
Control 3.36 (2.23) 2.95 0.18 
Week 20  Intervention 3.34 (2.07) 1.85 0.70 
Control 3.36 (2.23) 2.49 0.38 
Plaque Index Week 4 Intervention 1.42 (0.36) 0.89 1.47 
Control 1.45 (0.34) 1.44 0.03 
Week 20 Intervention 1.42 (0.36) 0.86 1.56 
Control 1.45 (0.34) 1.47 -0.06 
Escudier oro-
mucosal 
disease index 
Week 4 Intervention 31.12 (9.62) 23.93 0.75 
Control 27.97 (8.07) 28.46 -0.06 
Week 20 Intervention 31.12 (9.62) 21.40 1.01 
Control 27.97 (8.07) 25.65 0.29 
 
 
 
 
 
Table 59.  Clinical Trial 2.  Unadjusted mean pre and post treatment values, standard 
deviations, and Cohen’s d effect sizes. 
It is generally accepted that d values of 0.2 represent small change, 0.5 represent 
moderate change and those >0.8 represent a large change. Negative values represent 
deterioration from baseline. 
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3.9.8 Correlation Analysis 
Correlation analysis was performed to investigate the association of clinical 
outcome and oral health related quality of life.  Spearman correlations between 
OHIP ordinal score over all domains and VAS pain score, overall Plaque Index, and 
oro-mucosal disease score (site score, severity score and activity score) were 
calculated. 
There were significant correlations between OHIP ordinal scores and VAS pain 
score, the Spearman correlation coefficient being approximately 0.5 (except at 
Week 4), indicating moderate correlations between these two subjective 
measurements of oral health. 
There were no statistically significant correlations between OHIP ordinal score and 
Plaque Index or between OHIP and the Escudier Index at baseline and Week 4.  At 
week 20, the correlation of change from baseline between OHIP and Plaque Index 
is 0.30 (<0.01), indicating a small positive correlation.  At week 20, the correlation 
of results and changes from baseline between OHIP and all three OMDS scores is in 
the range of 0.23-0.37 (p<0.05), indicating a small correlation between OHIP and 
OMDS. 
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3.9.8 Economic evaluation 
Although oral hygiene aids were provided free as part of the trial this would not be 
the case in practice and hence an economic evaluation was undertaken to 
determine the cost-effectiveness of the intervention.  Data were only collected 
from the intervention group subjects as the control subjects did not receive the 
intervention as part of the study protocol.  The economic evaluation included the 
costs of the products provided and also the time taken to deliver the intervention 
excluding set up and surgery cleaning time. 
The cost of the toothbrush was set at the current price (2012) of £95. The cost of 
the remaining interdental aids was estimated at £23.50 per subject.  The costs of 
toothpaste provided to both intervention and control groups were ignored.  For 
the cost benefit analysis it was assumed that patients would purchase toothpaste 
whether or not they participated in the intervention and that any additional 
toothpaste costs could be ignored.   
The time input for the plaque control programme, delivered by a dental hygienist 
was estimated to be approximately 5 minutes.  The total cost of an hour of patient 
contact time including all overheads for a dental hygienist working in General 
Dental Practice in the UK was estimated to be £51 (PSSRU, 2011).  The cost for 5 
minutes was then calculated at £4.25.  
A cost-benefit analysis was carried out by comparing the costs including travel and 
time costs, with the benefits of treatment for the patients in the intervention group 
Patients in the treatment arm were asked to report estimates of travel costs 
including car parking.  They were also asked to report the total time spent 
attending treatment sessions and their gross salary (in bands of £10,000).  The 
assumption was made that patients worked full time for 1750 hours a year and 
hourly costs of patient time were estimated using the mid salary band value 
divided by 1750.  Valuing the time of non-working patients is contentious but it is 
highly unlikely that these patients value their time at zero (Brouwer and 
Koopmanschap, 1998).  Unemployed patients were assigned to the band £0 – 
£10,000 and retired patients to the band £10,000 - £20,000 to assign a value to 
their time. 
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The cost-benefit analysis assessed whether patients receiving the treatment 
judged it to be worth more than the cost.  Patient travelling and time costs were 
added to the treatment cost (toothbrush + accessories + hygienist time) to 
determine the total cost of treatment for each patient.  This value was subtracted 
from each patient’s stated maximum willingness to pay (WTP) for the treatment to 
determine the net value of the treatment.   
Private cost data and stated willingness to pay values for treatment were obtained 
from all intervention patients retained at the 20-week follow-up; all patients stated 
a positive maximum WTP value (mean £321, range £65 to £1500).  Out of pocket 
costs for patients were generally small.   
The net value of treatment ranged from -£97 to £1339.  The mean value was £172 
(CI £88 to £282); the median was £69 (CI £24 to £124); and the inter-quartile 
range was £2 to £194.  Three quarters of the sample stated a maximum WTP in 
excess of the total cost of treatment, which was £122.75. 
The cost-benefit analysis indicates that the benefit of the intervention perceived by 
patients exceeded the cost.  The majority of patients in the treatment arm valued 
the treatment in excess of the cost, and the mean value was significantly more than 
the cost.  Hence the cost-benefit analysis would indicate that the treatment is cost-
effective when compared to no treatment.  Without WTP data from the control 
group valuing their treatment the cost-benefit analysis cannot ascertain whether 
the treatment is cost-effective when compared against the control. 
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3.10 Discussion 
This study aimed to provide a comprehensive assessment of the impact of plaque 
control in patients with the gingival manifestations of oral lichen planus.  The total 
numbers of subjects previously involved in prospective studies exploring this 
relationship are few in number.  The sample size in this study was considerably 
larger (n=82) and although the a priori estimate of 98 subjects was not achieved, 
sufficient numbers of subjects were enrolled to detect measurable changes within 
the study groups.  A post hoc power calculation based upon the primary outcome 
measure OHIP, showed that the study was overpowered at 36 subjects per 
treatment group.  One alternative method could have been used to determine 
sample size that of an adaptive trial design whereby interim analysis may have 
informed the numbers of subjects required at an earlier stage.  This method is not 
without its opponents and was not carried out in this study as there is the potential 
for the study to incur bias by the knowledge of the interim results (FDA, 2010).  
Reasonable conclusions can therefore be made based upon the number of subjects 
recruited into the study. 
This study also aimed to address some of the methodological problems that exist 
with many oral lichen planus intervention studies (Thongprasom et al., 2011).  
This study builds on previous recommendations for assessing oral lichen planus 
interventions that usually account for patients’ symptoms through VAS scores, and 
use clinical criteria scores. 
The addition of a measure of oral health related quality of life, the Oral Health 
Impact Profile, a global transition score as well as those more commonly utilised 
assessment tools along with cost evaluations provide a comprehensive assessment 
of the intervention.  This methodology could be applied to future oral lichen planus 
interventions and is not overly burdensome in terms of data collection or subjects’ 
time. 
Evaluation of the effectiveness of a personalised plaque control programme used 
tools that were both objective and subjective measures of health and disease and a 
combination of both (Escudier weighted index).  The primary outcome measure 
was a change in OHIP score and discussion will initially focus upon the efficacy of 
the intervention and subsequently contextualise this with changes in OHIP scores. 
  
195 
 
The clinical evaluation of the intervention was based on Plaque Index (Silness and 
Löe, 1964) and the Escudier Index (Escudier et al., 2007). In this study the mean 
Plaque Index scores reduced for the intervention group by 39.5% at the 20-week 
follow up compared to the control group, whose mean plaque scores increased 
marginally by 4.1%.  Control subjects did not show any improvement at any week.  
The intervention was successful in reducing plaque compared to control at week 4 
and was sustained to the end of the study at 20 weeks. 
Early studies suggested that painful atrophic alveolar mucosa may discourage 
patients from brushing effectively, additionally it has been reported that powered 
tooth brushing can cause minor gingival abrasions (Erpenstein, 1985; Robinson et 
al., 2005).  The intervention therefore had the potential to exacerbate the lesions 
particularly with the friable, atrophic nature of the gingival tissue.  It has been 
suggested that plaque removal would potentiate new lesions resulting from 
mechanical trauma, however this hypothesis lacked any evidence (Hermann, 
1963).  Contrary to the thoughts of Erpenstein, 1985, the results of this study 
showed that the personalised advice and products provided to the subjects 
facilitated improvements in plaque control; intervention subjects were not 
discouraged by any initial discomfort or bleeding.  This acceptance may be in part 
due to the brush head design and method of action of the powered toothbrush that 
was used.  This, coupled with appropriate interdental instruction may have 
facilitated less traumatic cleaning than either subjects’ existing manual or powered 
brushing habits. 
Previous studies have used various plaque indices and comparisons between 
studies are possible using percentage change from baseline and effect size.  The 
personalised plaque control programme was comparable to improvements seen in 
two previous studies (Holmstrup et al., 1990; Guiglia et al., 2007).  A further study 
by Lopez-Jornet and Camacho-Alonso reported greater reductions in plaque 
through a behavioural motivational oral hygiene intervention that was reinforced 
1 month after commencement of the study (Lopez-Jornet and Camacho-Alonso 
2010a).  The duration of the Lopez-Jornet and Camacho-Alonso, 2010 study was 
only 8 weeks and it is uncertain if compliance would have been maintained beyond 
its relatively short follow-up.   
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In this study the reduction in plaque was maintained from week-4 to the 
completion of the study protocol at week-20.  The treatment effect in plaque 
removal was large at both the 4-week (d=1.47) and 20 week (d=1.56) follow up 
visits.  The effect size for PI reduction was greater than those observed by Guiglia 
et al (2007) using a combined regime of manual tooth brushing with a soft 
toothbrush using the modified Bass technique, interdental cleaning with dental 
floss and adjunctive topical corticosteriods (d=0.97) (Guiglia et al., 2007). 
The most common assessment of the extent of oral lichen planus lesions used a 
five point clinical criteria score subdivided into 6 areas of the mouth and lips 
(Thongprasom et al., 1992; Thongprasom et al., 2011).  In this study a less widely 
used scoring system developed specifically for oral lichen planus was used 
(Escudier et al., 2007).  The Escudier index contains a subjective component (pain 
score) but the total score is weighted in favour of the clinically observed scores 
representing the involved sites and severity.  Although using a different index has 
the potential to cause some problems with comparability of findings with previous 
oral lichen planus intervention studies, it does give a large weighting to the 
gingival involvement and was therefore the most appropriate to use in this study.  
The inclusion of effect sizes in the results attempts to maintain the comparability 
between studies.  The results of the mucosal disease scores suggested that 
improvements were observed not only in in the number of sites affected, but the 
severity, and activity of the mucosal lesions in comparison to control (p<0.001 for 
all domains).  Although the intervention was designed to reduce the inflammatory 
component in the gingival tissues, it was not intended to concurrently reduce the 
lesions affecting the remainder of the mouth.  The reduction in supragingival 
plaque in the intervention group led to an improvement in the mucosal and 
gingival lesions as demonstrated by the significant reduction at weeks 4 and 20 in 
the individual and weighted Escudier oro-mucosal disease scores (p<0.001).  The 
treatment effect was moderate at 4-weeks (d=0.747) and large (d=1.01) at 20 
weeks for the intervention group.  Whilst this study shows sustained improvement 
in the lesions to the end of the study, there was not complete resolution indicated 
by the final mean activity score (site x severity) of 9.50 (0.68) in the intervention 
group.   
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Plaque-induced gingival inflammation may play a synergistic role in oral lichen 
planus inducing local inflammation, which in turn is poorly controlled by the 
underlying immune mechanisms leading to epithelial desquamation.  The precise 
mechanism by which this is occurring remains unclear.  The findings give support 
to the conclusions of the original work by Erpenstein who proposed that the 
infection of the marginal gingiva gives rise to a non-specific inflammatory reaction 
that could sustain or even induce oral lichen planus lesions (Erpenstein, 1985). 
Subjective assessment was carried out through OHIP and VAS pain scales to 
provide assessment of the impact that the gingival manifestations of oral lichen 
planus have on the patient.  OHIP has not been used as a primary outcome 
measure for previous studies involving plaque control and oral lichen planus but is 
sensitive to change in a clinical trial setting (Allen et al., 2001).  A semi-quantitative 
system for recording symptoms was unable to detect small changes (Holmstrup et 
al., 1990). 
There were no significant differences at baseline for any domain (p>0.05) or 
ordinal OHIP sum score indicating similarities between the two groups at baseline.  
The mean OHIP ordinal sum scores at baseline were 49.7 for the intervention and 
49.4 for the control group.  In the original validation studies and development of 
the OHIP, subjects who were 60 years of age and over were evaluated.  In this 
study the mean age of participants was 61.4 and therefore comparisons can be 
drawn between these original reference values and those in this study (Slade et al., 
1998).  The mean OHIP for dentate subjects in the Slade study was 31.3 based 
upon a sample of 905.  The subjects in this study reported more impacts at 
baseline indicating poorer quality of life.   
Both intervention and control groups showed improvements in ordinal and 
dichotomous OHIP scores.  When the treatment difference was accounted for 
(intervention - control), the overall effect was a statistically significant reduction in 
OHIP ordinal and dichotomous sum scores in favour of the intervention.  The 
physical pain domain in OHIP contains questions that relate to the frequency that 
subjects experienced painful gums, sore spots and discomfort when eating.  These 
symptoms are commonly reported in outpatient clinical settings therefore, it is 
reasonable to assume that this domain would have the potential for change.  
Although improvements in domain scores were observed, they were not 
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statistically different from the control group (p>0.05).  The overall OHIP ordinal 
scores improved more than in the control group therefore the changes must lie in 
other domains.  In the functional limitation domain there were significant 
differences between control and intervention groups (p=0.0216, p=0.0137).  This 
domain contains questions relating to appearance, difficulty chewing, taste and 
digestion. It may be possible that improvements in clinical signs of inflammation 
then bring about these secondary outcomes measured in this and other domains.  
The largest differences between groups were observed with the psychological 
discomfort and physical disability domains.  The psychological discomfort domain 
relates to being worried, self-conscious, miserable, concerned about appearance 
and tension.  Perhaps the intervention is, by resolving the inflammation, reducing 
symptomatology with subjects consequently being less concerned about their oral 
health.  There may also be some positive effect by which participating in the study 
affects this domain; particularly a study that monitors subjects more frequently 
than through their conventional clinical pathway.  This may be particularly 
important when examining a cohort of patients with a potentially premalignant 
diagnosis (Holmstrup et al., 1988; Mattsson et al., 2002; Holmstrup, 2010).  Within 
the physical disability OHIP domain which contains questions relating to being 
unable to brush teeth, avoidance of eating and unsatisfactory diet, there were 
statistical differences between the groups in favour of the intervention group at 
week 20 (p=0.0035).  It is impossible to tell, without adjunctive further qualitative 
interviewing, which part of the intervention is the most important, the advice and 
reassurance or the provision of appropriate devices and aids that facilitate the 
perceived improvements in this domain. 
Comparatively few impacts were observed in the final three domains: 
psychological disability, social disability and handicap.  There were no statistical 
differences between the groups at either follow up visit (p>0.05) with the 
exception of the psychological disability domain at 20 weeks (p=0.0324).  Perhaps 
this suggests that the gingival manifestations of oral lichen planus do not have 
large disabling effects but carry significant psychological impact associated with 
the diagnosis and chronic discomfort.  Anxiety has previously been strongly 
associated with the initiation or oral lichen planus and frequent observation and 
monitoring during a clinical study may go some way to alleviating this anxiety 
(Allen et al., 1986; Vallejo et al., 2001). 
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The baseline pain scores in this study were similar to those of other lichen planus 
intervention studies.  The baseline mean VAS was 3.4 whereas the range is wider 
in the literature lying between 2.2 and 7.7.  It is generally accepted and despite 
there being slightly different thresholds, that VAS scores between 1-4 represent 
mild pain, 5-6 moderate pain and 7-10 represent severe pain (Serlin et al., 1995; 
Farrar et al., 2001; Jensen et al., 2003).  In this study the mean value represents 
mild pain however some subjects perceive their pain to be severe, with the 
maximum score of 8.1 recorded at baseline in the control group.  The symptoms 
vary at an individual level and other subjects did not perceive any pain at all at 
baseline.   
To ensure comparability of the findings, comparisons should be made to other oral 
lichen planus interventions which have been evaluated using change in VAS scale 
measurements as the primary outcome measure.  Changes in VAS scores have not 
always corresponded with a change in the clinical extent of the lesions.  Placebo 
controlled trials also report improvements in VAS scores for both intervention and 
placebo groups with few demonstrating a marked difference in post-treatment 
scores from baseline (Swift et al., 2005; Chainani-Wu et al., 2007).  Those oral 
lichen planus studies reporting the greatest reductions in VAS score applied topical 
clobetasol propionate treatments and achieved VAS change scores in excess of 3.9 
points for all formulations of the drug in comparison to the mean change of 1.6 
observed in this study (Carbone et al., 2009).  Interpreting change also poses a 
challenge, with some advocating change above threshold values on the VAS scale 
whereas others use percentage change.  It has been suggested that changes above 
15% represent a noticeable change, above 33% a clinically meaningful change and 
above 66% a substantial change (Jensen et al., 2003).  In this study, a 1.6-point 
change in the intervention group at 20 weeks represented a 47% change in VAS 
score, however the control group also improved by 0.9 or 26%.  There were no 
statistically significant differences between the groups at any week (p>0.05).  The 
treatment effect (intervention-control) of 21% reduction supports the findings 
that there was a noticeable but not clinically or statistically significant difference 
between the groups.  Despite these findings, pain remains an important symptom 
to measure and monitor over time. 
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In this study it was not ethical to discontinue subjects’ concomitant medication 
prior to their enrolment in the study.  Subjects’ medication was not changed as 
part of the study and the baseline scores might have been influenced by previous 
treatment.  Discontinuing treatment for any length of time prior to enrolment is 
likely to have exacerbated the lesions and symptoms and would have been 
challenged at ethical review.  This would only have been possible if only previously 
undiagnosed patients were included in the study, and whilst strengthening the 
study findings in one respect it would have significantly lowered the numbers of 
subjects that would have been recruited potentially weakening its power.  Unlike 
some previous studies the changes observed in the intervention group were not 
confounded by the concurrent initiation of topical corticosteroids at baseline.  
Whilst subjects were free to continue with their current treatment regimen (most 
frequently topical clobetasol propionate ointment 0.05% mixed with carmellose 
sodium 16.7% oral paste) the treatment effect was attributable to the oral health 
intervention. 
The cost-benefit analysis indicates that the benefit of the intervention as perceived 
by patients exceeded the cost.  The majority of patients in the treatment arm 
valued the treatment in excess of the cost and hence the treatment is cost-effective 
when compared to no treatment.  Without data from the control group, the 
analysis cannot ascertain whether the treatment is cost-effective when compared 
against the control group. 
In this study two sampling methods were applied to the collection of oral fluids; 
whole unstimulated saliva and GCF.  The relatively small subgroup from which the 
GCF and saliva samples were taken reduces the generalizability of the findings of 
the biomarker analysis.  
Within this cohort of predominantly middle-aged and older subjects there is the 
potential for local and systemic factors to confound the results and prevent 
meaningful conclusions from being drawn.  Saliva has its benefits because it does 
not require any specialised equipment chair-side to measure volumes and 
concentrations are more straightforward to determine from a volume of saliva.  
There are, however, it also has significant problems in collecting saliva from 
subjects with hypo-salivation, who use concomitant medication, or suffer from 
other inflammatory conditions that may confound the concentrations observed 
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alongside the potential for anxiety and discomfort during 5-10 minutes of 
collection (Rhodus et al., 2005).  It could also be argued that collecting pure 
unstimulated saliva is not possible as the effect of collecting a sample may 
inadvertently be stimulating saliva production.   
Tissue transudates have previously been collected directly from the oral lichen 
planus lesion and have been suggested to be the method of choice in erosive 
presentations.  In this study serum transudate (GCF) as well as saliva was used to 
determine local levels of inflammatory biomarkers because of accessibility and 
proximity to the desquamative lesions.  Screening for periodontitis was not carried 
out and does have the potential to confound the results of the GCF and salivary 
biomarker analysis.  This is relevant as underlying periodontitis affects 45% of the 
adult population in the UK and at higher percentages in elderly populations such as 
those observed in this study (Steele and O’Sullivan, 2011).   
The biomarker concentrations observed in the subgroup analysis exhibited no 
clinically significant difference between groups at baseline and follow-up.  It is 
likely that the subgroup was not large enough to detect differences between 
groups.  No conclusions should be drawn from the change following the 
intervention given the small sample size.   
Previous studies have suggested that blocking pro-inflammatory cytokines or 
promoting immunosuppressive cytokine activity in oral lichen planus could be the 
target of future therapies.  A large focus of recent research has been into the NF-B 
dependent cytokines (TNF-, IL-1, IL-6, IL-8) in oral lichen planus, which were 
elevated when compared to healthy controls in saliva and tissue transudate 
(Pezelj-Ribaric et al., 2004; Rhodus et al., 2005; Rhodus et al., 2007).   
CD4(+) T-cell produced cytokines including IL-2 are required for the generation 
and maintenance of regulatory T-cells that provide protection from autoimmune 
disease.  IL-2 was observed in relatively low concentrations in this study and in 
previous studies have not been detectable (Yamamoto and Osaki, 1995).  They 
regulate growth, proliferation and differentiation of T-cells and themselves are 
produced by T-cells during an immune response.  They promote the adaptive 
immune response against foreign antigens and pathogens (Sharma et al., 2011).  In 
autoimmune disease it is IL-2 and its receptors that are targeted in the treatment 
  
202 
 
of autoimmune disease.  In particular corticosteroids, ciclosporins and tacrolimus, 
used in the management of oral lichen planus, aim to suppress the immune 
response.  This may be achieved systemically or locally through inhibition of IL-2 
production by activated T-cells, given that most subjects in this study were using 
concomitant topical corticosteroids.  This may explain the low levels of IL-2 seen in 
the samples analysed. 
Macrophage inflammatory proteins (MIP) are produced by a number of cells 
including lymphocytes, are known for their pro-inflammatory effects, and are 
chemotactic for leukocytes as such they could be a potentially interesting protein 
to observe in oral lichen planus.  MIPs also synthesise other pro-inflammatory 
cytokines (IL-1, IL6, TNF-), and elevated levels are likely to indicate higher levels 
of inflammation.  There are also data implicating chemokines and in particular 
RANTES in the pathogenesis of oral lichen planus with T-cells themselves 
expressing RANTES (CCL5).  This pro-inflammatory cytokine is chemotactic for T-
cells, eosinophils, and basophils further attracting T-cells into the lesional area.  It 
may also attract mast cells into the developing oral lichen planus lesion and 
stimulate mast cell degranulation.  As this occurs mast cells release TNF- which 
further stimulates and up-regulates RANTES secretion from T-cells.  It has been 
proposed that this mechanism might be responsible for the chronic nature of oral 
lichen planus (Thornhill, 2001).  As well as recruiting leucocytes into inflammatory 
sites, RANTES may also prolong the survival of inflammatory cells in oral lichen 
planus and further contribute to chronic disease.  T-cell specific cytokines 
including MIP-1 and RANTES may be important in the recruitment of 
inflammatory T-cells into the connective tissue beneath the basement membrane, 
which is characteristic of oral lichen planus.  There are also some non-specific 
immune mechanisms that are likely to contribute to the oral lichen planus lesions.  
MMPs function to degrade connective tissue matrix protiens and are regulated by 
the action of endogenous inhibitors.  MMPs have been found in oral lichen planus 
lesional T-cells in much higher concentrations than would be found in healthy 
tissue supporting the findings in this study (Yamamoto and Osaki, 1995). 
The differences found in biomarker concentrations in GCF and saliva and the 
higher concentrations of levels found in close proximity to the lesions give strength 
to using GCF as a fluid in which to analyse changes in inflammatory biomarkers in 
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patients with oral lichen planus.  An alternative would be intralesional tissue 
transudate sample as previously reported (Rhodus et al., 2007).  Determining 
different levels of inflammatory mediators in GCF and saliva provides the 
opportunity to understand and monitor the therapeutic response to conservative 
or pharmacologically active treatments (Rhodus et al., 2005; Rhodus et al., 2007).  
This may ultimately lead to refinements in the available treatments that target 
specific parts of the immune response in an attempt to modulate that response 
rather than apply a more generic treatment aimed at symptomatic control.  
Further, comparisons could also be made with other chronic inflammatory 
diseases where therapeutics may target common inflammatory processes, but this 
requires consensus on reliable fluids to sample and standardisation of diagnostic 
processes. 
3.11 Conclusions 
A personalised plaque control intervention was effective in improving the oral 
health related quality of life and clinically observed gingival manifestations of oral 
lichen planus.  The intervention was cost-effective and this study provides 
evidence to include intensive plaque control within patients’ initial and on-going 
management.  These findings are relevant to oral medicine specialists and 
periodontists but potentially have the greatest impact through general dental 
practitioners and dental hygienists.  Successful translation of these findings 
requires a greater understanding of the barriers that exist to implementing 
research findings, these will be investigated further in Chapter 4. 
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Chapter 4 
A qualitative study to investigate the perceived barriers to 
implementing clinical research findings in general dental practice 
in North East England 
4.1 Introduction 
Healthcare is facing an exponential growth in the volume of articles published each 
year and some estimates suggest that the knowledge base in medicine is doubling 
every 6-8 years.  Researchers are encouraged by their institutions to publish in 
specialist journals, with high impact factors.  For universities and other institutions 
they are an esteem indicator that relates to frequency by which articles are 
subsequently cited by other researchers.  Impact factors do not, however, measure 
changes in clinical practice, arguably a truer impact, brought about by the results 
of the publication.  Clinical impact is difficult to assess, unless the evidence is 
widely adopted or incorporated into national or international clinical guidelines.  
Selective publication in specialist journals risks disseminating the results of the 
work to a niche audience that, by its very nature, is not based in primary care.  This 
strategy for dissemination risks isolating research from primary care where the 
vast majority of dentistry is delivered.  An understanding of how dental 
practitioners engage with continuing education and how researchers should 
engage with practitioners is critical to bridging the divide between research and 
practice.  If ignored and research cannot be easily translated into clinical practice, 
this divide is likely to widen.   
The plaque control interventions that have been evaluated previously are 
potentially straightforward for dentists and hygienists to deliver.  Personalised 
interventions have the potential to bring about improvements in oral healthcare 
and, even, quality of life.  If these and other research findings are not accessible, 
understandable, or practitioners cannot relate to them, they are unlikely to be 
adopted into clinical practice.   
Accessing journals can form a component of dentists’ continuing education but a 
number of competing sources of continuing education now exist.  The focus of this 
study was therefore to explore some of the difficulties that general dental 
  
205 
 
practitioners have in selecting reliable research evidence to support an evidence-
based clinical practice.  It also looked to determine which methods of continuing 
education and dissemination of research are the most effective.  The results should 
inform clinical researchers, government organisations, regulators and 
manufacturers about how best to engage with dental practitioners, particularly in 
presenting and disseminating research findings. 
4.2 Aim 
The aim was to investigate the effectiveness of continuing professional 
development amongst general dental practitioners and to identify barriers to 
adopting new clinical evidence and applying this to their clinical practice. 
4.3 Materials and methods 
A number of methods have been described in the literature for qualitative research 
with healthcare professionals using questionnaires, meetings, workshops, focus 
group interviews, discussion groups and informal interviews (Baker et al., 2010).  
This study used semi-structured interviews and a focus group with general dental 
practitioners to explore the aim of the study.  The study was insured and risk 
assessed through Newcastle University with Zurich Municipal and reviewed 
externally by North of Tyne NHS Primary Care Trust Research and Development.  
The NHS ethical review process did not apply as patients were not involved in the 
design or conduct of the research.  
4.3.1 Subjects 
A purposive sampling method was used to ensure that the demographics of the 
interviewees and focus group participants were representative of general dental 
practitioners in the North East of England.  This sampling method was preferred 
over convenience sampling to provide data applicable to the research topic that 
was relevant (Tong et al., 2007).  The demographics of the practitioners were 
stratified to include representation from: male and female general dental 
practitioners; within two years of their primary dental examination; those 2-10 
years post qualification; and those qualified 10 years and over.  This information 
was available through North of Tyne Primary Care Trust Performer’s lists and the 
General Dental Council register.  Potential participants were contacted at their 
practices and were invited to participate by letter and/or email.  They were 
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provided with an approved participant information sheet and asked to consider if 
they would like to be involved in the study. 
Fifteen potential participants were approached, thirteen accepted and two were 
unable to attend for the focus group date and time.  In total, four, one-to-one semi-
structured interviews and one focus group of seven participants took place. 
4.3.2 Inclusion and exclusion criteria 
The following criteria were applied to the potential participants before enrolment 
in the study: 
Inclusion criteria: 
 Hold a primary dental qualification (BDS/BChD or equivalent); 
 Must be a current registrant of the General Dental Council; 
 Currently undertake primary care dentistry in either NHS or private practice; 
 Practise dentistry in the North East of England; 
 Be willing to participate in one-to-one interviews or small focus groups. 
Exclusion criteria: 
 Does not practise or is retired from primary care dentistry; 
 Not registered or currently suspended from the GDC register. 
4.4 Conduct of the research 
An initial topic guide was created prior to the first interview based upon a review 
of the literature.  This was refined and added to following each one-to-one 
interview and prior to conducting the focus group. The constant comparative 
method (grounded theory) was used so that data collected were coded and 
analysed prior to conducting the next interview or focus group.  This ensured that 
interviews were not conducted unnecessarily once a saturation point of ideas and 
concepts was reached (Glaser, 1965; Glaser and Stauss, 1967; Ritchie et al., 2003).  
4.5 Data management 
Following review of the interview transcripts, major emergent themes (meta 
themes) were identified.  Data transcripts were not returned to participants for 
correction but as part of the quality assurance process, participants were asked to 
comment on whether the conclusions drawn from the analysis were an accurate 
interpretation of the discussions that took place (member checking) (Lincoln and 
Guba, 1985).  The resultant analysis was then entered into a framework to assist 
data handling and management with the aim to preserve the individual responses 
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and narratives that were described during the focus groups as well as report the 
emergent themes (Holmes et al., 2008).  Triangulation and confirmation of the 
emergent themes was carried out following independent review of the transcripts 
by a researcher experienced in qualitative methodology (peer examination), who 
was independent of the research team (Lincoln and Guba, 1985). 
4.6 Results 
Data saturation was reached following the four interviews and one focus group.  
Interviews were conducted in participants’ workplaces with the focus group 
conducted at Newcastle University between September and November 2012.  No 
other people were present during the interviews other than the participant and the 
interviewer.  The interviews and the focus group discussions were recorded to 
digital audio (MP3) format and lasted between 27 and 53 minutes, with the focus 
group lasting 104 minutes in duration.  These were then professionally transcribed 
verbatim.  Participant identifiers were removed and replaced with codes detailed 
in Table 60.   Four emergent meta themes were identified: peer review, 
postgraduate education, practice pressures and the relevance of research.  Sub 
themes were also identified. 
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Participant ID Gender Position in the practice Registration 
with GDC 
ID1 Male Associate 1990 
ID2 Female Associate and SPCDS Dental Officer (DO)* 2005 
ID3 Male Principal 2005 
ID4 Male Associate 2005 
ID5 Female Associate 2011 
ID6 Male  Associate 2006 
ID7 Female  Associate 2006 
ID8 Female  Associate 2010 
ID9 Male  Principal 2005 
ID10 Male Principal 1985 
ID11 Male  Principal 1984 
 
 
 
 
 
Table 60.  Anonymised subject identifiers for general dental practitioners involved in 
semi-structured interviews and focus group.  
*SPCDS Salaried Primary Dental Care Service. 
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Peer review 
The strongest emergent theme was the importance general practitioners placed on 
their engagement and interactions with colleagues through peer review.  These 
interactions took place in a variety of ways but most commonly occurred through 
informal discussion with other dentists during surgery hours and lunch-breaks.  Its 
value was placed such that it was viewed as an integral part of everyday general 
practice.   
“Before we make any changes the first thing I would do would be to seek peer review, 
so chat to other dentists in the area…peer review is probably the most important 
non-verifiable stuff.”  (Principal, ID3) 
Obtaining a variety of opinions was important to be able to make an informed 
decision regarding particular treatment options, procedures or new materials.  
Some practitioners opinions were held in greater esteem than others with 
particular preference given to those with knowledge of general practice or 
themselves were experienced practitioners.   
“I might go and speak to him and if he had certain feelings about it I might be swayed 
in one way than another.”  (Associate/DO, ID2) 
Experience was highlighted as a particular strength in being able to distinguish the 
usefulness of new information.  The adoption of new techniques and materials 
used by experienced practitioners provided further justification for less 
experienced dentists in their own decision making.  Concerns were raised about 
the ability to implement certain techniques particularly if they were seen to be 
“academic”.  These comparisons also emphasised some divisions between different 
practising environments and the importance of selecting the most appropriate 
person to be involved with the peer review process: 
“If one is in the hospital and one in practice they’ll find it difficult to relate to each 
other…especially on cases and treatment plans, the barrier isn’t the people it’s the 
environment in which they work.”  (Principal, ID8)  
In deciding how much weight to give to one view, comparisons were made 
between the person providing the opinion and the individual practitioners.  Two 
distinct types of preference were expressed.  Some practitioners favoured a ‘true 
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peer’, someone with similar scope of practice with whom they could easily relate to 
but at the same time were seen to be conscientious practitioners.  Others were 
looking for an ‘expert peer’ with a different practising demographic to act as a local 
key opinion leader.  These were people who were active in undergraduate and 
postgraduate education or experienced practitioners with private practice 
commitments.  
A variety of other contexts were highlighted as opportunities for peer review 
alongside informal discussion with colleagues.  These included: contacting former 
colleagues; participation in postgraduate courses; part-time teaching in dental 
schools; vocational training; practice study groups and involvement in national 
examinations.   
Practitioners also felt that the information presented at postgraduate courses or 
conferences may be biased, with presenters favouring specific techniques or 
materials. Peer review was seen to triangulate the applicability of new information 
into practice. 
“Sometimes people present all the positives of something but don’t give you the 
pitfalls.”  (Associate/DO, ID2) 
Particular formats of postgraduate course allowed greater opportunities for peer 
review: 
“The ones with really long coffee and lunch breaks as you learn just as much talking 
to your colleagues in the break as the person standing at the screen.”  (Associate 
ID1) 
There were perceived risks of not taking part in peer review, general practice was 
seen as somewhere that could be isolating particularly if the practitioner had been 
working in the same place for a number of years.  The interrelationships between 
practitioners in different practices were particularly important to allow discussion 
and communication.  There was a need to actively seek out interaction with other 
general practitioners and it was important not to become complacent about 
current practise.  It was suggested that for those involved in vocational training, 
discussions with vocational practitioners formed a significant part of ‘non-
verifiable’ CPD and was an incentive to maintain their knowledge. 
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It was acknowledged that the pressures of general practice could limit the 
opportunities for peer review.  Other job roles that practitioners had previously 
held in secondary care settings were seen to actively facilitate interaction with 
other more experienced colleagues: 
“When you are in a hospital it is very easy to pick up what is going on and current, 
you just have to be involved with the building.”  (Associate, ID6) 
Postgraduate education 
Continued professional development has been a legal requirement of General 
Dental Council registration since 2002 (GDC, 2012).  It is delivered in a variety of 
formats, accredited qualifications, courses run by postgraduate deaneries and 
attendance at national and international conferences.  Accreditation is provided by 
a number of publications for reading journal articles which may act to incentivise 
the reader.  The success or failure of this format is essential to the current strategy 
employed by universities and researchers to disseminate the majority of research 
findings.  Increasingly large numbers of providers are also offering courses either 
by formal taught programmes, single study days or through web based or online 
continued professional development.  This meta-theme focuses on how successful 
these formats are and their associated problems. 
Most postgraduate courses and conferences were not available free of charge, 
therefore the value (not necessarily the cost) of the course was important when 
deciding on whether to attend.  This was most apparent with conferences, which 
would typically last between 2-3 days and be associated with higher fees.  The 
benefit of courses or conferences conducted over a number of days was 
questioned: 
“I’m sufficiently self-aware to recognise that after 3 o’clock on the first day I’m not 
taking any more in and so I’d have a day and a half where it was pointless me being 
there.”  (Associate, ID1) 
“2 years ago…I probably learnt 3 or 4 things and it was £600…I decided that it wasn’t 
a great use of money.” (Associate/DO, ID2) 
Two distinct types of conference were identified, those aimed at generalists such 
as the BDA annual conference and those aimed at academics or specialists such as 
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the British Society of Periodontology conference.  The latter were not seen as being 
relevant to GDPs or a high priority. In general, there were mixed feelings about 
conferences, in particular with the breadth of topics covered.  The more general 
form of conference was criticised for lacking focus and having a commercial bias 
towards marketing and cosmetic dentistry.  It was felt that these were more suited 
to practice owners and improving the business of dentistry rather than improving 
clinical practice.  Others felt that the focus and the level at which the presentations 
delivered in a conference were not always appropriate to their scope of practice. 
“They were either pitched ridiculously easy so an hour and a half on fissure sealants 
or pitched so far leftfield, like aesthetic things that I’m sure are relevant to somebody 
but never anything we would do regularly…so either very straight forwards and no 
content or very leftfield and not applicable.”  (Associate/DO ID2) 
“Maybe 50% of what’s covered…I’m not saying that it’s not relevant but it might be 
something that you might not want to focus on.”  (Associate, ID4) 
The larger conference format was not the best delivery method for being able to 
learn with the choice of speaker and topic being particularly important to select.  
Smaller conferences e.g. Association of Dental Implantology whose focus was 
narrower were better received but it was acknowledged that the topic might not 
be universally relevant. 
Practitioners felt that there was a limited amount of time in which to attend 
postgraduate education citing practice pressures and the importance of 
maintaining a work life balance with their families.  Generally, it was felt that 
taking 2-3 days out of a working week to attend a conference was too much.  Single 
or half-day courses were preferred as there was a limit to the amount of time spent 
attending courses outside of the ‘core’ subjects specified by the GDC.  There was a 
reluctance to take more than one day off at time out of general practice and in 
particular that patients’ appointments should not be cancelled.  Despite being well 
delivered and received, the costs of attending some postgraduate courses were 
seen to be prohibitively expensive.  Some felt that courses in London were 
inaccessible, with the initial cost of the course not being the problem but the 
additive costs of travel, accommodation and subsistence making them so.  This was 
particularly the case for newly qualified practitioners and VDPs.  Others would 
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travel further afield if they felt the value and relevance of the course justified the 
costs.  Patients with particular conditions also motivated practitioners to attend 
postgraduate courses: 
“I was thinking, you know, I need to know more about this so I can help my patients.”  
(Associate, ID1) 
Good organisation was required to be aware of which topics had been covered 
recently, an up-to-date personal development plan was seen as best practice.  Five 
years was seen to be an adequate time period to cover most topics with the 
exception of medical emergency training.  If carried out more frequently it was 
seen as more of an administrative exercise to fulfil the GDC’s requirements. 
“You wonder if you are going to take a day off work to recap what you have already 
been taught.”  (Associate, ID4) 
The increase in volume of postgraduate courses and providers has led to difficulty 
in deciding which courses would be worthwhile attending. 
“That has changed so much since I qualified, there has been an explosion.”  (Principal, 
ID11) 
Reputation and experience of the speaker was an important consideration but the 
value for money of high profile speakers with national or international reputations 
was questioned. 
Formal courses run by universities leading to qualifications e.g. MClinDent/MSc 
were seen to provide some structure to continuing professional development as 
well as providing long term career benefits.  Despite being expensive, some viewed 
this type of course as a passport into a more mixed or private practice.  The variety 
of delivery methods used by these programmes, including ample opportunities for 
peer review, would appeal to a variety of learning styles.  There was also a feeling 
that many of these courses were directed towards younger practitioners and 
formed part of a newly emergent career structure in general practice. 
“BDS isn’t enough anymore, you have to continue doing exams to stay one step ahead 
of the competition.”  (Associate, ID5)  
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The format by which postgraduate courses were delivered was important at an 
individual level with mixed preferences discussed.  Discrepancies were highlighted 
in the perceived benefit provided by hands on courses.  The practical elements of 
some dental courses were criticised for not being delivered in the most 
appropriate way and did not always add value to the course.  
“You were asked to prepare a cavity and fill it with this new material when in effect 
all I was doing was what I do a hundred times a day…it didn’t improve my ability to 
do the task.”  (Associate, ID3) 
It was important that if a hands-on element was provided then it should be the 
primary focus of the course otherwise it could be seen as an afterthought.  The 
ability to see the presenter carry out a technique by a live demonstration allowed 
practitioners to make direct comparisons and appraise their own techniques.  If 
this was not possible then recorded and edited video was seen as a good 
alternative.  It was important for the speaker to have had experience of general 
practice to demonstrate that the content was relevant.  Any practical or small 
group teaching should be informal enough to allow the presenter to interact with 
the participants and provide feedback on their work.   Essential topics such as 
cardiopulmonary resuscitation updates were best delivered through “real life” 
scenarios using simulators or with their team in their own practice.   
Day symposia also received a mixed response.  They were seen by some as less 
effective than small interactive groups but more beneficial by others because of the 
opportunities for peer review.  They also gave practitioners a sense that they 
belonged to part of a wider dental community facing similar problems.  Courses 
run during the normal working week were associated with a double cost, one for 
the loss of a day’s self-employed earnings and the other with the course fee. 
Most practitioners regularly accessed online content associated with verifiable 
CPD from the journals that they subscribed to, most frequently Dental Update and 
the British Dental Journal (BDJ).  Recognising that that there would be questions 
associated with particular articles was an incentive to read them.  A number of 
other online sources were discussed with some requiring annual subscriptions 
(Dental Juice, Dental Channel, CopDend, Tipton Training).  Younger practitioners 
were seen to be more accepting of, and engaged in, a higher volume of online CPD 
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whereas older practitioners preferred interaction with colleagues and the 
opportunity for peer review.  The volume of verifiable online content was seen as 
being a positive but the resources were not always presented in the most 
appropriate formats.  It was seen as being time and cost-effective but “soul 
destroying” (Associate, ID1) as the delivery did not promote a change in behaviour 
or practice.   One significant disadvantage was that there was no summary or notes 
from which to refer to or reflect upon after the event.    
One successful format of online CPD was through webinars that allowed 
practitioners to connect via the internet to a speaker.  This environment was seen 
to be ‘safe’ in that they felt comfortable asking questions in this format either 
verbally through a microphone or typed onto a shared screen.  It was a potentially 
cost-effective way of seeing speakers without the expense of taking time out of 
practice.  Online CPD also allowed practitioners who were taking a career break to 
access up-to-date content and maintain their GDC registration.   
Practice pressures 
General dental practice was viewed as a busy, high-pressured environment in 
which to work, almost all participants found that one of the greatest pressures in 
general practice was time.   
“Dealing with the patients and treatment itself is quite taxing on the mind and during 
lunch time and after hours you’re then dealing with staff and the management of the 
business and all the problems with that.”  (Principal, ID3) 
The extent of these pressures meant that some practitioners felt that taking time 
out to attend postgraduate courses during the working week was either 
problematic or not feasible. 
“I don’t find time to take a day off to go and do a course for myself…I can’t see that 
changing.”  (Principal, ID11) 
Others felt that these pressures were increasing in number particularly in NHS 
practice because of contractual obligations and NHS targets.  Although taking time 
out of practice would be preferable, they felt that their targets were equally if not 
more important to reach. 
“It’s getting more arduous to get it all in.”  (Associate, ID1) 
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“I don’t find the time to take a day off and do a course for myself…I can’t see that 
changing.”  (Principal, ID11) 
It was for this reason that one participant felt that committing to a formal taught 
postgraduate course forced them to take time to commit to their own 
development: 
“I felt I needed to commit to something to make sure I kept up to date with my CPD, I 
felt if it was off my own back, it was difficult, because you are so busy in the practice 
working 9-5 head-down its difficult unless you make time and commit to something 
to keep up-to-date...” (Principal, ID3) 
Potential barriers existed within individual practices to implementing novel 
techniques.  These directly related to the employment status of the practitioner 
with distinct differences between associates and practice owners.  This study 
highlighted that the owners or dental corporates are the gatekeepers of techniques 
and materials that are used in primary care and themselves are potential barriers 
to changing behaviour of their colleagues.  Principals generally wanted to trial and 
evaluate materials as well as assess the impact of the costs prior to deciding to 
order them for the practice.   
If the practice owner deemed the cost to be prohibitively expensive or the material 
was considered not essential then the associate would have to personally purchase 
additional materials.  Whilst some were prepared to do this, others were not 
limiting the availability and use of the most-up-to-date materials and techniques.   
Principals also felt that this was a potential source of conflict within the practice:   
“I’d certainly feel more comfortable using new things myself before saying the 
associates have to start using it…Depending on outlays I’d be quite keen to try it 
myself before buying it for everyone. I wouldn’t like associates to all be having 
different materials, as you want everyone using the same. Some associates do like to 
buy things themselves but it causes problems with other associates saying they want 
to use it as well but don’t want to pay for it.”  (Principal, ID9) 
The most up-to-date materials were seen by associates as being beyond the reach 
of NHS primary care dentistry.  Private practice was seen to be more flexible in 
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ordering of materials as any increase in overhead could be more easily passed onto 
the patients.   
Some also felt that as a result of the economic downturn, patients were seeking 
and demanding of cheaper alternative treatment options.  For example, some were 
not willing to pay for crowns and practitioners were being forced to place larger 
plastic restorations and required suitable alternative materials. 
“I found that they were no longer suitable for amalgam fillings, patients were less 
willing to pay for expensive crowns and prefer to try fillings, so, I found myself doing 
an awful lot of posterior composites.”  (Associate, ID3) 
One way of becoming aware of new materials and techniques was through practice 
visits by manufacturer’s representatives.  The dental industry and to some extent 
clinical researchers are reliant upon manufacturers’ representatives engaging with 
primary care practitioners in the dissemination of products and research findings.  
They were seen as being useful to make practitioners aware of new products, 
obtain product samples and provide verifiable CPD for nurses.  There were some 
strong feelings against them largely because of the inability to relate the handling 
properties of materials and the clinical applicability.  Another criticism was the 
perception that the representatives had only sufficient knowledge to sell the 
product. 
“If you wanted to be a smart alec and wanted to give them an uncomfortable time 
you could tie them in knots very quickly.”  (Associate, ID1) 
The small community of dentists meant that practitioners were aware of who the 
more knowledgeable representatives were, despite this they remained sceptical of 
their opinions because they were paid on commission.  Dentists would be seen to 
be more reliable representatives. 
Contractually, practitioners working under the regulation of an NHS contract had 
an obligation to carry out clinical audit.  The areas that were evaluated were 
usually ones that practitioner’s had specific interest in or wanted to evaluate the 
success or failure of a new technique or material.  Most felt that it would not have 
been possible to conduct an audit during surgery hours because of time constraints 
and pressures from principals to maintain productivity and achieve NHS 
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contractual targets.  There was a perception that both the Salaried Primary Care 
Dental Service and hospital posts allowed more flexibility to be able to carry out 
audit within their practicing day.  In general practice there were no incentives to 
carry out audit, particularly working as an associate and more commonly informal 
ad hoc self-appraisal took place.  Practitioners would change their behaviour more 
readily based on information they had received on a course or through peer review 
rather than formally auditing their current practice. 
The Health and Social Care Act 2008 changed the way in which primary care 
dentistry was regulated; from April 2011 all primary care dental practices were 
regulated by the Care Quality Commission (CQC).  The CQC being an independent 
regulator of all health and social care in England, its role is to measure the quality 
and safety of the care provided against a series of essential standards.   
Practitioners were concerned about the power and the focus of their new 
regulator: 
“There is a fear factor within primary care dentistry of the CQC…the CQC is having an 
effect on the focus of the practice as its aimed so much towards satisfying the CQC 
requirements, which in terms of patient care and quality are way down the list of 
what they’re looking for – they’ve got rid of Dental Reference Officers…There is 
somebody that will come in to check you have got a vulnerable adults policy which 
the cleaner knows about and have signed at the bottom that they know about this 
policy but there isn’t anybody checking whether you’re leaving apical radiolucencies 
and discharging sinuses everywhere – strange times.”  (Associate, ID1)  
Practitioners also followed a number of national guidelines such as those 
published by the National Institute for Health and Clinical Excellence (NICE), 
Cochrane collaboration, NHS delivering better oral health: An evidence based 
toolkit for prevention and from the BDA.  Some of these guidelines were criticised 
for either being too difficult to understand (e.g. Cochrane) or were sometimes 
based on opinion rather than evidence (e.g. NICE).  As a result practitioners would 
judge if the guideline had a high strength of evidence, if lacking, they would rely 
upon their own experience and only use them if they were deemed relevant. 
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Relevance of research 
Practitioners had difficulty relating the application of scientific research into 
general practice, perhaps in part due to the difficulty in understanding and 
interpreting research papers: 
“There wasn’t much exposure to research papers while I was at University…it was 
only when I began to do my own postgraduate training I learnt how to interpret 
them.”  (Associate, ID3) 
The majority of practitioners accessed printed dental journals, those most 
commonly mentioned were the British Dental Journal (BDJ) and Dental Update 
along with magazine style publications such as Dentistry and the Dental Tribune.  
These were a good source of CPD in conjunction with the online components of the 
Journal.   
The BDJ was seen as a credible publication because the articles had been peer 
reviewed, some saw it as the authoritative text for the UK profession.  Its broad 
range of topics was generally seen as a positive aspect of the publication, but 
despite this it was seen as being too academic for some practitioners.  The main 
criticism of the articles published in the BDJ was that the settings that research 
was carried out in were usually university teaching hospitals and therefore not 
always relevant to general dental practice.   
“Maybe they’ve been carried out in universities in a very controlled way and that 
might not be necessarily applicable to your practice.”  (Principal, ID 9) 
It was thought that the rigorous process for submission and acceptance of articles 
might not allow the journal to become practitioner friendly.  It was acknowledged 
that the format had changed over the last 10 years in an attempt to become more 
relevant. 
“The BDJ is a lot better than it used to be, it used to be criticised for being very 
academic but is developmental now and in 10-years’ time I think it could be very GDP 
friendly.”  (Principal, ID11) 
Suggestions were made to improve the relevance further: 
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“At the end of it [article] they have a list of questions, why did you do this research 
and possibly there could be something from a GDP saying how it is relevant to 
general practice.”  (Principal, ID11) 
The format and content of Dental Update was preferred to that of the BDJ, in 
particular the straightforward, clear manner in which the information was 
presented further, it was perceived to be more practice focussed and therefore 
relevant. Illustrated clinical application of techniques and materials was also 
preferred to graphs and diagrams which could be difficult to understand or 
interpret. 
Access to other journals was difficult unless the practitioner had an affiliation to a 
teaching hospital or university. Other publications including the Journal of 
Paediatric Dentistry, Disability, and Journal of Clinical Periodontology, were 
criticised for having a limited amount of relevant material in them to general 
practice.  It was thought that these were more relevant to academic or SPCDS roles. 
One practitioner also felt that they were not intelligent enough to understand the 
relevance of specialist publications: 
“Even then you might only find one article that is semi-relevant to you. I’m sure if I 
was cleverer it would be relevant.”  (Associate/DO, ID2) 
Practitioners engaged with the printed press in different ways, some would focus 
solely upon the articles that were associated with verifiable CPD whereas others 
would read all of the articles in an issue of that journal.  Most commonly 
practitioners would make a judgement about the relevance of an article based 
upon the title and abstract.  Abstracts were seen as usually being sufficient upon 
which to base an opinion, if the abstract indicated that the article might change 
current practice then the full article would be read. 
“You can either skim to get the answers or if you find that it actually looks interesting 
you can read the full article.”  (Principal, ID11) 
“So just to keep up with the CPD I would read the articles, but also as a proportion of 
the journal that I read, which is relevant to myself, it’s probably quite a small 
proportion, quite small, maybe 20%.”  (Associate, ID4) 
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“I’ll read the title of the abstract and them jump to the conclusion to see if it can be 
applied to my work.”  (Associate, ID7) 
“I tend to read it cover to cover but if there is anything particularly dreary I tend to 
miss that out but generally I do read most of it.”  (Associate, ID2) 
Accessibility to journals was important, despite having a printed copy of the 
journal delivered to either their home or practice this didn’t always mean that they 
were read.  Access to the online version of the journal meant that practitioners 
could be more selective about the articles that they read. 
“I suppose the thing is they come through your door so you are probably going to 
look at them, but you can also find you’ve got however many BDJs still with the cover 
on that you haven’t opened at all.  So the thing is nowadays with computers and 
information [is available] instantaneously online.”  (Associate, ID1) 
Practitioners perceived the evidence base for much of what is done in general 
practice to be inadequate and that it could be improved.  Involving practices in 
research was seen as a positive step but it was seen as a difficult place in which to 
conduct research in because of the time pressures involved.  Despite this some 
practices were involved in or had been invited to participate in practice-based 
multicentre research studies such as FiCTION, IQUAD and INTERVAL.  There were 
financial incentives to the practice owners for being involved in the research 
studies 
“We joined the (NAMED) trial for financial reasons.  The topic was quite interesting 
but it was the financial part as a practice owner that will make you more keen to do 
it.”  (Principal, ID9) 
Associates were not involved in deciding if the practice would be taking part in 
research studies and therefore not aware that they were taking place.  The 
incentives that practice owners received were not passed on to the associates.  
“We’ve just started dong the (NAMED) trial as well and as an associate we don’t get 
paid any of the money awarded to the practice for doing the research.  We were 
asked if we would take the time out of our day lists to do it but I opted out as I would 
get behind with my target for no financial gain even though I was quite interested in 
the topic of research.”  (Associate, ID5) 
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Practitioners felt that in the short term that research articles that were published 
should be written specifically stating the relevance to general practitioners and in 
the longer term further involve practices in new studies.  Research institutions 
could also be more dynamic in the way that they engage with dental practices, this 
could include providing summaries of recent research studies to practices, or 
hosting annual update events for practitioners to attend.  
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4.7 Discussion 
In 2002 the General Dental Council (GDC) introduced a legal requirement for all 
dentists to carry out a minimum of 250 hours of continuing professional 
development in a 5-year period.  75 hours of which must be verifiable, this in 
practical terms requires a certificate of completion of the activity which itself must 
have pre-published aims and objectives, anticipated outcomes and quality control 
measures (GDC, 2012).  Further changes occurred in 2008 when the GDC 
registered dental nurses, and technicians introducing CPD requirements for these 
groups for the first time.  This legislation imposed by the professional regulator 
recommended core CPD topics, however these may differ from an individual 
practitioner’s learning needs (Bullock et al., 2010).  These requirements have led 
to an industry wide exponential increase in the volume of CPD providers with 
significant challenges in selecting material that is relevant, beneficial and 
practitioners are able to identify innovations that have meaningful impact to their 
clinical practice.   
There is relatively little knowledge of the effectiveness of CPD interventions, this 
may partly explain the importance that practitioners placed on peer review in this 
study (Sohn et al., 2004; Rivas et al., 2012).  Triangulation of new information with 
their own and others current practice appears to be important in examining the 
applicability and validity of new information (Schostak et al., 2010). 
Despite the previous Government recommendations and inclusion in previous NHS 
dental contracts, there is little evidence in dentistry that peer review is useful.  
Publications prior to the general dental services (GDS) contract change in England 
and Wales in 2006 had more modest news about the importance of peer review 
(Health, 2001a; Watt et al., 2004).  Dentists were also criticised for appearing to 
lack the critical and evaluative skills that are required for audit and peer review 
(Watt et al., 2004).  The pre-2006 arrangements encouraged dentist participation 
and the contract reimbursed practitioners for undertaking audit and structured 
peer review (Health, 2001a).  The 2006 GDS NHS contract removed the contractual 
obligations and financial incentives of audit and peer review, the role of clinical 
governance then fell under the requirements of the Primary Care Trusts (Health, 
2005b).  Evidence suggests that financial incentives will incentivise participation 
and bring about changes in practice behaviour although it may not necessarily 
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improve patient care (Flodgren et al., 2011a).  With the removal of this formal peer 
review process, practitioners now rely upon their own networks to engage in peer 
review.  This presents a challenge for researchers to promote an evidence-based 
approach, particularly if practitioners feel that they could not relate to a hospital or 
university-based practitioner.  Evidence published suggests that periods of 
structured peer review in medicine are positive and can lead to a service 
improvement.  Hospital and university practitioners could then bring a different 
skill set and perspective, further enriching the process.  The reliance upon small 
networks to undertake their own peer review risks the perpetuation of a limited 
knowledge pool with access to limited resources.  It also risks being influenced by 
stronger characters within a group who may have particular opinions supported 
only by personal experience rather than evidence.  The importance placed upon it 
in this study could strengthen the support for regional or national organised audit 
and structured peer review in the future (Cannell, 2012).  There is the potential for 
the finding of clinical trials of relevance to general practitioners to be discussed 
and evaluated as part of a formal peer review structure.  This may deepen the 
understanding of how clinical trials are conducted in hospital and university 
settings and begin to forge some local networks by which the final step of 
evaluation could be conducted in general practice. 
The concept of a career structure in General Dental Practice appears to be 
emerging and becoming more important to younger practitioners.  A formal career 
pathway through the Faculty of General Dental Practitioners (UK) is one example 
but the plethora of privately run courses mean that less formal routes of career 
development exist (FGDP(UK), 2008).  In 2001 the Department of Health 
recommended that all healthcare professionals had a personal development plan 
(PDP) to structure their career development (Health, 2001b).  Planning of 
continuing professional development in this way has been shown to enhance its 
benefit (Bullock et al., 2007; Eaton et al., 2011).  This study suggests that personal 
development planning is encouraged immediately post-graduation and forms a 
part of foundation training but it is not widely used after this period.  PDP planning 
may become an increasingly important role for postgraduate tutors in the future to 
ensure that the potential of these tools are fulfilled, and that the CPD carried out by 
practitioners remains relevant and patient and practice-centred (McGlone et al., 
2001; Evans et al., 2002; Wright and Franklin, 2007).  A career structure may also 
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become more relevant to general practitioners as the GDC introduce their 
revalidation process for practitioners’ registration (Jennings, 2007; GDC, 2011). 
Postgraduate courses leading to qualifications were seen to be important to 
younger practitioners supporting the findings of other studies investigating trends 
in dental CPD (Leggate and Russell, 2002).  The impact of a sustained period of 
postgraduate education has been viewed positively in this and previous studies.  
Practitioners viewed this as having the potential to alter the type of treatment they 
offer and change their scope of practice (Calnan et al., 2000; Silvester et al., 2000; 
Bullock et al., 2009). This may be a reflection of an increasingly competitive 
employment market in primary care, possibly as a direct result of the numbers of 
graduating dentists in the UK (Smith, 2011).  Competition may increase further 
with the opening of a new privately funded dental school in the UK and the 
introduction of direct access to dental hygienists and therapists by the GDC (Smith, 
2011; Buckingham, 2012, GDC, 2013). 
Practitioners found the most successful type of postgraduate course to be one that 
they believed had direct relevance to general practice and was interactive, these 
findings were supported by a previous systematic review into continuing medical 
education (Cantillon and Jones, 1999).  Previous studies have suggested that local 
courses run at a deanery level were provided at no cost to participants, although 
courses are subsidised, practitioners make partial payment towards costs of the 
course (Bullock et al., 2010).  Practitioners were self-selecting about the courses 
they attended and also factored in costs, and it has been suggested that this 
method reinforces current knowledge and risks failing to address deficiencies 
(Firmstone et al., 2004).  The format by which courses were delivered was 
important at an individual level with previous studies supporting hands on 
elements (Christensen, 2004; Watt et al., 2004).  This study highlighted mixed 
views about the delivery and quality of these formats unless they were the primary 
focus and the structure allowed close observation and appropriate opportunities 
for feedback.   
Similar strengths and weaknesses of printed materials (journals) were outlined to 
those found previously (Bero et al., 1998; Watt et al., 2004).  Those most 
commonly read included the British Dental Journal and Dental Update.  The limited 
numbers of journals that were subscribed to suggested that generally practitioners 
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did not have access to specialist level publications.  This may be by choice in that 
they did not feel that the publications were relevant or because they did not see 
any potential benefits from additional subscriptions.  The limited access to a 
variety of dental journals potentially results in large numbers of clinical trial 
findings being inaccessible to general practitioners.  This raises the issue of 
whether the research community should support open access publications and in 
doing so allow more practitioners to read the work.  The costs of allowing such 
access are likely to be prohibitively high at US$3000 per article.  Practitioners 
criticised the volume of printed literature and the applicability of the content of 
some journals to everyday clinical practice with particular reference to the settings 
within which the research was conducted (Bero et al., 1998).  Open access could 
lead to further criticism of journals with an even greater volume of material being 
available.  Journals had little direct impact on changing behaviour and there is little 
evidence that printed or online journals generally do so (Bero et al., 1998).  The 
British Dental Journal in particular being viewed as less practice friendly and more 
academic (Watt et al., 2004).  The expansion of online CPD allowed participants to 
more easily obtain verifiable credit for the journals they read.  Researchers 
conducting clinical trials therefore must be mindful of these barriers and be 
creative in disseminating findings using a variety of media including journal 
publication.  The results suggest that specialist publication alone will however not 
translate findings into practice.  Conferences were also seen as poor value-for-
money in relation to the learning experience, supporting the conclusions of a 
systematic review into continuing medical education that suggested that didactic 
teaching and printed material (journals and guidelines) had very little impact on 
changing practice (Bloom, 2005).   
The difficulties for dentists undertaking a career break have previously been 
described (Leggate and Russell, 2002).  The advent of online CPD appears to have 
made maintaining registration easier to achieve and the increasing quantity was a 
positive feature.  This is likely to become increasingly important as the 
demographic of the profession changes in the future (McKay and Quinonez, 2012).  
One significant shortcoming of a large proportion of online CPD was way in which 
it was presented, it was felt that the format did not lend itself to changing clinical 
practice and there was no reinforcement of the information after the event.  
Positive online formats were webinars that allowed interaction with a remote 
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speaker in a non-threatening environment.  It is perhaps this format which could 
be engaged with further by clinical researchers. 
Patient-based factors were a motivational incentive for practitioners to seek out 
more information about certain topics, something that has be shown to have 
variable effectiveness in previous reports (Bero et al., 1998).  The potential impact 
of the worldwide economic recession may also impact on the choices that patients 
make in terms of their healthcare, with treatments delayed or practitioners being 
forced to make compromises about their treatment away from perceived best 
practice (Vujicic et al., 2012).  
Previous studies have suggested that local primary care research networks are 
examples of best practice in primary dental care research, noting the successes of 
the Prep-panel and Birmingham Research in Dental General Practice.  Both 
exemplify how research can be accomplished in primary dentistry (Hopper et al., 
2008).  The potential for some practitioners within the practice to be unwilling to 
participate in research has not been previously reported, with some practitioners 
fearful that their involvement would result in failure to fulfil their contractual 
obligations, particularly within NHS practice.   
The outcome measures for continuing professional education interventions vary 
widely, this has led to problems in systematically reviewing these outcomes and 
leading to problems with meta-analysis (Bero et al., 1998; York, 1999).  Academic 
institutions will in the future be competing for smaller sums of funding and will be 
assessed by the true impact of their research as well as its scientific originality 
(REF, 2012).  Researchers should be mindful of this in the design, conduct and 
disseminate their research findings in a manner that is likely to elicit a behaviour 
change for healthcare improvement.  Future research should investigate the true 
cost-benefit obtained from the different formats of CPD as well as focussing on the 
underlying theory of behaviour change (Bero et al., 1998; Eccles et al., 2005).  This 
may mean a change away from the printed press to more intensive and dynamic 
formats of continuing education (Freemantle et al., 1997; Bero et al., 1998; 
McGlone et al., 2001).  No evidence was found evaluating the impact that the 
change in healthcare regulator has had on the educational needs of General Dental 
Practitioners. 
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4.8 Conclusion 
This study highlighted the challenges that general dental practitioners face in 
selecting and engaging with postgraduate education.  Informal peer review was 
seen as being particularly important in the triangulation and evaluation of new 
information and techniques.  Generally practitioners accessed a limited number of 
dental journals that were not of a specialist nature.  Barriers remain to the 
successful translation of contemporary clinical research unless dissemination 
occurs outside of these specialist publications.  Collaborative research 
partnerships incorporating primary dental care, may begin to challenge some 
these barriers between researchers and practitioners and foster a translational 
approach. 
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 Chapter 5 
Discussion 
Translational research involves the transfer of knowledge from the laboratory into 
a clinical situation where an intervention and can be evaluated and accepted.  In 
this way, research findings can be successfully implemented to bring about 
improvements in health for the wider population. The investigations reported in 
this thesis typify translational research, and demonstrate impact in understanding 
the underlying processes of health and disease (Figure 40).   
Initially, established gingivitis was used as a model to evaluate and develop a 
personalised plaque control programme.  This model brought together traditional 
clinical monitoring techniques and pioneering laboratory technologies to evaluate 
sequential plaque control interventions.  Having established the efficacy of the 
intervention, it was adapted, and subsequently applied to a new clinical situation: 
the gingival manifestations of oral lichen planus.  Comprehensive evaluation of the 
intervention was necessary incorporating measures of clinical effectiveness 
alongside those that would capture changes in symptomatology.  In patients with 
painful and refractory disease, this necessitated the use of outcome measures 
which could capture changes in pain and quality of life.  Clinical observations 
recorded changes in plaque and extent of the disease providing information as to 
the clinical effectiveness of the intervention.  Clinicians and those commissioning 
healthcare services must ensure that limited financial resources are used to the 
greatest effect.  Health economic analysis was undertaken to determine whether 
patients placed value on the intervention in excess of the costs of its delivery.  The 
final step in the transfer of knowledge is from research finding into practice.  In 
dentistry the general dental practitioners are the key stakeholders in delivering 
healthcare.  Understanding the barriers that exist in disseminating, accepting and 
implementing recommendations is of utmost importance to facilitate changes in 
healthcare delivery.  An investigation was undertaken to evaluate the attitudes of 
general dental practitioners towards research and continuing education in an 
attempt to identify the most successful methods for bringing about these changes. 
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Figure 40.  Overview of the translational studies reported in this thesis. 
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In the established gingivitis model, the intervention of a powered toothbrush and 
subsequently a professional prophylaxis brought about the expected resolution of 
the clinical signs of gingivitis.  The laboratory analysis using multiplexing 
technologies enabled the detection and quantification of multiple biomarkers and 
microbial pathogens from relatively small sample volumes of GCF and plaque.     
The pathogenesis of established gingivitis in this model allowed the use of host-
derived biomarkers to be evaluated in conjunction with bacterial profiling.  The 
presence or absence of specific inflammatory mediators or bacterial species may 
themselves be indicative of health or disease.  Interactions occur between 
pathogenic microorganisms functioning in complex biofilms and host derived 
biomarkers that function as part of networks of inflammatory stimulation and 
suppression (Preshaw and Taylor, 2011).  The pro-inflammatory cytokines 
indicative of inflammation have been the focus of significant research, particularly 
into the pathogenesis of periodontitis.   A number of other host-derived proteins, 
inflammatory mediators and tissue breakdown products have previously been 
analysed in both gingivitis and periodontitis (Buduneli and Kinane, 2011).  In the 
gingivitis model, it has been possible to detect a number of host-derived mediators 
of inflammation using multiplexing technologies.  Not all of these are likely to be 
predictors of progressive disease and some may only be expressed transiently in 
different phases of inflammation.  
In this established gingivitis model, the clinical measures showed improvement 
following sequential plaque control interventions with the biofilm profile changing 
towards one of more commensal and aerobic species.  Only small, transient 
changes were observed in the host-derived mediators of inflammation.  These 
findings challenge other outcomes that might be expected in response to the non-
surgical management of chronic periodontitis (Kinane et al., 2003; Buduneli and 
Kinane, 2011).  These transient changes may represent tissue remodelling at levels 
below the threshold for tissue degradation.  Ultimately it is the response of the 
tissues to microbial endotoxins that initiates gingivitis whilst local genetic 
expression and modifying systemic factors are most likely to be responsible for the 
severity and magnitude of the response.   
The profiling of samples from patients with different stages of gingivitis (and 
subsequently periodontitis) may ultimately lead to the establishment of some 
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threshold values above or below which, destructive disease may be predictable 
(Kinane et al., 2011).  Furthermore, correlating and quantifying the levels of 
bacterial species present, with host-derived biomarkers, may identify key 
surrogate predictors of inflammatory and more destructive disease.  It may now 
also be possible to look back and challenge (by using these new technologies) the 
key species associated within gingivitis and periodontitis.  This is important as 
those species, now detectable using DNA probes, may have previously been 
difficult or impossible to culture. 
The heterogeneity of the methods of analysis along with the experimental use of 
novel technologies has, so far, prevented a systematic review from being 
conducted into the diagnostic potential of biomarkers.  The key to the success of 
future investigations is for researchers to work together with commonly agreed 
methods and protocols for biomarker analysis and reporting that allows 
comparability between studies and furthers the understanding of how periodontal 
inflammation develops, becomes established, resolves, and crucially, at what stage 
professional intervention is indicated. 
Clinical measures remain important in evaluating and comparing the efficacy of 
plaque control interventions.  In the established gingivitis model, the initial plaque 
control intervention of a powered toothbrush brought about expected resolution 
of mild gingival inflammation that was detectable clinically and by the shift in a 
broad bacterial profile that occurred towards those species historically associated 
with health.  Improvements were observed following the subsequent intervention 
of scaling and prophylaxis with the hygiene phase having the greatest impact on 
clinically observed signs.  Following evaluation of the sequential plaque control 
interventions, the intervention was applied to patients with gingival inflammation 
associated with oral lichen planus.  The oral manifestations of lichen planus 
include an intense and refractory desquamative gingivitis which is frequently 
treated with topical immunosuppressive medication.  Previous guidance lacked 
robust evidence, but suggested that some benefits may be elicited through effective 
plaque control (Erpenstein, 1985; Holmstrup et al., 1990, Guiglia et al., 2007; 
Lopez-Jornet and Camacho-Alonso, 2010a).  An enhanced hygiene phase 
intervention was used to include additional interdental cleaning aids.  It was 
subject to evaluation through clinical observations, patient-centred outcome 
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measures and subjected to a health economic evaluation.  The overarching 
objective of the intervention was to address clinical signs of inflammation 
associated with oral lichen planus through self-performed plaque control. 
The enhanced plaque control intervention brought about similar improvements in 
plaque scores to those observed in the original established gingivitis model as well 
as improving the extent and severity of the oro-mucosal disease.  The effectiveness 
of plaque control in patients with oral lichen planus was unequivocal, suggesting 
that personalised plaque control programmes are important in managing the 
gingival manifestations of oral lichen planus. Plaque control should, therefore, 
form an important component of the initial treatment phase.  It is also possible that 
reductions in inflammation may impact upon, and reduce the frequency, by which 
topical corticosteroids are subsequently required. 
Host-derived biomarker analysis was also carried out for a small subset of the oral 
lichen planus population.  Higher concentrations of IL-1, MIP-1, MIP-1, 
RANTES, MMP-8 and MMP-9 were detectable in comparison to those observed in 
the established gingivitis model using the same methods of collection and analysis.  
Statistical comparisons were not performed but the concentrations were in the 
order of two-times those observed for IL-1β, MIP-1α, MIP-1β, RANTES, MMP-3, 
MMP-8 and MMP-9 in the gingivitis model.  Possible explanations may be 
attributed to the immunological disregulation in the pathogenesis of oral lichen 
planus (Lodi et al., 2005a).  Given the chronic and refractory nature of oral lichen 
planus, it is not just pro-inflammatory but also regulatory cytokines that act on the 
gingival tissues (Yamamoto and Osaki, 1995).  If the balance shifts towards those 
cytokines responsible for down-regulation then healing should occur, conversely 
increased levels are associated with inflammation.  The local levels of cytokines 
observed support previous evidence that identified pro-inflammatory cytokine 
concentrations 2-3 times greater in oral lichen planus than in chronically inflamed 
tissue and 10-20 times those concentrations found in healthy gingiva (Yamamoto 
and Osaki, 1995).  It is uncertain what impact topical immunosuppressant 
medication has on the local levels of inflammatory biomarkers, however it is 
reasonable to assume that higher concentrations might be observed in the 
untreated patient. 
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The inflammatory infiltrate observed in oral lichen planus lesions consists mainly 
of T-cells and in tissues exhibiting clinical signs of tissue destruction including 
atrophy and ulceration.  It is also reasonable to assume that macrophages will be 
present in large numbers.  IL-1 regulates the proliferation and differentiation of 
T-cells (Yamamoto and Osaki, 1995).  The strong pro-inflammatory effect of IL-1 
is likely to be partly responsible for the cellular infiltrate in oral lichen planus with 
higher levels associated with inflammation.  Blocking of IL-1 activity has been 
recognised as a treatment for systemic autoimmune disease but not specifically 
oral lichen planus (Dinarello, 1994; Dinarello, 2011).   
Expert clinical evaluation may be relatively straightforward to categorise the 
extent and severity of a disease into mild, moderate or severe or in the case of oral 
lichen planus reticular, atrophic or erosive.  This clinical categorisation may, 
however, bear little or no resemblance to the symptoms that a patient experiences 
during the course of a chronic disease which are only really meaningful at an 
individual level.  The chronicity of the disease is likely to play a key part in the 
impact that it has from the patients’ perspective.  The symptoms that are often 
recorded by clinicians relate to pain and discomfort, therefore treatment is 
initiated and based upon these symptoms alongside the presenting clinical picture.   
Evaluation of the personalised intervention was developed from that used in the 
gingivitis model to include assessment of the impact that chronic oral 
inflammatory disease has on a patient’s quality of life.  The OHIP questionnaire 
aimed to further understand the frequency and nature of the impact of the disease 
and its management.  When examining the baseline data it was clear that the 
subjects in the study reported impacts on their quality of life more frequently than 
healthy patients in a similar age cohort previously published (Slade and Spencer, 
1994).  Subjects in the intervention group reported significant improvements in 
their oral health related quality of life, but small improvements were also reported 
in OHIP and global change scores in both groups at 4-and 20-week follow up.   
The impacts detected within the OHIP occurred in all domains, with the 
intervention reducing the frequency of these impacts compared to control.  This 
was often in areas that would not usually be investigated as part of the routine 
clinical history.  Those OHIP domains in which significant differences were 
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observed in the intervention group at both the 4- and 20-week follow up were in 
the functional limitation, psychological discomfort and physical disability domains.  
Analysis was not carried out at an individual question level and in-depth 
interviews were not carried out with subjects in this study.  This may have 
provided further insight into the pre-existing effect that oral lichen planus has on a 
person’s quality of life, and in what specific ways the intervention brought about 
these changes. 
The initiation of lichen planus lesions has previously been reported to be co-
incident with increases in stress and anxiety.  It is possible that frequent 
observation through participating in a clinical trial may at some level, provide 
some psychological benefit.  This observation is neither a placebo effect (this study 
was not placebo controlled) nor a result of the Hawthorne effect (the changes in 
behaviour as a result of being observed) (Roethlisberger and Dickson, 1939).  
Whilst potentially controversial, subjects may have placed value upon being 
monitored over time at more frequent intervals than they would ordinarily have as 
part of their conventional management pathway.  Perhaps it was that participation 
itself provided a level of personal reassurance that their oral health was being 
closely monitored (Mahoney and Baker, 2002).  This effect may be particularly 
important in a disease where patients are aware that there is a higher risk of 
malignant change.   
The evaluation was then developed further through application of health 
economics.  Economic evaluation provides supporting evidence to adopting an 
intervention if the benefits obtained by the patient exceed the costs of delivering it.  
Clearly if an intervention brings about clinical and/or symptomatic improvement 
but it is more expensive that alternative treatments clinical practice is unlikely to 
change.   Cost-benefit and cost-effectiveness analyses are still relatively uncommon 
in clinical trials in dentistry and if resources are to be used effectively, evaluations 
of this kind should become an integral component of clinical trials.  In this case the 
majority of subjects placed a higher value on the intervention than the actual costs 
of providing it, supporting its use in clinical practice.   
On-going personalised supportive periodontal care should therefore be provided 
to patients with the gingival manifestations of oral lichen planus.  The aim being to 
encourage patients to optimise plaque control, and minimise inflammation.  The 
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clinical observations of the reductions in plaque levels and reduction in the activity 
of mucosal disease scores provide some evidence to justify managed care networks 
between oral medicine specialists, GDPs and hygienists.  The demographics of 
these care pathways may change with the recent introduction of direct access to 
dental care professionals in the UK.  This may allow referral of the patient directly 
from oral medicine specialist to dental hygienists or even oral health educators. 
The challenge for this and other clinical research studies is in the translation and 
implementation of recommendations into everyday clinical practice.  A number of 
pressures exist that encourage the status quo within general dental practice.  Not 
all of these lie within the control of the individual practitioner but are subject to 
the pressures of regulation and working within much larger organisations, for 
example the NHS in the UK.   
Conventional methods for disseminating research have focussed upon publication 
in esteemed academic journals.  The interviews and focus groups conducted 
investigating this final translational step showed those who are engaged and at the 
forefront of primary care practice simply do not read, or even have access to, many 
of these academic publications.  Consequently, the final step in the process of 
translating findings from biological and clinical research to the interface between 
clinician and patient may never be realised.   
With the exception of peer reviewed publications and formally accredited 
programmes, few of the available sources of continuing professional development 
in the UK are quality assured in a rigorous way.  They are also open to the personal 
and commercial biases of those organising and delivering the courses.  Along with 
the exponential increase in continuing professional development, there is a risk 
that practitioners do not engage at all with journals, choosing instead to select 
sources that are easy to obtain certification from.  Researchers must be cognisant 
of these changes and be adaptive to new methods and routes to disseminate their 
findings alongside more established routes of journal publication and presentation 
at specialist scientific conferences.   
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5.1 Conclusions 
 Plaque control interventions comprising powered toothbrushing and 
professional prophylaxis are effective in reducing established gingivitis. 
 The greatest improvements in plaque control were observed during the self 
performed hygiene phase of treatment. 
 Sequential plaque control interventions brought about shifts in 
microbiological species towards those species associated with health. 
 Transient increases in host-derived inflammatory changes were observed 
following sequential plaque control interventions. 
 A personalised plaque control intervention was effective in reducing 
plaque, clinical signs of inflammation and bringing about improvements in 
quality of life for patients with gingival manifestations of oral lichen planus. 
 A personalised plaque control programme for managing the gingival 
manifestations of oral lichen planus was cost-effective. 
 Personalised plaque control should form part of the initial management 
phase for patients presenting with the gingival manifestations of oral lichen 
planus. 
 Barriers exist to the successful translation and implementation of 
contemporary clinical research. 
 Results from clinical research should continue to be published in peer 
reviewed publications but researchers should seek to disseminate findings 
using pathways that are more accessible to general dental practitoners. 
 Clincal researchers should engage with postgraduate educators to ensure 
that research findings are disseminated to general dental practitioners 
more effectively. 
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5.2 Recommendations for further work 
 Investigation of previously researched diseases should do so using 
pioneering methods and technologies which add to the understanding of 
the underlying pathology. 
 Clinical intervention studies should, where possible, utilise self-reported 
outcome measures alongside clinical evaluations to understand the 
effectiveness of the intervention.   
 Further qualitative work is required to further understand the impact of 
chronic oro-mucosal disease and its management from patient’s 
perspectives.  This may lead to the development of a shortened condition 
specific instrument that may be able to measure these constructs and 
inform clinical management.  
 New interventions should be evaluated for their cost-effectiveness 
compared to standard treatments. 
 New routes for the effective dissemination and translation of research 
findings should be explored and evaluated. 
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Appendix 1. The Oral Health Impact Profile 
 
The conceptual dimensions and item numbers of the oral health impact profile.  Items 
were administered in the original questionnaire format and the original order (1-49), 
responses were obtained on a Likert type scale from 5 options: never, hardly ever, 
occasionally, fairly often or very often. 
 
Functional limitation 
1.  Difficulty chewing   
2. Trouble pronouncing words 
3. Noticed a tooth that doesn’t look right 
4. Appearance affected 
5. Breath stale 
6. Taste worse 
7. Food catching 
8. Digestion worse 
17. Dentures not fitting 
Physical Pain 
9. Painful aching 
10. Sore jaw 
11. Headaches 
12. Sensitive teeth 
13. Toothache 
14. Painful gums 
15. Uncomfortable to eat 
16. Sore spots 
18. Discomfort 
Psychological discomfort 
19. Worried 
20. Self-conscious 
21. Miserable 
22. Appearance 
23. Tense 
 
Physical Disability 
24. Speech unclear 
25. Others misunderstood 
26. Less flavour in food 
27. Unable to brush teeth 
28. Avoid eating 
29. Diet unsatisfactory 
30. Unable to eat (dentures) 
31. Avoid smiling 
32. Interrupt meals 
Psychological Disability 
33. Sleep interrupted 
34. Upset 
35. Difficult to relax 
36. Depressed 
37. Concentration affected 
38. Been embarrassed 
Social Disability 
39. Avoid going out 
40. Less tolerant of others 
41. Trouble getting on with others 
42. Irritable with others 
43. Difficulty in doing jobs 
Handicap 
44. Health worsened 
45. Financial loss 
46. Unable to enjoy people’s company 
47. Life unsatisfying 
48. Unable to function 
49. Unable to work 
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Appendix 2. Clinical Trial 1: Participant information sheet 
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Appendix 3. Clinical Trial 1: Consent form 
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Appendix 4.  Clinical Trial 2: Participant information sheet 
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Appendix 5.  Clinical Trial 2: Consent Form 
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